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A b s t r a c t
Galectin-3 is a (3-galactoside-binding lectin implicated in renal collecting duct 
development and differentiation. Autosomal recessive polycystic kidney disease 
(ARPKD) affects 1 in 20,000 humans, and is characterised by cyst 
development from collecting ducts. Galectin-3 retards cystogenesis in at least 2 
in vitro models. Hence, I hypothesised that endogenous galectin-3 may reduce 
cyst formation in vivo, and investigated this in the congenital golycystic kidney 
mouse (cpk), a well-characterised ARPKD model. Widespread galectin-3 
expression was detected in cpk cyst epithelia in a distinct distribution compared 
to other developmental markers and renal galectins, and also in other cystic 
mice and human PKD, raising the possibility that galectin-3 may be a common 
part of a ‘cystogenic’ pathway.
Next, I investigated whether reduced galectin-3 accelerated cyst formation in 
vivo using cpk and galectin-3 mutants to generate double cpk/galectin-3 
mutants. Initial results on a mixed genetic background demonstrated large 
variability, but still significantly increased cysts in mice lacking galectin-3. I then 
backcrossed onto a pure 129Sv background but offspring developed 
unexpected increased mortality and pancreatic cysts, which confounded this 
experiment. Hence, we imported different galectin-3 mutants to reassess on the 
C57BL/6j background: cyst formation was less rapid than mixed/129Sv, but 
significantly more cortical cysts were again observed in galectin-3 null mutants.
I detected galectin-3 in the primary cilium and centrosomes both in vivo and in 
vitro in normal and cystic samples for the first time. At least some of the 
galectin-3 appears on the outside of the cilia and paclitaxel, a therapy that 
retards PKD in cpk mice, caused increased extracellular galectin-3, a location 
where the lectin might interact with cilia. Preliminary experiments were also 
performed to investigate ciliary function using atomic force microscopy.
These data raise the possibility that galectin-3 may act as a ‘natural’ brake on 
cystogenesis in cpk mice, perhaps via ciliary roles.
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O v e r v ie w
Galectin-3 is an important molecule which has been implicated in renal 
development and cyst formation in human ARPKD (Winyard et a i, 1997;
Bullock et ai, 2001). Preliminary evidence from a previous PhD student in my 
host laboratory (Dr Tanya Johnson) also suggested increased expression in the 
cpk mouse model of ARPKD, and that excess galectin-3 reduced cpk cyst 
formation in vitro.
I characterised galectin-3 expression in cpk mice, comparing it with other 
collecting duct markers and renal galectins and also investigated the effects of 
reduced galectin-3 in vivo, by crossing cpk mice with galectin-3 mutant mice. 
Then I investigated galectin-3 in the primary cilium, and examined whether 
paclitaxel and galectin-3 might act via common ciliary mechanisms to reduce 
cyst formation. Finally, I began to investigate cilia using the atomic force 
microscope.
These studies generated considerable new insights into potential functional 
roles for galectin-3 in cpk mice, and parts of this work are included in a recently 
accepted paper “Galectin-3 associates with the primary cilium and modulates 
cyst growth in congenital polycystic kidney disease”, to be published in the 
American Journal of Pathology in December 2006. These findings may also be 
applicable to other PKD, including human ARPKD, and future studies of this 
lectin are certainly warranted as galectin-3 must now be considered a potential 
therapy for this devastating condition.
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In t r o d u c t io n
C h a p t e r  1: A u t o s o m a l  r e c e s s iv e  p o l y c y s t ic  
KIDNEY DISEASE
Autosomal recessive polycystic kidney disease (ARPKD) is a type of polycystic 
kidney disease (PKD) that mainly affects children. PKD is a genetic disorder of 
the kidneys and is characterised by the presence of multiple cysts in both 
kidneys which results in kidney enlargement and eventually kidney failure (see 
fig 1.1). ARPKD is distinguishable from other forms of PKDs by its specific 
mutation of the PKHD1 gene (Ward et al., 2002; Onuchic et a i, 2002), its early 
onset and the fact that most cysts in ARPKD are derived from the collecting 
tubules. Human ARPKD kidney histological samples are dominated by 
collecting duct cysts.
ARPKD affects approximately 1 in 20000 human live births (Zerres et al.,
1998). The disease manifests either in utero or at birth, though a small 
percentage of patients begin to develop renal cysts in adolescence or even 
adulthood. Prenatal diagnoses are made by fetal sonography or by serial 
monitoring in families with affected members. Affected fetuses characteristically 
have enlarged kidneys and oligohydramnios (reduced amniotic fluids) due to 
poor renal output in utero (Kemper et al., 2001). As a result of the 
oligohydramnios, these infants develop the “Potter’s sequence” (Potter, 1964), 
a syndrome consisting of pulmonary hypoplasia, characteristic facial 
appearance (sidely set eyes, a beaked nose, mild retraction of lower jaw, and 
large, low-lying ears with incomplete cartilaginous development) and 
deformaties of the spine and limbs.
Approximately 30% of ARPKD infants die at birth or shortly after that mainly 
due to malformation of the lungs and suppression of the diaphragm by the 
massive kidneys (Sharp et al., 2005). However, infants that survive mechanical 
ventilation have a good chance of survival. For those who survive the first 
month of life, 92% were alive at 1 year and 87% were alive at 5 years (Guay-
Woodford and Desmond, 2003), but a third of ARPKD patients require dialysis 
or kidney transplantation by the age of 10.
In the kidney the disease is characterised by cyst growth in the collecting 
tubules. As much as 90 per cent of collecting tubules in affected neonates are 
dilated. The disease is often accompanied by congenital hepatic fibrosis (CHF), 
which is a disease of the liver caused by malformation of the ductal plate during 
liver development and abnormal portal vein branching. The outcomes of CHF 
are scarring and blood flow restriction, though liver function tests often remain 
normal even for symptomatic individuals. Other clinical features of ARPKD are 
hypertension, which can lead to cardiac hypertrophy and death; hyponatraemia 
resulting from the inability of patients to dilute their urine; and pyuria.
At the moment there are no effective therapeutic drugs against renal 
cystogensis. Treatment is based on dialysis and kidney transplantation.
Figure 1.1. Kidneys from ARPKD patients.
The kidneys are grossly enlarged and are filled with dilated tubules and 
cysts, A) a cross-section of the kidney. B) A histological section of the 
kidney shows the radially oriented, fusiform cysts that are characteristic 
of ARPKD. (Figure adapted from Coffman 2002).
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PKHD1 gene and its encoded protein
The gene mutated in ARPKD was initially identified and characterised by two 
different research groups using two different methods: a conventional 
positioning cloning approach and a comparative genomic approach (Ward et 
al., 2002; Onuchic et al., 2002). Both determined a mutation of a gene PKHD1 
(Polycystic Kidney and Hepatic Disease 1) at a single locus on chromosome 
6p21.1-p12. PKHD1 consists of at least 86 exons with a longest continuous 
open reading frame (ORF) of 67 exons, spanning ~472kb of genomic DNA. It 
encodes for a large protein called polyductin or fibrocystin.
For this thesis, the protein is referred to as fibrocystin. The protein is predicted 
to contain 4074 amino acids with an unglycosylated molecular weight of 447 
kD. To date the best reported mutation detection rate of this gene associated 
with ARPKD is 82.7% (Sharp et al., 2005), in an ethnically diverse population 
with a wide range of ARPKD associated phenotypes. The mutation detection 
rate is not an absolute reflection of the presence of a mutation in PKHD1, as it 
is a very large gene; the gene structure and its splice variants are not yet 
completely characterised. No other genes have been found to cause ARPKD, 
perhaps suggesting that PKHD1 is the only gene that when mutated causes 
ARPKD.
Mutations are found scattered along the gene. Analysis of 14 families revealed 
6 truncating and 13 missense mutations; 8 patients were compound 
heterozygotes in which 6 had one truncating and one missense mutation and 2 
had two missense mutations (Harris, 2002). A more comprehensive analysis of 
PKHD1 mutations in a cohort of 75 unrelated ARPKD patients was carried out 
(Sharp et al., 2005). The study found 124 pathogenic sequence variants among 
150 chromosomes, in other words 124 mutations were found. Among the 
putative mutant alleles, 22 were predicted to cause chain termination with 16 
frameshift variants (deletions, insertions and duplications) and 6 nonsense 
mutations. Out of 56 patients analysed, homozygous mutations were detected 
in 12 patients and the remaining patients were compound heterozygotes. The 
wide range of mutations in different locations of the gene may explain the
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variety of clinical presentation of ARPKD patients. A study on the 
genotype/phenotype correlations of these 56 patients suggested that neither 
the location nor the type of amino acid substitution correlates with disease 
severity. The finding disagrees with another report that milder presentation of 
ARPKD correlates with the presence of amino acid substitution mutations (Furu 
et al., 2003). Clearly, more work has to be carried out to find out if there are any 
correlations between the types of mutation and the phenotype of the disease. 
Success in finding such correlations would aid the diagnosis of ARPKD 
patients.
Predicted structure of fibrocystin
Fibrocystin is predicted to have a single transmembrane domain (TM) near the 
carboxyl terminus. The protein contains several TIG/IPT domains, Ig-like fold 
shared by plexins and transcription factors near its carboxyl terminal; and 
Parallel p-Helix 1 (PbH1) repeats which can bind carbohydrates in its amino 
terminus (Ward et al., 2002; Onuchic et al., 2002), see figure 1.2. In addition 
there are 64 potential N-glycosylation sites and 2 potential phosphorylation 
sites can be found in the carboxyl terminus (Sweeney, Jr. and Avner, 2006). 
Northern blot analysis of PKHD1 transcripts detects a smear of products, which 
may represent multiple splice forms (Ward et al., 2002). Several splice variants 
are predicted to encode truncated products that lack the TM domain and may 
be secreted. Fibrocystin is a novel protein that share structural features with 
hepatocyte growth factor receptor and plexins, which are involved in the 
regulation of cellular adhesion and repulsion as well as cell proliferation (Guay- 
Woodford, 2002; Harris, 2002).
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Figure 1.2. Predicted structure of fibrocystin.
Fibrocytsin consists of a large extracelluar portion that contains various 
different domains (signal peptide, TIG, TIG-like, TMEM homology). At 
the C-terminal, which is also the cytoplasm portion of the protein, there 
are four potential phosphorylation sites. Adapted from (Hogan et al., 
2003).
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Expression of fibrocystin
Commercially acquired human adult and human fetal multiple-tissue northern 
blots analysis reveals that PKHD1 is expressed in adult kidney and pancreas, 
with a lower level in liver. Moderate expression in fetal kidney is also detected 
(Onuchic etal., 2002). RT-PCR analysis in mouse found that the gene is most 
strongly expressed in new born and adult kidney, with lower levels in liver, 
pancreas and lung, and no expression in brain, spleen, colon, thymus, heart 
and skeletal muscle (Ward etal., 2002). In situ hybridisation studies of Pkhdl 
on mouse tissues shows a high level of expression in renal and biliary tubular 
structures at all time points between E12.5 to 3 month postnatal (Nagasawa et 
al., 2002). The gene expression pattern is consistent with the ARPKD
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phenotype, with the highest expression in renal collecting ducts, as well as in 
the ductal plate and bile ducts in the liver.
During embryogenesis, the gene is widely expressed in epithelial derivatives, 
including neural tubules, gut, pulmonary bronchi, and hepatic cells (Zhang et 
al., 2004). In mouse developing kidneys, the protein is expressed at the apical 
surfaces of epithelia of the early ureteric bud and mesonephric tubules, as the 
bud penetrates into the metaneprhogenic mesenchyme (Zhang et al., 2004). 
This apical expression persists as the ureteric buds branch and differentiate 
into collecting ducts. However, no significant immunostaining is detected in the 
condensing mesenchyme, the comma-shaped body, the S shaped body or 
developing glomeruli of the nephrogenic zone. In adult kidney, PKHD1 is widely 
expressed in the epithelia of proximal convoluted tubules with a cytoplasmic 
distribution. Expression is also detected in collecting ducts and thick ascending 
limbs of Henle’s loop, mainly at the apical surface (Zhang et al., 2004).
The function of this protein is not yet known. However, sequence analysis 
suggests that it may be involved in the regulation of cell adhesion or it may 
function as a receptor (Harris and Rossetti, 2004).
PKHD1 homolog
A PKHD1 homolog, PKHDL1 has been identified by Hogan et al., 2003. The 
gene is in chromosome region 8q23 through analysis of human genomic 
sequence. PKHDL1 contains 78 exons, covering a genomic region of 168kb; its 
transcript of 13081 bp encodes for a large protein called fibrocystin-L. No 
mutation of this gene is found in ARPKD patients with no PKHD1 mutations, 
suggesting that PKHDL1 is not associated with ARPKD. Similar to fibrocystin, 
fibrocystin-L is predicted to be a large receptor protein (4243aa, 466kDa) with a 
signal peptide, a single transmembrane domain and a short cytoplasmic tail. 
The two proteins share an overall identity of 25.0% and similarity of 41.5%. RT- 
PCR studies reveal that PKHDL1 is widely expressed in most tissues with the
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most prominent expression is found in blood-derived cell-lines. Low level 
expression is detected in many primary immune cell subtypes but up-regulated 
specifically in activated T lymphocytes, suggesting a role in cellular immunity 
(Hogan et al., 2003).
Other forms of polycystic kidney disease
Autosomal dominant PKD has a much higher incidence, 1:800 to 1000 (Nauli 
and Zhou, 2004; Wilson, 2004a), arguably being the most common genetic 
disease. Although it is somewhat similar to the recessive form of PKD, as both 
are characterised by cyst growth in kidneys, there are clear differences 
between them. ADPKD usually occurs later in life, at the fourth decade. 
Affected patients have cysts developed and dilated tubules at any point along 
the nephron and rapidly close off from the nephron of origin. In contrast, in 
ARPKD, initially the proximal tubules are dilated and later cysts arise from the 
collecting tubules, which remain connected to the nephron of orgin (Wilson, 
1995). Due to the high frequency of human ADPKD, studies into kidney cystic 
diseases have most often been carried out in the ADPKD models. This gives 
important information into the mechanisms of cysts growth which in turn, if 
there is common mechanisms, and also enhances our potential understanding 
of the development of ARPKD.
Cystic kidneys are also common in other genetic diseases such as 
Nephronophthisis, Oral-facial-digital syndrome type I, Bardet Biedel syndrome 
and Fraser syndrome (Otto et al., 2003; Ansley et al., 2003; Romio et al., 
2003). Although they are classified as different diseases, there are many 
similarities in terms of the pathophysiology of renal epithelial cells which lead to 
cyst formation.
The following section describes the pathophysiologies that are common to all 
forms of PKD.
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Pathophysiology of PKDs
The exact disease mechanism that results in cyst growth in the kidney is yet to 
be resolved. However, several common features are present in cystic kidneys.
Abnormal proliferation and apoptosis
Many investigators have found a significant increase in proliferation rate in 
renal cystic epithelia (Grantham, 1993; Nadasdy et al., 1995; Ostrom et al., 
2000). Using immunohistochemistry to detect the presence of proliferating cell 
nuclear antigen, PCNA, a marker for cells undergoing proliferation, Nadasdy et 
al (Nadasdy et al., 1995; Nadasdy et al., 1998) calculated the proliferative index 
(PI -  percentage of PCNA positive cell nuclei) among epithelial cells lining the 
renal tubule or cysts of developing kidney tubules, normal kidney tubules, and 
cystic epithelia of human ADPKD and ARPKD. They found that in normal 
developing kidneys, the PI decreases as the kidney matures and in adult 
kidneys, there are less than 0.5% of proliferating epithelial cells per tubule. 
However compared with that of developing kidneys which is between 5.9% and 
12.4% in cystic kidneys, the PI value is significantly higher compared with 
normal (Pl= 2.58% in ADPKD and 10.5% in ARPKD). This phenomenon occurs 
particularly in ARPKD where the level of proliferating cells is comparable to that 
of developing kidneys (Nadasdy etal., 1995; Nadasdy et al., 1998).
Increased levels of apoptosis are also common in cystic kidneys, both in the 
cystic epithelia and in the surrounding tissues (Woo, 1995; Winyard et al.,
1996; Ostrom et al., 2000). The latter may contribute to cyst growth by allowing 
cysts to expand. The importance of apoptosis in cystogenesis is highlighted in 
the knockout experiments where Bcl-2 (B-cell leukaemia/lymphoma 2) was 
inactivated (Veis et al., 1993). Bcl-2 protects cells from apoptosis by modulating 
the permeability of the mitochondrial membrane. It induces the release of 
cytochrome c which then activates caspase-9 and caspase-3, leading to 
apoptosis (Gross etal., 1999). During early kidney development, the protein is 
highly expressed in the ureteric bud and metanephric mesenchyme and the
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level gradually declines to low levels as the kidney matures. It is thought that 
tight regulation of apoptosis, hence Bcl-2 expression, is essential for normal 
kidney development (Novack and Korsmeyer, 1994). Mice lacking functional 
Bcl-2 develop polycystic kidney disease (Nakayama et al., 1994). In the 
polycystic kidneys there is widespread apoptosis in the interstitium around 
undilated tubules distant from cysts, in undilated tubules between cysts and in 
cystic epithelia (Winyard et al., 1996). Another study on caspase activity in the 
Han:Sprague-Dawley-cy (Han:SPRD-cy) rat, a phenotypic ADPKD model, 
shows an increase in caspase activity and apoptosis in affected rats. Moreover, 
treatment with the caspase inhibitor IDN-8050 significantly reduces tubular 
apoptosis and proliferation and slows disease progression in this animal model 
(Tao et al., 2005). These studies emphasise the importance of the regulation of 
apoptosis in renal cytogenesis.
Polarity and fluid secretion
Polarity of epithelial cells refers to the specific localisation of characterised 
proteins at the cell surface. Common epithelial cells differentiate in a uniform 
way which produces a defined protein composition in each surface domain of 
the cells: apical and basolateral surfaces. The two domains are separated by 
tight junctions, which act as semi-permeable seals around the cells. During 
epithelial cell differentiation, microtubules align along the apico-basal polarity 
axis of the cell (Musch, 2004). In renal epithelial cells, microtubules create 
asymmetry by orienting their minus-ends toward the apical domain and their 
plus-ends towards the basal surfaces.
Maturation of murine nephrons relies on intense proliferation during postnatal 
development which drives the lengthening of tubules (Fischer et al., 2006). The 
direction of cell growth is goverened by planar cell polarisation. In normal 
mouse kidneys, the mitotic spindle alignment is parallel with the tubule axis; 
whereas the alignment is distorted in HNF1 /^deficient mice and in pck rats, 
both develop renal cysts. The mitotic angles in these mutant animals are 
between 30° and 90° to the tubular axis (Fischer et al., 2006). Defective planar
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cell polarisation in these animals leads to cell growth in the wrong direction, 
resulting in dilation of tubules instead of elongation.
The specific ends of the microtubules aid the transport of vesicles to their 
destined surface domains (Musch, 2004). These vesicles contain specific 
proteins that dock and fuse with either the apical or the basolateral domains. 
The distribution of enzymes, ion transporters, channels, pores, growth factors 
and matrix receptors are tightly regulated. In renal cystic epithelia, some of 
these proteins are mis-located to the opposite domain. In cystic epithelial cells, 
epidermal growth factor receptor (EGFR), Na+/K+-ATPase are expressed in the 
apical cell membrane instead of their normal location at the basolateral site 
(Sweeney and Avner, 1998; Avner et al., 1992). Aquaporin 2 which is normally 
expressed at the apical site is found to be mis-localised to the basolateral site 
in cystic epithelial cells of 3 weeks old cystic cpk mice. At this stage the kidneys 
are mostly composed of collecting duct cysts (Gattone et al., 1999). In contrast, 
studies of human ADPKD uninephrectomy samples showed that both 
aquaporin 2 and 3 are expressed in the correct domain even in cystic epithelia, 
but only two samples were examined (Hayashi et al., 1997).
Importantly, the mislocalisation of Na+/K+-ATPase and aquaporin-2 may partly 
be responsible for the fluid accumulation in renal cysts (Avner et al., 1992; 
Rohatgi et al., 2003). Fluid reabsorption in the normal kidney is controlled by 
sodium ion gradients established by Na+/K+-ATPase in the basolateral domain 
and the presence of aquaporin-2 at the apical site and aquaporin-3 at the 
basolateral sites which allow water to permeate through the cell from the 
luminal to the basolateral compartments. Compared with control age-matched 
collecting tubules, ARPKD cells absorb Na+ at a rate approximately 50% 
greater. The expression of aquaporin-2 is upregulated and partially mislocated 
in cystic kidneys (Gattone et al., 1999; Rohatgi et al., 2003). This may result in 
a reversal of fluid transport.
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Adhesion
In cystic kidneys, the abnormal expression of adhesion molecules and altered 
extracellular matrix (ECM) biology leads to atypical cell-matrix interactions, 
thickened basement membranes, alterations in matrix composition and 
abnormal numbers of integrin receptors are frequent in PKD (Joly et al., 2003; 
van Adelsberg, 1994; Nakamura etal., 2000). ECM structure is altered by 
increased activity of fibroblasts (Murcia et al., 1999) and matrix 
metalloproteinases (MMPs) (Obermuller etal., 2001). Fibroblasts from cystic 
kidneys exhibit increased proliferation In vitro and increase ECM deposition in 
vivo, which may participate in the formation of abnormal cystic tubular 
microenvironment. MMPs are responsible for ECM degradation, and their 
expression in cpk kidneys is upregulated, which contributes to the restructuring 
of the tubular basement membrane (Rankin et al., 1996).
Studies on PC-1 reveal that the protein is expressed on several different sites 
in renal cells including the cell-cell junctions and at focal adhesions (Huan and 
van Adelsberg, 1999). PC-1 colocalises with cell adhesion molecules E- 
cadherin and catenin, it coprecipates with these proteins and comigrates with 
them on sucrose density gradients. Hence, PC-1 is part of a complex with these 
adhesion molecules (Huan and van Adelsberg, 1999). Furthermore, PC-1 
colocalised with a2(31 -intergrin in focal clusters in adherent renal epithelia 
(Wilson et al., 1999). These findings suggest that PC-1 may function as a 
modulator in cell adhesion. The composition of PC-1/E-cadherin/catenin 
complexes can be modulated by Ca2+(Geng etal., 2000). High calcium 
treatment of human renal collecting tubules cells increases PC-1-E-cadherin 
interactions.
Bcl-2 null mice, which develop polycystic kidneys, have abnormal intergrin 
subunits expression in tubular epithelial cells, with an increased level of a3-, 
a5- and a6-integrin in cystic kidneys as well as a slight decrease in p1-integrin 
compared with their wild-type counterparts (Ziehr et al 04). PC-1 contains 
cysteine-flanked leucine-rich repeats (LRR), which interact with a number of
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ECM components including fibronectin, laminin and collagen I (Malhas et al., 
2002). All these point towards the importance in regulating adhesion in kidney 
epithelial cells, which when disrupted may cause cystogenesis.
Defective primary cilia
Primary cilia are cellular organelles expressed singly in most vertebrate cells 
except bone marrow-derived cells and the intercalated cells of the kidney 
collecting duct (Praetorius et al., 2004). Ciliary dysfunction is associated with 
the development of PKD (Ong and Wheatley, 2003; Pazour, 2004; Praetorius 
and Spring, 2005). Many proteins mutated in PKD are expressed in the primary 
cilia, either in the shaft of the cilia or at the basal body. Examples of such 
proteins in human are PC-1, PC-2, fibrocystin, OFD, nephrocystin, Bardet-Biedl 
syndrome proteins; and in mouse are inversin, polaris, cystin, bicaudal C 
(Yoder et al., 2002a; Guay-Woodford, 2003; Ward et al., 2003; Otto et al.,
2003; Ansley et al., 2003; Romio et al., 2004; Wolf et al., 2005). Several studies 
have shown that structural or functional defects in primary cilium result in 
development of tubular cysts (Calvet, 2003; Lin et al., 2003; Ong and Wheatley, 
2003; Nauli and Zhou, 2004). Detailed description of this organelle can be 
found in Chapter 2.
Molecular mechanisms of PKD protein 
Fibrocystin
To date, not much is known about the cellular functions of fibrocystin, the 
protein mutated in ARPKD. Fibrocystin was identified just before this project 
began. It belongs to a new class of protein therefore not much is known about 
its possible role in cells. It is implicated in tubulogenesis of IMCD cells (Mai et 
al., 2005). Yeast two-hybrid system identifies that intracellular C-terminus of 
fibrocystin interacts with calcium modulating cyclophilin ligand, a protein 
involved in Ca2+ signalling (Nagano et al., 2005).
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More investigations have been done on polycystin-1 (PC-1, Pkd1) and 
polycystin-2 (PC-2, Pkd2).
Polycystin-1 and polycystin-2
PC-1 is a large protein of 4302 amino acids; it contains 11 transmembrane 
domains, a short cytoplasmic tail and a large extracellular region (Hughes et al., 
1995). The extracellular part of the protein has homology to many recognised 
domains which are usually involved in protein-protein or protein-carbohydrate 
interactions. The large portion of the protein is a homolog to a group of sea- 
urchin proteins that are involved in sperm-egg interactions (Moy etal., 1996). 
The overall structure of PC-1 suggests that it is involved in cell-cell and/or cell- 
matrix interactions. The large extracellular region comprises a unique 
combination of potential adhesion and protein-protein interaction domains. The 
amino-terminus of PC-1 contains a leucine-rich repeat, a low-density- 
lipoprotein-A domain, a Receptor-for-Egg-Jelly domain and a calcium- 
dependent lectin domain (Hughes et al., 1995). The carboxy-terminus of PC-1 
contains several phosphorylation sites and a putative coiled-coil domain which 
interacts with the carboxy-terminus of PC-2 (Qian et al., 1997). Its features 
suggest that PC-1 is a large, multifunctional protein that is involved in 
carbohydrate motif recognition, ligand binding and Ca2+ regulation. PC-1 also 
interacts with a variety of other proteins, such as G proteins. The interaction 
with G protein may activate Gj/0-type proteins. This interaction is antagonised 
by PC-2 binding, indicating that the two proteins may compete for binding 
position (Delmas et al., 2002).
PC-2 is an ion channel of 968 amino acids. It is predicted to have cytoplasmic 
N- and C- termini and 6 transmembrane domains with a homology to voltage- 
activated calcium and sodium channels (Mochizuki et al., 1996). The 
transmembrane region is homologous to PC-1 and also to voltage activated 
and transient receptor potential channel subunits. There are strong suggestions 
from various studies that PC-2 is a calcium channel and that its action may 
partly be triggered by its interaction with PC-1 (Hanaoka et al., 2000).
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PC-1 and PC-2 have been shown to assemble at the plasma membrane to 
regulate Ca2+ entry (Hanaoka et al., 2000). It appears that PC-1 and PC-2 act 
together to regulate intracellular levels of calcium, where PC-1 acts as a 
receptor by binding to extracellular ligands which then in turn triggers the action 
of PC-2 (Harris, 2002; Nauli et al., 2003). One of the expression sites of these 
two proteins is on the primary cilia. Calcium influx is triggered by the bending of 
this organelle, a process that requires the functions of both PC-1 and PC-2 
(Nauli et al., 2003); see chapter 2.
The functions of PC-1 and PC-2 do not completely depend on each other. 
Immunohistochemistry shows that PC-1 and PC-2 are expressed in different 
locations in the kidneys and in different sub-cellular location (Foggensteiner et 
al., 2000). PC-1 is found highly expressed in human fetal kidney tissue in 
developing glomeruli, epithelia of ureter-derived structures and the comma and 
S-shaped bodies (Geng etal., 1996; Ward etal., 1996; Foggensteiner et al., 
2000). Whereas PC-2 is expressed in the primitive tubules later in gestation at 
week 30 compared to week 17 for PC-1 expression. PC-2 is not found in the 
comma and S-shaped bodies (Foggensteiner et al., 2000). In human adult 
kidney, colocolisation of the two proteins is only found in a subset of cortical 
tubules. PC-1 is more widely expressed than PC-2. PC-1 can be found in the 
Bowman’s capsules, proximal tubules and the collecting tubules. Whereas PC- 
2 is expressed in the medullary thick ascending limbs of the loop of Henle and 
cortical distal tubules where PC-1 is also expressed (Geng et al., 1996; 
Foggensteiner et al., 2000). Subcellularly, PC-2 is mainly expressed in the 
basolateral domain whereas PC-1 is predominantly found in the lateral location 
of the basolateral domain, overlapping with E-cadherin (Foggensteiner et al., 
2000). The differences in localisation of the two proteins suggest that they can 
function independently of each other.
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Calcium and PKD
Studies into the function of primary cilia suggest that calcium influx is impaired 
in PKD cells at least in vitro. Defects in either PC-1 or PC-2 in renal epithelial 
cells disrupt intracellular Ca2+ homeostasis or Ca2+signalling leading to cyst 
growth (Murcia et al., 1998; Gonzalez-Perrett et al., 2001; Nauli and Zhou, 
2004).
Primary culture of ARPKD cystic cells have a reduced intercellular Ca2+ level 
(Yamaguchi etal., 2006), indicating that fibrocystin may also be involved in 
regulating calcium concentration. All these point toward the importance of Ca2+ 
homeostasis in the initiation and/or the progression of cyst growth. But how 
does calcium level affect cyst growth in PKD epithelial cells but not in normal 
cells? The most convincing evidence came from studies on cAMP.
cAMP
Adenosine-3’,5’-cyclic monophosphate, commonly known as cAMP or cyclic 
AMP, is important in many biological processes. It is a second messenger used 
for intracellular signal transduction, for example transferring the effects of 
hormones such as glycagon and adrenaline, which cannot pass through the 
cell membrane. Its main purpose is the activation of protein kinases, though it is 
also used to regulate the passage of Ca2+ through ion channels. The 
concentration of cAMP depends on the rate of synthesis from ATP by 
adenylate cyclase and its rate of breakdown to cAMP by a specific 
phosphodiesterase, see figure 1.3 below.
Figure 1.3. Synthesis and breakdown of cAMP.
PPi H20
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cAMP is found to stimulate both fluid secretion and proliferation of cyst 
epithelial cells (Belibi et al., 2004; Yamaguchi et al., 2004). In vitro studies show 
that cAMP accelerates proliferation of PKD cells by stimulating the B- 
Raf/MEK/ERK pathway (Yamaguchi etal., 2006). In contrast, cAMP inhibits 
proliferation of normal human kidney (NHK) cells (Yamaguchi et al., 2006). One 
physiological difference between PKD cells and NHK cells is that the former 
(cells derived from either ADPKD or ARPKD) have a lower intracellular level of 
Ca2+ (Yamaguchi et al., 2006). Experimentally impairing Ca2+ concentration in 
NHK cells, using Ca2+ entry blockers, transformed the cells to take up the 
phenotype of PKD cells. These cells then respond to cAMP by stimulating 
proliferation, in the same way as PKD cells (Yamaguchi et al., 2004). 
Additionally, when Ca2+ levels are restored in PKD cells, the mitogenic 
response to cAMP is completely reversed (Yamaguchi et al., 2006). Thus, the 
response of epithelial cells to cAMP can be modulated by intracellular Ca2+ 
concentration.
Animal models for the study of ARPKD -  cpk mouse
Animal models are employed to study the development of PKD, these include 
genotypic animals (pck rat -  Pkhdl gene in human; pkdl and pkd2 mice -  
genotypic animals to the same genes, genetically engineered animals; inv 
mouse, genotypic model of Nephronophthisis type II), phenotypic animals {cpk, 
bpkjck, orpk mice) and chemically induced renal cystic disease using 
glucocorticoids.
Cpk (congenital polycystic kidney) mice were used in these studies. This model 
arises from a spontaneous mutation on the C57BL/6j background (Russell and 
McFarland, 1977). It is a good model for the study, although it is not a 
genotypic model, it exhibits very similar kidney pathology to the human ARPKD. 
In addition, it is genetically and phenotypically well characterised and can be 
easily genotyped by polymerase chain reaction; its rapid progression to end 
stage renal failure allows researchers to progress quickly. Dilated tubules first
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appear at approximately embryonic day 16 and are localised primarily in the 
proximal tubules. Cyst growth gradually changes to be derived predominantly 
from the collecting ducts. Affected animals usually reach end stage renal failure 
and death by 3 to 4 weeks of age. At this stage, the kidneys are massively 
enlarged, and can be seen distending at the back of the animal (Guay- 
Woodford, 2003). Histological examination shows that kidneys of 3 weeks old 
cpk mice were mostly filled with collecting duct cysts.
The cpk mouse does not exhibit liver lesions at least not on the C57BL/6j 
background. The study carried out in this thesis concentrated on kidney 
cystogenesis, therefore the lack of phenotype in the liver did not affect this 
study.
The cpk gene
The cpk locus maps to mouse chromosome 12 (Guay-Woodford, 2003); the 
human orthologue is located to chromosome 2p25.1 (Fliegauf et al., 2003). 
Although mutations in cpk mice causes severe cystic kidney disease, no cpk 
mutations have been detected in human using mutation analysis of eight 
families affected by humans cystic kidney disease through autosomal recessive 
transmission (Fliegauf et al., 2003). However, one can argue that analysis of 
only 8 families was not an extensive study given that we know there are many 
different mutations that cause mouse PKD. Protein sequence comparison of 
the human cystin (CYS1, 158 aa) and murine cystin (Cys1 145 aa) shows 57% 
identity and 64% similarity.
The mouse cpk gene is encoded by 5 exons spanning 14.4 kb of genomic 
DNA. The ATG start codon sits in exon I. The 435bp open reading frame 
extends into exon III; exon IV and V are untranslated. A putative cryptic splice 
site (gaacagCTG) within exon V appears to account for the 1,856bp and 
1,786bp splice variants (Hou et al., 2002). An atypical polyadenylation signal 
(ATTAAA) lies 22 nucleotides upstream of the poly-A tail. In cpk mice, PCR
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amplification and direct sequence analysis identified tandem 12bp and 19bp 
deletions in exon 1 of the cpk gene. The resulting frameshift truncates the 
predicted protein leading to a nonsense mutation of the protein, see figure 1.4 
for a schematic view of the mutant gene (Hou et al., 2002).
Characterisation of cpk mutations allowed accurate genotyping of each sample 
using specific primers that flanks the two tandem deletions (see fig 1.4). 
Polymerase Chain Reaction (PCR) is used to amplify the DNA fragment flanked 
by the primers and the genotype is determined by the size of the fragment: the 
mutant allele produces a smaller fragment - 320bp, whereas the wildtype allele 
gives a fragment of 351 bp. Heterozygotes, which do not develop cystic 
kidneys, would have one of each allele.
Figure 1.4. The organisation of cpk gene.
The five exons of cpk are shown at the top of the figure as boxes with 
roman numbers below them. Untranslated regions are in white, 
translated regions in black and the grey box represents the splice variant 
due to the cryptic splice site (gaacagCTG) within exon V. cpk mutation is 
caused by the two deletion (12bp and 19bp, in red) within exon I, just 
after the start codon (ATG, highlighted in red). The primers used for 
genotyping are shown as blue arrows. They sit within exon 1 and flank 
the two deletions. (Adapted from Hou et al 2002).
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Characterisation of cpk encoded protein, cystin
The cpk gene encodes a novel, hydrophilic protein, named cystin. Motif 
searches have identified two potential myristoylation sites (AA 2-7 and AA 43- 
48), the former is coupled to a polybasic domain (AA 12-16). A potential PEST 
-  polypeptide enriched in proline (P), glutamic acid (E), serine (S), and 
threonine (T) -  sequence is predicted at position 101-118 (Hou et al., 2002). 
Other identified domains include a cAMP phosphorylation site, several putative 
phosphorylation sites and a possible tyrosine sulfation site. There are no 
predicted N-glycosylation sites. The highly conserved middle portion of the 
protein and the C-terminal end do not share any predictable protein motifs. 
There is no evidence for specific DNA-binding motifs, but the protein is proline 
rich (10%) and is predicted to have at least two potential nuclear localisation 
signals (Hou et al., 2002; Fliegauf et al., 2003).
Protein expression studies of human fetal tissue using western immuno-blot 
analysis indicates that cystin is expressed in the kidney, but not in the liver, 
brain and lung. This result is consistent with the finding in mouse, where high 
cystin expression is detected in the kidney but not in the liver, brain and lung 
(Hou et al., 2002). Pancreatic expression of human cystin is also reported 
(Fliegauf et al., 2003). Subcellular localisation of cystin as analysed in mouse 
collecting duct cells shows that the protein is mainly expressed in the primary 
cilia, both at the basal body and the ciliary axoneme. In addition, the protein is 
found in the lipid raft compartment, after physical fractionation of kidney cells on 
a sucrose density gradient (Prof. Guay-Woodford, personal communication). 
The molecular function and biological processes of the protein are currently 
being investigated.
The N-terminal myristoylation site plays an important role in membrane 
targeting of the protein such as Rous sarcoma oncogene (c-SRC) and proto- 
ocogene protein c-Ki-ras, and its polybasic domain suggests that the cystin is 
associated with the plasma membrane and/or membranes of intracellular 
organelles (Hou et al., 2002; Resh, 2004). More importantly, mutation analysis
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of the myristoylation site in cystin retards the transport of cystin to the 
membrane (Yang et al., 2004). It is unknown how the protein is transported and 
anchored to the membrane but it may involve the lipid raft.
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C h a p t e r  2: P r im a r y  c il ia  a s s o c ia t io n  w it h  PKD
During my PhD study, an organelle called the primary cilium became the centre 
of attention for much research into PKD.
Primary cilia are cellular organelles expressed singly in most vertebrate cells 
except bone marrow-derived cells and the intercalated cells of the kidney 
collecting duct (Praetorius and Spring, 2005). Ciliary dysfunction is associated 
with the development of PKD (Ong and Wheatley, 2003; Pazour, 2004; 
Praetorius and Spring, 2005). Many proteins mutated in PKD are expressed in 
the primary cilia (Table 2.1 and Fig 2.1). Several studies have shown that 
structural or functional defects in the primary cilium results in development of 
tubular cysts (Lin et al., 2003; Ong and Wheatley, 2003; Nauli et al., 2003).
What is the primary cilium?
The primary cilium has a 9 + 0 axoneme, which refers to its nine peripherally 
located doublet microtubules and the absence of the central microtubule pair 
seen in motile cilia or 9 + 2 cilia (Praetorius and Spring, 2005).
The primary cilium is formed in many G1/G0 cells in culture and in vivo. It is 
often reabsorbed very late in the cell cycle as cells enter prophase prior to cell 
division (Wheatley et al., 1996). In proliferating cells, the cilium appears several 
hours after mitosis; in fibroblasts, it takes 2 to 4 hours after cell division for the 
cilium to be fully formed and in pig kidney epithelial cells, the cilium is only 
found during S phase (Alieva and Vorobjev, 2004).
The primary cilium is derived from the mother centriole, also known as the 
mature centriole (see fig 2.1). During cell differentiation, the centrosome 
migrates to the plasma membrane. The mother centriole is then attached to the 
plasma membranes at its distal end, a process which involves the appendages 
of the mother centriole (Ishikawa et al., 2005). The centrosome sits at the 
bottom of the cilium forming the basal body. Not all cultured cells develop
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primary cilia, those where the mature centrioles had no satellites and 
appendages (e.g. Chinese Hamster kidney cells) never develop the organelle 
even in the fully differentiated state (Alieva and Vorabjew 2004). This finding is 
further supported by investigations into the function of a protein called outer 
dense fibre 2 (Odf2, also known as cenexin). Odf2 is a scaffold protein that is 
specifically localised at the distal/subdistal appendages of mother centrioles 
and not in the daughter centrioles because the latter do not have the 
appendages. In vitro studies reveal that mutant cells with no functional Odf2 
lose their centriolar appendages. Although these cells are able to undertake the 
normal cell cycle, they have lost the ability to develop primary cilia. The loss of 
primary cilia in Odf2''' cells can be rescued by exogenous Odf2 administration. 
Odf deficiency appears to affect the docking of centrioles to membranes, which 
may explain the lack of primary cilia (Ishikawa et al., 2005).
The close relationship between the cilium and the centrosome leads to 
speculation that the cilium acts as a regulator of cell cycle (Quarmby and 
Parker, 2005). Though some cell lines that have gone through many passages 
do not express primary cilia, but they do divide, therefore primary cilia do not 
govern cell division completely. However one can argue that in their absence, 
the regulation of division rate may be disturbed (Wheatley et al., 1996).
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Table 2.1. Human PKD diseases and murine models of PKD and the
expression of mutated proteins in renal cilia.
Below are a list of diseases that result in polycystic kidney disease in 
human and a list of murine models of PKD. Most of the proteins are 
expressed on the renal cilia.
Human PKD Protein mutated Ciliary expression (Shaft or basal 
body)
ADPKD PC-1 Yes, shaft
ADPKD PC-2 Yes, shaft
ARPKD Fibrocystin Yes, shaft
*Nephronophthisis Nephrocystin Yes, shaft
*Bardet-Biedl
syndrome
BBS1-11 Yes, not all BBS proteins are identified to 
be located in the primary cilia, but the 
majority are found in the basal body.
Oral-Facial-Digital
syndrome
OFD1 Yes, basal body
Fraser syndrome FRAS-1, FREM- 
1, FREM-2
Not yet determined.
Tuberose
Sclerosis
Tuberin Not yet determined.
Von Hippel- 
Lindau
VHL Not yet determined. However, the 
expression of VHL correlates to 
ciliogenesis (Lutz and Burk, 2006).
Murine models Protein mutated Ciliary expression (Shaft or basal 
body)
Cpk Cystin Yes, Shaft
Bpk Bicaudal C Yes, not stated
Orpk Polaris Yes, Shaft
Inv Inversin Yes, Shaft
Jck Nek-8 Yes, Shaft
Kat Nek-1 Yes, Shaft
Pcy NPHP3** Not yet determined
Han:SPRD-cy SamCystin Not yet determined
Pck Fibrocystin Yes, Shaft
BCL-2 null BCL-2 Not yet determined
Congenital cystic Hepatocyte Not yet determined, although human
kidney disease nuclear factor -1 homologue of the mouse HNF-3 is
and diabetes beta (HNF-13) expressed in the cilia.
* Ciliary disfunction disorders (Fliegauf et al., 2006; Yen et al., 2006; Badano et 
al., 2006). ** Not confirmed (Olbrich et al., 2003).
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Figure 2.1. Diagrammatic illustration of selected PKD proteins 
express in the primary cilium.
Various PKD associated proteins are depicted, all of which when 
mutated lead to the development of kidney cysts. Ciliary microtubules 
(long grey bar inside the cilium) are derived from the mother centriole, 
which sits at the bottom of the cilia as basal bodies. Kinesin-2 and 
dyneinl B are motors that run along the ciliary axoneme in the direction 
shown. These motors are responsible for transporting intraflagellar 
transport (IFT) proteins up and down the cilia in order to assemble and 
maintain the cilium.
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The formation of primary cilia
The formation of the primary cilium has been observed in cultured cells using 
serial sectioning at different time points (Alieva and Vorobjev, 2004). At the end 
of mitosis, the centrosome migrates to near the apical surface of epithelial cells, 
which then engages with the membrane. The triplet microtubules from the distal 
end of the mother-centriole then extend to form the doublet microtubules of the 
primary cilium. The next step is the elongation of the axoneme that requires 
growth of the membrane vesicle. Later on the membrane vesicles surrounding 
axoneme fuses with the plasma membrane and the primary cilium comes to the 
cell surface.
The primary cilium is assembled and maintained by a process called 
intraflagellar transport (IFT) (Pazour et al., 2000; Lin et al., 2003). IFT is a bi­
directional movement of non-membrane bound proteins along the doublet 
microtubules of the ciliary axoneme, between the axoneme and the plasma 
membrane. The movement of IFT proteins is carried out by two different 
motors, the anterograde kinesin-2, which travels towards the tip of the cilia; and 
the retrograde dyneinl B which travels towards the cell body. There is a 
constant turnover of proteins within the axoneme, therefore the IFT is important 
for the maintenance of the cilia.
In the orpk mouse model, a hypomorphic mutation of an IFT protein, Tg737 
(encodes for polaris, a homolog to Chlamydomonas IFT88) blocks ciliary 
assembly and leads to the development of PKD as well as other organ defects 
such as liver biliary duct hyperplasia and dysplasia and pancreatic cysts; all 
three organs contain duct lined with ciliated epithelium. Work on IFT proteins in 
other organisms (Chlamydomonas, Caenorhabditis, Tetrahymena, sea urchins) 
all shows that disruption of the expression of IFT proteins: IFT172, kinesin-2 or 
dyneinl B, block ciliary assembly (Pazour, 2004). Mutations in the IFT88 and 
IFT 172 leads to phenotypic changes similar to those when hedgehog signalling
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is defective, suggesting that IFT88 and IFT172 are part of the signalling 
pathway (Huangfu et al., 2003).
Structural or functional defects in the renal cilium lead to PKD
Studies have shown that structural defects of the primary cilium are associated 
with the development of cyst in kidneys. Inhibition of renal ciliogenesis leads to 
the development of cysts in kidneys (Lin et al., 2003; Yoder et al., 2002b). 
Tissue-specific inactivation of KIF3A, a subunit of kinesin-ll that is essential for 
cilia formation, in renal tubular epithelial cells results in viable offspring with 
normal-appearing kidneys at birth, but with renal cysts appearing at postnatal 
day 5 and renal failure by postnatal day 21 (Lin et al., 2003).
The earliest observed phenotype in orpk mutant embryos is the loss of cilia 
expression on ventral node cells leading to malformation of neural tubes 
(Murcia et al. 2000). Other phenotypes include polydactyly (containing more 
than the normal number of digits on the hands and/or feet), hydrocephalus (an 
accumulation of cerebrospinal fluid in the ventricles of the brain), abnomalities 
in the photoreceptor rod cell outer segment and retinal degeneration, 
hypogonadism (smaller than normal testis), male sterility and left-right 
asymmetry defects (Murcia et al., 2000; Taulman et al., 2001; Yoder et al., 
2002b; Zang et al., 2003). Motile cilia in the trachea appear normal when 
examined under transmission or scanning electron microscopy in these mutant 
mice. In vivo analysis of renal ciliary structure showed the majority of cystic 
cells in orpk mice either lack the expression of primary cilium or express a 
shortened cilium (Pazour etal., 2000; Brown and Murcia, 2003).
Functional defects of the primary cilium are linked to cystogenesis. Many 
proteins responsible for causing PKD when mutated are expressed on the 
primary cilium; PC-1, PC-2, fibrocystin, OFD, nephrocystin, BBS and cystin. 
They may act as channels or receptors on the cilium and that defects in ciliary 
signalling pathway are important to the cause of the disease.
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Bending of the primary cilium leads to calcium influx
Cytoplasmic calcium concentration modulates various cellular functions, such 
as gene expression, metabolism, proliferation, secretion, neural excitation and 
fertilisation (Gomes et al., 2006). It is certain that calcium influx is important to 
the primary cilia in regulating the normal functions of the kidney epithelial cell 
and how it leads to cystogenesis. Recent work has shown that disruption of 
calcium influx plays a big role in the development of renal cysts.
Several studies reveal that the cilium is involved in the initiation of calcium 
influx in response to fluid flow (Praetorius and Spring, 2001; Nauli et al., 2003; 
Shiba et al., 2005; Liu et al., 2005). In vitro experiments using Madine Darby 
Canine Kidney cells, MDCK, show that primary cilia develop in confluent 
monolayer culture. Experiments by Praetorius and Spring (2001) showed that 
by physically bending the cilium, either by suction with a micropipette or by 
increasing the flow rate of perfusate, causes an increase in intracellular calcium 
concentration. They further demonstrate that the calcium increase in one cell 
can spread to adjacent cells by diffusion of a second messenger through gap 
junctions. Removal of extracellular calcium after the initial response does not 
significantly alter the magnitude or time course of the increase and spread to 
adjacent cells. This shows that the widespread calcium influx is caused by the 
release from intracellular storage of the ion (Praetorius and Spring, 2001). This 
study suggests that at least in MDCK cells, the primary cilium is mechanically 
sensitive and responds to flow by greatly increasing intracellular calcium, 
although it does not address the mechanism behind the initial calcium influx nor 
suggest how ciliary dysfunction results in cyst formation.
Further studies on the mechanosensation in the cilium have been carried out in 
cell lines with disruption in the functions of PC-1 and PC-2. Using these in vitro 
models, Nauli et al (2003) assessed the function of PC-1 and PC-2 in response 
to fluid flow in mouse embryonic kidney epithelial cells. Wild-type cells respond
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to fluid shear stimulation with an increase in intracellular calcium throughout the 
cell population. Compared to experiments in MDCK cells (Praetorius and 
Spring, 2001), these embryonic kidney epithelial cells give the same calcium 
influx response but quicker. Cells with mutations in PC-1 do not activate flow- 
induced Ca2+ signalling. Various antibodies directed against extracellular 
domains of PC-1 and PC-2 block the calcium influx response of wild-type cells 
to flow stimulation. In addition, using medium depleted of Ca2+, Nauli et al 
proved that Ca2+ entry is required to initiate flow-induced Ca2+ signalling and 
that PC-1 and PC-2 play an important role in initiating Ca2+ entry through the 
primary cilia, presumably through the PC-2, which is an ion channel (Nauli et 
al., 2003). Furthermore, isolated renal tubules in Tg737 mutants, which express 
a reduced number and size of primary cilia, display blunted increases in 
intracellular Ca2+ concentration in response to fluid stress compared to normal 
tubules (Liu et al., 2005).
By contrast, inv (encodes for inversin, which is found at the base of primary 
cilia) mutant epithelial cells respond to fluid flow by inducing Ca2+ influx at the 
same rate compared to normal cells, inv mutant mice also produce cystic 
kidneys (Shiba et al., 2005). This suggests that not all PKD mutations disrupt 
Ca2+ influx in response to flow. Experiments in zebrafish show that Inversin is 
involved in the Wnt-p-caterin signalling pathway (Simons et al. 2005). It acts as 
a molecular switch between different Wnt signalling cascades by inhibiting the 
canonical Wnt pathway by targeting cytoplasmic dishevelled for degradation 
(Simons et al. 2005). It is unclear whether the functions of inversin take place in 
the primary cilium but further experiments in zebrafish link primary cilia to Wnt 
signalling (Oishi et al., 2006). Knockdown of dub in zebrafish enbryos results in 
defects in primary cilia. The function of dub is regulated by phosphorylation, 
which in turn depends on Frizzled-2-mediated non-canonical Wnt signalling.
PC-1 has a number of large extracellular putative binding domains that may act 
as mechanosensors. If that is the case, these domains must be rigid enough to 
withstand the physiological force of bending. Hence, the domains must be able
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to resist unfolding when placed under mechanical forces. Atomic force 
microscopy (AFM) can be used to measure the mechanical properties of 
proteins. It has been used to assess the stability of PC-1 under mechanical 
stress. The experiment concluded that the first four extracellular domains of 
PC-1 were exceptionally stable, similar to that of immunoglobulin domains in 
the giant muscle protein titin. The results suggest that these domains in PC-1 
will remain folded under external force (Forman et al., 2005), supporting the 
hypothesis that PC-1 in the primary cilia acts as a mechanosensor and 
transfers the physical force to a signal that induces calcium entry through the 
opening of PC-2.
Nodal cilia
Loss of left-right axis determination (or situs inversus) are found in several 
forms of cystic diseases and animal models, e.g. inv mutant, Tg737 (orpk) 
mutant and pkd2 mutant (Pennekamp et al., 2002; Morgan et al., 2002; Brown 
and Murcia, 2003); as well as in human PKD: Bardet-Biedl syndrome, 
Nephronophthisis type 2 (Otto et al., 2003; Ansley et al., 2003). The association 
between PKD and defects in left-right determination prompted studies on the 
nodal cilium, which is structurally very similar to the renal primary cilium. Nodal 
cilium is a motile form of the 9 + 0 cilium. It does not beat from side to side as 
does the 9 + 2 cilium, but exhibits a characteristic twirling movement that 
generates the nodal flow which is crucial for the development of left-right 
symmetry in the developing embryo (Nonaka et al., 1998). Mutation in KIF3B 
disrupts the formation of nodal cilia; mutation in inv leads to a weaker twirling 
movement of the nodal cilia thus insufficient nodal flow; or mutation in Pkd2, all 
result in defects in left-right axis determination (Nonaka et al., 1998; Okada et 
al., 1999; Pennekamp et al., 2002). These findings support the link between 
PKD and situs inversus through the functions of cilia.
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C h a p t e r  3: T he  g a le c tin  f a m il y
Galectins are involved in many important biological functions: such as cancer, 
immunity, and organogenesis. With regard to this study, several galectins (-1, - 
3 and -9) are implicated in kidney development. Studies of galectin-3 in renal 
cyst development were initiated by work on kidney collecting ducts cells,
MDCK. Addition of exogenous galectin-3 suppresses the growth of MDCK cysts 
in 3D collagen culture, an in vitro cytogenesis model (Bao and Hughes, 1995). 
Galectin-3 is expressed during human nephrogenesis and childhood cystic 
diseases (Winyard etal., 1997). Details of galectin-3 and its role in 
cystogenesis can be found in chapters 4 and 5. In this chapter, brief summaries 
of all mammalian galectins are described.
The galectin family is part of a super-family of proteins called lectins. By 
definition, lectins are protein or glycoprotein substances of non-immunoglobulin 
nature, capable of specific recognition of and reversible binding to carbohydrate 
moieties of complex glycoconjugates, without altering the covalent structure of 
any of the recognised glycosyl ligands. Some antibodies and enzymes also 
bind to carbohydrates, however they are not considered to be lectins.
Specific interactions between carbohydrate moieties and lectins play a critical 
role in various developmental, physiological, and pathological processes. 
Mammalian lectins are classified into five major categories: C-type lectins, I- 
type lectins, P-type lectins (mannose-binding lectins), pentraxins, and galectins 
(also called S-Type lectins): see figure 3.1 for summary. They are classified 
based on their saccharide-specificity and consensus sequence.
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Table 3.1. Summary of the five types of lectin.
The five different types of lectin each with different defining features in 
protein sequence, calcium dependency and their specific carbohydrate 
recognition.
Lectin Defining features in Calcium Carbohydrate
groups protein sequence dependence recognition
C-type
Consensus sequence in 
CRD*
Yes (most) Variable
I-type Immunoglobulin-like domains No Sialic Acids
P-type Unique repeating motif Variable
Mannose-6-
Phosphate
Pentraxins Multimeric binding motifs Yes (most) Variable
Galectins Consensus sequence in
CRD* and binding affinity to No p-Galactosides
p-Galactosides
* CRD = carbohydrate-recognition domain
Characteristics of galectins
The galectin family was formally identified in 1994. It was initially defined by 
their calcium independent binding affinity for p-Galactosides and by conserved 
sequence elements in the carbohydrate recognition domain, CRD (Barondes et 
al., 1994). The sequence of each CRD has been shown to be mainly encoded 
by 3 exons. Most of the conserved residues are found in the sequence 
encoded by the middle one of these three exons. This sequence includes four 
adjacent p-strands and intervening loops in the structure. All residues that 
interact directly with a carbohydrate ligand are conserved among galectins. The 
importance of some of these residues for carbohydrate binding activity is 
supported by site-directed mutagenesis (Barondes et al., 1994).
Another shared feature between the galectins is that although they are found in 
the cytoplasm and in the extracellular domain, none of them have a known
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secretion signal peptide. Hughes and his colleagues have shown however that 
some galectins can be secreted through a novel mechanism in transfected 
baby hamster kidney (BHK) cells overexpressing galectin-3; 
immunofluorescence visualisation showed galectin-3 positive vesicles blebbing 
from the cell surface (Hughes, 1999). This suggests that the proteins may be 
secreted through a non-classical vesicle based mechanism.
To date, there are 15 mammalian galectins, named numerically from galectin-1 
to -15. Galectins are also found in many non-mammalian species including 
birds, amphibians, insects, worms, sponges, fungi and possibly in plants and 
viruses (Cooper and Barondes, 1999; Gray et al., 2004; Chiariotti et al., 2004).
Galectins are classified into three groups, based on the content and 
organisation of the domains. The majority of galectins belong to the prototype, 
group containing galectin-1, -2, -5, -7, -10, -11, -13, -14, -15 and three of the 6 
isoforms of galectin-8. These galectins contain only one CRD and their 
molecular weights are approximately 14kDa. The second group is the tandem 
repeat galectins, which includes galectin-4, -6, -8, -9 and -12. They contain two 
CRDs within a single polypeptide chain, with molecular weight of around 
36kDa. The third group is the chimera galectin; there is only one galectin in this 
group: galectin-3. It contains one CRD, a N-terminal domain and an intervening 
proline-, glycine- and tyrosine-rich repeating domain of roughly 100 residues. 
The latter domain varies between species in the number of repeats; 8 in 
human, 11 in rat and 14 in dog, giving rise to various sizes of galectin-3 from 
29kDa in murine to 30.3kDa in dog (Herrmann et al., 1993; Bidon-Wagner and 
Le Pennec, 2004).
Galectins and kidney
Galectin-1, -2, -3, -7, -8, -9 and the two avian galectins has been found to be 
expressed in the kidneys (Hadari et al., 1995; Saussez et al., 2006; Stierstorfer 
etal., 2000; Wada et al., 1997; Wasano etal., 1990; Winyard et al., 1997).
50
Although their expression pattern during nephrogenesis and in mature kidneys 
vary from each other. The most studied galectins in the kidneys are galectin-1, 
galectin-3 and galectin-9, perhaps due to their strict regulation during 
development.
Galectin-1 is most widely expressed in mesodermally-derived cells during 
mouse embryogenesis, including the kidney (Poirier et al., 1992). In the kidney, 
these cells form the mesodermal mesenchyme which gives rise to the non- 
tubular epithelia. As the kidney develops, the expression of galectin-1 is down- 
regulated (Wasno etal., 1990).
The expression of galectin-3 in the kidney is also developmentally regulated. It 
is most widely expressed in the derivative of the ureteric bud in human 
(Winyard etal., 1997) and in mouse (Bullock etal., 2001). Similar to galectin-1, 
the expression of galectin-3 is developmentaly regulated and it is down- 
regulated in adult kidney although expression can be found in the collecting 
tubules (Winyard etal., 1997; Hikita etal., 1999). A detailed description of the 
role of galectin-3 in the kidney can be found later in Chapter 5.
In the kidney, galectin-9 functions as a sugar-regulated urate 
channel/transporter (Lipkowitz et al., 2004), expressed mainly in the apical 
domain of proximal tubules and in collecting tubules of the cortex, with a lower 
level of expression in the medulla. In mice, galectin-9 expression is 
developmentally regulated. It is expressed at a low level beginning at E12, 
increased through embryonic development and postnatally, and reaches high 
and constant levels in the adult kidney (Hughes, 2004).
Galectin-2 mRNA is expressed in adult rat kidneys, although its expression is at 
least 6 times lower than in stomach and intestine. Galectin-7 is found in 
hamster kidney. It is expressed in the Bowman’s capsule, perivascular tissue 
around arcuate artery and vein and extracellular matrix of the outer and inner 
stripes of the outer medulla (Saussez et al., 2006). Galectin-8 mRNA is found in
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adult rat kidney (Hadari et al., 1995). The expression of galectin-2, -7 and -8 
has only been reported in mature kidneys, therefore it is unknown whether their 
expressions in the kidney is developmentally regulated.
Expression studies of the two galectins in chicken kidneys have been carried 
out using histochemical analysis and electron microscopy. The two avian 
galectins, CG-14 and CG-16, are expressed in the epithelial cells of the 
mesonephric proximal tubules and of the metanephric collecting ducts. In 
addition, CG-16 is detected in early glomerular podocytes. CG-14 exhibits a 
diffuse cytoplasmic expression whereas CG-16 is mainly observed in 
mitochondria (Stierstorfer et al., 2000).
Individual summary of each galectin
In this section, the expression and known functions of all 15 mammalian 
galectins are described as well as two avian galectins. A detailed description of 
galectin-3 can be found in chapter 4.
The following table gives a summary of the expression sites of all mammalian 
galectins as well as the two avian galectins.
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Table 3.2. Summary of expression sites of all known mammalian 
and avian galectins.
Galectins are widely expressed in many different part of the body. Some 
members are expressed in the same organ, and some even in the same 
cell type; hence, overlapping expression of two different galectins is 
possible.
Galectin Structural type Major expression site
1 Prototype Smooth muscle, skeletal muscle, nerves tissues 
and kidneys
2 Prototype Epithelial cells of gastrointestinal tract (also a 
low level in kidneys)
3 Chimera Notochord; developing bone, skin and kidney; 
macrophages
4 Tandem repeat Epithelial cells of gastrointestinal tract
5 Prototype Erythrocytes
6 Tandem repeat Epithelial cells of gastrointestinal tract
7 Prototype Skin and mature kidney
8 Prototype/ 
Tandem repeat
Highly expressed in lung and to lesser extend in 
liver, kidney, spleen, hind-limb and cardiac 
muscle
9 Tandem repeat Kidney; also detected in liver, heart, brain and 
lung
10 Prototype Eosinophilic and basophilic leukocytes
11 Prototype Ovine stomach
12 Tandem repeat Adipose tissue
13 Prototype Placenta
14 Prototype Eosinophils
15 Prototype Ovine uterus
CG-14 Prototype Avian galectin. Intestine, also found in kidney
CG-16 Prototype Avian galectin. Liver, also found in kidney
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Galectin-1
There may be at least 3 variants of galectin-1 in human tissues. It is found 
abundantly in smooth muscle, skeletal muscle, and the nervous tissues and 
less abundantly in many other tissues including the kidneys. This galectin is 
synthesized on free ribosomes. Amino acid sequence analysis reveals that the 
N-terminal of this polypeptide is acetylated. Both these pieces of evidence 
suggest that galectin-1 is a cytosolic protein. Indeed, immunofluorescence 
staining shows that the galectin-1 is found predominantly in the cytoplasm, with 
a diffuse distribution (Liu et al., 2002). Nuclear localisation was not found in 
mouse C2 myoblasts and in Chinese hamster ovary cells. However, 
immunofluorescence of cryostat sections of adult chicken kidney and calf 
pancreas show that galectin-1 is located in both nuclei and cytoplasm (Liu et 
al., 2002). The functions of galectin-1 include modulation of cell-matrix 
interactions and in regulating apoptosis (Horiguchi et al., 2003). Both galectin-1 
and galectin-3 are found in the nuclear extracts (NE), which is capable of 
carrying out pre-mRNA splicing. NE depleted of these two galectins 
concomitantly lose their splicing activity, suggesting that these galectins 
function as redundant splicing factors in the nucleus (Patterson et al., 2004).
Galectin-2
Human galectin-2 was first isolated in HepG2 hepatoma cells (Gitt et al., 1992). 
Studies of galectin-2 using Northern and Western blot analysis in various rat 
tissues indicate that this galectin is highly expressed in the stomach and 
intestine. A significantly reduced expression is found in the kidney, less than 
1/6 of that of stomach (Oka et al., 1999). RT-PCR/immunohistochemistry 
examination of human tissue revealed that this galectin is expressed in most 
epithelial cells of various organs, with overlapping expression with galectin-1 
and -7 in certain organs. Expression is observed in cytoplasm and nucleus 
(Saal et al., 2005). In vitro studies found that galectin-2 can induce apoptosis in 
activated T-cells (Sturm et al., 2004).
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Galectin-3
Galectin-3 is one of the most extensively studied galectins. The expression 
pattern of galectin-3 has been examined in the developing mouse embryo by in 
situ hybridisation and immunohistochemistry. The lectin is first detected in 
notochord and later found in developing bone and skin in mouse embryo 
(Fowlis et al., 1995). In adults, it is normally expressed in activated 
macrophages and gut epithelia and the epithelial cells of the collecting ducts in 
kidneys. Their functions include the regulation of cell-matrix interaction, 
proliferation, pre-mRNA splicing and inflammation. It is also implicated in the 
development of several cancers. A complete review of galectin-3 will be given 
in Chapter 4.
Galectin-4
Galectin-4 expression has been examined using in situ hybridisation. In both 
mouse embryos and adults, the expression of galectin-4 is found only in the 
epithelial cells of the gastrointestinal tract. The lectin is expressed at about 
equal levels in colon and small intestine but much less in stomach (Gitt et al., 
1998). Galectin-4 is very closely related to galectin-6, which exhibits a very 
similar expression pattern.
Studies on lipid rafts (glycosphingolipid/ cholesterol-enriched membrane 
microdomains) in intestinal epithelia reveal galectin-4 to be enriched in these 
compartments of the cell membrane. Lipid rafts are commonly defined as 
membrane complexes insoluble in non-ionic detergents. They are rich in 
glycospingolipids, which contain a high degree of acyl chains that raise the 
melting temperature of the lipid, resulting in a more stablised and ordered lipid 
phase (Brown and London, 1998). Their discoveries have changed the 
perception of the role of membrane lipids, which have been promoted from a 
passive barrier function to molecular players of equal importance to proteins. 
There are several types of lipid rafts, identified by their solubility in different 
detergents at variable temperature. Their functions include signal transduction,
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pathogen invasion, drug targeting and cholesterol transport (Danielsen and 
Hansen, 2003).
Galectin-4 is the most prominent protein in a type of intestinal microvillar rafts 
called superafts. It appears that galectin-4 acts as a stabiliser/organiser for 
other more loosely raft-associated proteins. Its affinity towards p-galactosyl 
residues and its ability to form lattices results in a “gluing” effect which keeps 
the glycolipids and glycoproteins in place (Braccia et al., 2003). One suggested 
function of galectin-4 is to salvage the digestive enzymes at the brush border 
that would otherwise have been lost to the gut lumen by the proteolytic/ lipolytic 
actions of the pancreatic secretions during the digestive process (Danielsen 
and van Deurs, 1997; Danielsen and Hansen, 2003).
Galectin-5
Galectin-5 was first isolated in extracts of rat tissues. Further analysis revealed 
that the galectin was localised in the erythrocytes, and the cDNA sequence has 
been isolated from a rat reticulocyte cDNA library. Galectin-5 is a weak 
agglutinin of rat erythrocytes in comparison with galectin-1 and -3 (Gitt et al., 
1995). This galectin is also reported in the bone marrow (Lensch et al., 2006).
Galectin-6
Galectin-6 was isolated while studying mouse colon mRNA for galectin-4. 
Compared with galectin-4, galectin-6 lacks the 24-amino acid stretch in the link 
region between the two CRDs. Otherwise, these two galectins have 83% amino 
acid identity. The expression of galectin-6 is very similar to that of galectin-4: 
both of them are confined to the epithelial cells of the embryonic and adult 
gastrointestinal tract. Unlike galectin-4, which has a reduced expressed in 
stomach, galectin-6 is expressed at about equal levels throughout the 
gastrointestinal tract. The two genes are clustered on proximal mouse 
chromosome 7, the syntenic human region is 19q13.1-13.3 (Gitt et al., 1998).
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Galectin-7
Galectin-7 is a keratinocyte protein. It is excreted in the medium by 
differentiated keratinocytes although it does not contain a known secretion 
peptide signal. Localisation studies using mouse tissue reveal that galectin-7 is 
mostly expressed in skin (both fetal and adult) and can also be detected in 
oesophagus, stomach, anus and tongue (Sato et al., 2002). The production of 
this galectin coincides with the degree of stratification of the epithelia (Timmons 
et al., 1999). In fact, galectin-7 is reported to be a marker of all types of 
stratified epithelia (Magnaldo etal., 1998).
The suggested functions of galectin-7 include regulation of cell-cell and/or cell- 
matrix interactions, regulation of apoptosis and corneal epithelial cell migration 
in response to damage. Galectin-7 is remarkably down regulated in SV40 
transformed K14 keratinocytes that are anchorage independent and unable to 
differentiate. These cells lack strong adhesion to the surrounding cells, they 
attach and detach with ease from other cells as they move. This evidence 
together with the localisation of galectin-7 in areas of cell-to-cell contact, 
suggests that galectin-7 may be involved in the regulation of cell-cell interaction 
(Madsen et al., 1995). Studies on transfectants of HeLa and DLD-1 cells found 
that cells ectopically expressing galectin-7 are more susceptible to apoptosis 
than control transfectants. Further analyses demonstrate that galectin-7 
functions intracellularly upstream of c-Jun N-terminal kinases activation and 
mitochondrial cytochrome c release (Kuwabara et al., 2002). In vivo 
assessment of the role of galectin-7 in re-epithelialisation of corneal wounds 
reveals that expression of its mRNA and protein is markedly up-regulated in the 
corneal epithelium after injury. In vitro studies show that exogenous galectin-7 
stimulates re-epithelialisation of corneal wounds (Cao et al., 2003).
Assessment of hamster adult kidneys using immunohistochemistry shows that 
galectin-7 is expressed in the Bowman’s capsule and in perivascular tissue 
surrounding the arcuate artery and vein (Saussez et al., 2006).
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Galectin-8
Galectin- 8  was first cloned from a rat liver cDNA expression library. Northern 
blot analysis using mRNA extracted from rat tissues reveals that galectin- 8  is 
widely expressed. It is highly expressed in lung; and in lower level in liver, 
kidney, cardiac muscle, hind-limb and brain. There are six isoforms of galectin- 
8 ; three of which contains 2 CRDs, whereas the other three contain only 1 CRD 
(Hadari et al., 1995). Adhesion studies of different cell types cultured in serum- 
free medium on immobilised galectin- 8  suggest that it is a physiological 
modulator of cell adhesion. At maximum dosage, the galectin is equipotent to 
fibronectin in promoting cell adhesion and spreading. Truncation of one of the 
CRDs abolishes its ability to modulate cell adhesion; therefore, both CRDs are 
essential for the adhesion property of galectin-8 . In constrast, excess soluble 
galectin- 8  (like fibronectin) forms a complex with integrins that negatively 
regulate cell adhesion (Levy et al., 2001). Various studies show that galectin- 8  
is widely expressed in tumour tissues. Its level of expression may correlate with 
the malignancy of human colon cancer and the degree of differentiation of lung 
sequamous cell carcinomas and neuro-endocrine tumours (Bidon-Wagner and 
Le Pennec, 2004).
Galectin-9
The biological functions and expression of galectin-9 have been investigated in 
embryonic, newborn and adult mice tissues. Northern blot analyses illustrate 
that this galectin is widely distributed and its expression is developmentally 
regulated. The transcript is seen in various fetal tissues (i.e. heart, brain, lung, 
liver and kidney) and its expression increases with successive stages of 
embryonic development extending into the postnatal period. In adult tissue, the 
transcript is highly expressed in thymus, small intestine and liver, and to a 
lesser extent in lung, kidney, spleen, cardiac and skeletal muscle. Galectin-9 
induces apoptosis in T cell lines and thymocytes but not hepatocytes (Wada et 
al., 1997; Kashio et al., 2003). The galectin may induce apoptosis via the 
Ca(2+)-calpain-caspase-1 pathway at least in CD4(+) and CD8 (+) T cells and it
58
may play a role in immunomodulation of T cell-mediated immune responses 
(Kashio et al., 2003).
In situ hybridisation has been performed on sections of adult kidney. Galectin-9 
mRNA expression is seen in glomerular and tubular cells of the renal cortex, 
whereas its expression in the renal medullary tubules is low (Wada et al.,
1997). Galectin-9 is a urate channel/ transporter and it plays an important role 
in renal and gastrointestinal urate excretion (Leal-Pinto et al., 1997). Glucose 
significantly increases the opening of the urate channel but only when it is 
added to the extracellular face, suggesting a role for extracellular glucose in 
regulating the channel activity (Leal-Pinto et al., 2002).
Galectin-10
Galectin-10, also known as Charcot-Leyden crystal protein, is expressed 
uniquely in eosinopilic and basophilic leukocytes (Dyer and Rosenberg, 2001). 
A study carried out an assessment of the expression of various galectins in 
myeloid cell differentiation. It demonstrates that galectin-10 mRNA expression 
is increased during eosinophilic and neutrophilic differentiation. It has been 
proposed that the changes in galectin- 1 0  expression together with changes in 
galectin-3 and -9 expression are important in myeloid cell differentiation into 
specific lineages (Abedin et al., 2003).
Galectin-11
Galectin-11 was isolated in sheep stomach tissue infected with the nematode 
parasite, Haemonchus contortus (Dunphy et al., 2000). The mRNA is greatly 
up-regulated in helminth larval infected gastrointestinal tissue subject to 
inflammation and eosinophil infiltration. Immunohistochemistry reveals that the 
protein is expressed in the cytoplasm and nucleus of upper epithelial cells of 
the gastrointestinal tract. The protein is also detected in mucus samples 
collected from abomasum of infected sheep; the abomasum is the fourth and 
last stomach that is most similar to the monogastric stomach. These results
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imply that galectin- 1 1 may be involved in gastrointestinal immune/inflammatory 
responses (Dunphy et al., 2000).
Galectin-12
Galectin-12 was identified separately by two different groups simultaneously 
(Hotta et al., 2001; Yang et al., 2001). The first group isolated the galectin from 
EST clones from a G1 phase Jurkat T-cells V cDNA. Cell cycle synchronisation 
of Jurkat cells revealed that galectin-12 is up-regulated in cells synchronised at 
the G(1) phase or the G(1)/S boundary of the cell cycle. Ectopic expression of 
galectin-12 in cancer cells causes cell cycle arrest at the G(1) phase and cell 
growth suppression. These results suggest that galectin-12 is a novel regulator 
of cellular homeostasis (Yang et al., 2001).
Another group successfully identified galectin-12 in a human adipose tissue 
cDNA library. Galectin-12 mRNA is predominantly expressed in adipose tissue 
of human and mouse and in differentiated 3T3-L1 adipocytes. 
Immunocytochemistry revealed a nuclear localisation of the galectin in 
adipocytes. Like some other galectins, galectin-12 is present in the cytoplasm 
in a dotted pattern. Ultracentrifugation-fractionation studies demonstrate that 
this galectin is detected in the nuclear and mitochondrial fraction but not in the 
cytosolic fraction (Hotta et al., 2001). Immunoblot analysis fails to show the 
presence of the protein in the culture media of 3T3-L1 adipocytes therefore this 
galectin may not be secreted. Transfection with galectin-12 cDNA induces 
apoptosis of cos- 1  cells, suggesting that galectin- 1 2  may participate in the 
regulation of the cell cycle, possibly by inducing apoptosis (Hotta et al., 2001).
Lastly, studies on the involvement of galectin-12 in the development of insulin 
resistance using 3T3-L1 cells illustrate that the galectin is down-regulated by 
various insulin resistance-inducing hormones. Thus suggests a role of galectin- 
12 in the pathogenesis of insulin resistance (Fasshauer et al., 2002).
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Galectin-13
Galectin-13 was first isolated from human placental tissue (Bohn et al., 1983) 
Almost two decades later, this protein was demonstrated in human fetal tissue, 
predominantly expressed in placenta, cos-7 cells transfected with the cDNA of 
galectin-13 sequester the protein in nuclei (Yang etal., 2002). Using affinity 
chromatography, PAGE, MALDI-TOF mass spectrometry and post source 
decay, annexin II and (3/y actin have been identified as proteins specifically 
bound to galectin-13 in the placenta and fetal hepatic cells. 
Immunocytochemistry of syncytiotrophoblasts, outer layer of trophoblasts that 
actively invade the uterine wall, reveals galectin-13 expression in the 
perinuclear and in the membrane of brush border, which implies the secretion 
of the protein to the outer cell surface, possibly by ectocytosis in microvesicles 
containing actin and annexin II (Than etal., 2004).
Galectin-14
Galectin-14 was first cloned from ovine eosinophil-rich leukocytes. It is most 
closely related to galectin-9, a potent eosinophil chemoattractant. Northern blot 
and western blot analyses indicate that galectin-14 is mostly expressed in 
eosinophil and not in other leukocytes. Flow cytometry and cytospot staining 
demonstrate that the protein localises to the cytoplasm of eosinophils. Western 
blot analysis of bronchoalveolar lavage fluid reveals that upon challenge with 
house dust mite allergen, galectin-14 is released from eosinophils into the 
lumen of the lungs. Galectin-14 may play an important role in eosinophil 
function and allergic inflammation (Dunphy et al., 2002).
Galectin-15
Galectin-15 is a 14kDa lectin that contains a separate putative integrin binding 
domain. It is found in sheep uterus (Gray et al., 2005) and has been proposed 
to function extracellularly to mediate implantation of blastocysts and 
intracellularly to regulate trophectoderm (the outer cell layer of the blastocyst). 
In addition the galectin is found in gastrointestinal tissue and secreted into the
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intestinal lumen in response to inflammation and eosinophil infiltration after 
infection. Galectin-15 is most similar to human galectin-10 and human galectin- 
13 (Gray et al., 2004).
Avian galectin-14 and galectin-16
Two avian galectins have been found, chicken galectin-14 (CG-14) and chicken 
galectin-16 (CG-16). They are mainly found in the intestine and the liver 
respectively and they are both expressed in the kidney (Stierstorfer et al.,
2000). Similar to mammalian galectins, their expression is developmentally 
regulated. The numbers given to the name of these galectins apply to the size 
of the protein: CG-14 is 14kDa and CG-16 is 16kDa. Therefore they do not 
imply correlation with mammalian galectins. Comparison of the primary 
structures of the avian galectins to vertebrate ones suggests that CG-14 and 
CG-16 are produced by gene duplication of an ancestral lectin gene at a time 
close to the divergence of birds and mammals (Sakakura et al., 1990). The 
nearest equivalent of CG16 is mammalian galectin-1 (Hughes, 2004).
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C h a p t e r  4: G a l e c t in -3
Galectin-3 is the most studied galectin due to its wide expression and 
particularly its role in cancer progression. Its involvement in kidney 
development and cystogenesis lead us to its investigation here. During 
development the lectin was first detected in notochord and was later found in 
developing kidneys, bone and skin. In adults, it is normally expressed in 
activated macrophages, gut epithelia and the epithelial cells of collecting ducts 
in kidney. In this chapter, the general properties and functions of galectin-3 are 
depicted. The specific roles of galectin-3 in kidney development and renal 
diseases are described in chapter 5.
Identification of galectin-3
The name galectin-3 was given in 1994 when the galectin family was formally 
recognized (Barondes et al., 1994). Before then, the protein was identified 
separately by different groups with different names (e.g. Mac-2, CBP35 and L- 
34). Sequenced alignment analysis confirmed that these proteins are indeed 
the same (Cherayil et al., 1990).
Galectin-3 was first identified in mice by Ho and Springer in 1982 using 
monoclonal antibodies: a macrophage antigen named Mac-2 was found on the 
surface of macrophages in response to specific differentiating signals (Ho and 
Springer, 1982). A year later, a separate group isolated a protein which they 
named carbohydrate-binding protein CBP35, from extracts of cultured 3T3 
fibroblasts. It was shown that the protein recognised galactose-containing 
glycoconjugates and showed agglutination activity when assayed with rabbit 
erythrocytes (Roff and Wang, 1983). Another group had also successfully 
isolated galectin-3 from cDNA libraries of the murine UV-2237-IP3 fibrosarcoma 
cell line. A 34 kDa endogenous galactoside-specific lectin was identified and it 
was named L-34 (Raz et al., 1987). Elevated levels of the protein was found in 
a wide variety of neoplastic cells and correlative evidence suggested that it is
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involved in tumour metastasis in vivo and in galectin-3 transformed cells in vitro 
(Raz et al., 1990).
Galectin-3 characterisation 
Galectin-3 gene structure
The human LGALS3 gene was mapped to chromosome 14q21-q22 by 
fluorescence in situ hybridisation and the location was confirmed by isotopic 
hybridisation with a tritium-labelled probe (Raimond et al., 1997). The gene 
structure was characterised by screening the genomic library. Comparison of 
the genomic sequence with the published human galectin-3 cDNA sequences 
revealed that the gene consists of six exons and five introns, spanning a total of 
approximately 17kb (fig. 4.1). The translation start site is in exon II. The proline- 
glycine-tyrosine repeat motif is found entirely within exon III and the 
carbohydrate-recognition sequence is found entirely within exon V. The open 
reading frame of LGALS3 in human is 750bp corresponding to a deduced 
polypeptide of 250 amino acids (Kadrofske et al., 1998).
Figure 4.1. Genomic organisation of the human LGALS3 gene.
The Roman numerals indicate the positions of exons. The dark boxes 
indicate exon sequences corresponding to the open reading frame. The 
hatched box represents the 3’ untranslated region (UTR). The white 
boxes represents the 5’-UTR, and the white ovals represent Alu-family 
middle repetitive sequences (figure adapted from Karofske et al 1998).
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The galectin-3 gene is highly conserved across species. Sequence alignment 
indicates a 82% to 8 8 % identity between human galectin-3 mRNA sequence 
and that of other species. However, differences were observed. Comparison of 
the genomic sequence between human and mouse galectin-3 revealed that the 
mouse galectin-3 gene has an alternative mRNA transcript (Rosenberg et al.,
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1993). Mouse galectin-3 gene has two transcription initiation sites (a and 6 ), 
each of which is specifically associated with the use of alternative donor splice 
sites, resulting in two distinct mRNA transcripts, type I and type II messages. 
The former being 27bp longer. The human transcriptional start site corresponds 
to a position similar to the mouse 5 initiation sites, but not to the a sites. 
Therefore humans lack the corresponding type I messages (Kadrofske et al.,
1998). Analysis of mRNA isolated from mouse 3T3 fibroblasts indicated that 
type II message level varies only a little over the first 2 0  hours after serum 
stimulation, whereas the type I message peaks at 16 hour post mitogen 
addition (Voss etal., 1994).
Galectin-3 protein structure
The major difference between galectin-3 and other galectins is that it contains a 
unique proline, glysine, tyrosine-rich tandem repeat at the N-terminal domain. 
The number of repeats varies between species, giving rise to differences in the 
protein size. There are 8  such repeats in human, 11 in rat and mouse and 14 in 
dog. (Cherayil etal., 1990; Herrmann etal., 1993; Mehul etal., 1994;
Kadrofske etal., 1998).
Figure 4.2. Galectin-3 protein structure.
Secondary structure of galectin-3. The dark box indicates the CRD and 
the hatched box represents the proline, glysine and tyrosine-rich tandem 
repeat (figure adapted from Moriki et al 1999).
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Galectin-3 protein consists of two domains: the C-terminal domain containing 
the CRD (carbohydrate-recognition domain) and the N-terminal domain 
consisting of the proline, glysine, tyrosine-rich (YPGXXXPGA) repeat and a 
number of recognition sites for collagenase cleavage. The two domains appear 
to be structurally independent. However, studies indicate that the N-terminal
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interacts with the CRD and participates in carbohydrate binding and self­
association of the protein (Moriki et al., 1999; Barboni etal., 2000; Birdsall et 
al., 2 0 0 1 )
The CRD domain contains sequence shared by other galectins’ CRDs. It is 
highly conserved between species. Sequence alignment indicates that the 
human galectin-3 CRD is 97% identical to that of mice in a stretch of over 70 
amino acids. Overall, the human galectin-3 protein sequence is 84% and 82% 
similar to that of murine and rat galectin-3 respectively. CRD of galectin-3 has a 
high affinity to lactose with dissociation constants ranging from 10' 3 to 10‘ 5 M 
depending on experimental conditions (Hsu et al., 1992; Moriki et al., 1999). 
The sugar is often used to inhibit the functions of CRD.
The N-terminal domain is unique to galectin-3 among the galectin family. This 
domain can be acetylated and phosphorylated (Herrmann et al., 1993). 
Experiments using truncated galectin-3 that has no or a truncated N-terminal 
domain revealed the roles of the N-terminal domain in carbohydrate binding 
and in secretion. Within the N-terminal domain, proline to alanine mutagenesis 
of the sequence YP(90)SAP(93)GAY greatly reduced secretion. Similar 
mutagenesis of proline pairings present elsewhere in the N-terminal segment 
had no effect (Menon and Hughes, 1999). Cross linking studies indicate that N- 
terminal fragment of hamster galectin-3 can efficiently self-assemble into 
oligomers (Mehul et al., 1994). It also has structural features seen in certain 
polypeptides from ribonucleoprotein (RNP) complexes (Kadrofske et al., 1998).
Galectin-3 binding to glycoligands
A signature of all galectins is their ability to interact with p-galactoside via their 
CRDs. The CRD which encompasses 135 amino acid residues, is composed of 
5 stranded (F1-F5) and 6  stranded (S1-S6a/6b) p-sheets, which associate in p- 
sandwich arrangement. Galectin-3, like all galectins, has a relatively high 
binding affinity to lactose. More specifically to galectin-3, when the hydroxyl
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group in lactose is exchanged for a more hydrophobic acetamide group to 
make A/-acetyllactosamine (LacNAc), the binding affinity is increased by over 
six fold; while the addition of a hydrophilic Gal residue to the 3-hydroxyl group 
of LacNAc futher enhances the affinity for galectin-3 by over 23 fold in 
comparison to lactose (Ochieng et al., 2004). Moreover, galectins binds to poly- 
A/-acetyllactosamine (branched or repeated units of LacNAc) with higher affinity 
(Hirabayashi et al., 2002). Galectin-3 can be phosphorylated at N-termial Ser6; 
it was shown that phosphorylation of galectin-3 significantly reduced its 
saturation binding to its ligands by greater than 85%, and the ligand binding 
can be fully restored by dephosphorylation with protein phosphatise type 1 
(Mazurek et al., 2000).
In cells, the preferred ligands for all galectins are generated in the Golgi by 
Mgat5 ((31,6 A/-acetylglucosaminyl-transferase V), which catalyses the addition 
of (31,6GlcNAc to complex type N-glycans, leading to elongation with poly N- 
acetyllactosamine (Lagana et al., 2006).
Self-association of galectin-3 involving the CRD and the N-terminal 
domain
Galectin-3 possesses many biological activities that are based on its multivalent 
binding of carbohydrate moieties. Since galectin-3 has only one CRD, it must 
be able to dimerise or polymerise in order to give some of its polyvalent 
functions.
Dimerisation and oligomerisation of galectin-3 was first suggested by Hsu et al 
in 1992 when they studied the binding capacity of the protein and its C-terminal 
domain to solid phase IgE. It has been found that the C-terminal domain alone 
is able to bind lactose and IgE. More importantly, addition of unlabelled 
galectin-3 increases the binding of labelled galectin-3 to IgE; however the 
binding is blocked by the addition of the C-terminal domain (Hsu et al., 1992). 
Similar observation is shown using immobilised galectin-3. In addition it has
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been determined that the C-domain alone does not self-associate, suggesting 
the involvement of the N-terminal in self-association (Kuklinski and 
Probstmeier, 1998).
The C-terminal domain of galectin-3 can bind to a C-terminal domain of another 
galectin-3 in the absence of its saccharide ligands. This interaction is inhibited 
by lactose and various saccharide ligands of the lectin. A galectin-3 mutant 
generated with a tryptophan to leucine replacement (W181L) in the C-terminus 
CRD exhibited diminished carbohydrate-binding activity and it does not bind to 
galectin-3C-Sepharose 4B. However, it retains its binding affinity towards the 
whole galectin, suggesting the involvement of N-terminal domains in self­
association (Yang etal., 1998).
The N-terminal of galectin-3 interacts with the CRD engaging in carbohydrate 
binding. Molecular modelling predicts that the N-terminal domain can lie across 
the carbohydrate-binding pocket of the CRD where it could participate in sugar- 
binding. Binding studies showed that tyrosine 102 and adjacent residues are 
important in the participation of carbohydrate recognition (Barboni et al., 2000). 
Monoclonal antibodies against N-terminus domain epitopes reduced the 
binding affinity of galectin-3 to IgE and its haemagglutination activity (Liu et al., 
1996). It was also shown that the N-terminus fragment could self-assemble into 
oligomers (Mehul et al., 1994). Also the N-terminal domain mediates pentamer 
formation in the presence of multivalent ligands, thereby cross-linking 
glycoproteins in proportion to ligand concentration. The resulting superstructure 
of galectins and glycoproteins generates a molecular lattice (Partridge et al., 
2004).
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Figure 4.3. Schematic models for galectin-3 self-association.
Galectin-3 self-associates in the absence of saccharide ligands, 
predominantly through the C-terminal domains and possibly by the N- 
terminal interaction as well. In the presence of ligands, the C-terminal 
domain interaction is interrupted, but the protein can still self-associate 
through the N-terminal. N = N-terminal domain; R = tandem repeats; C = 
C-terminal domain (figure adapted from Yang et al 1998).
Saccharide ligand
^  Multivalent 
ligand
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Localisation of galectin-3
Galectin-3 has been found in the nucleus and the cytoplasm within cells and is 
also secreted into the extracellular space. Its localisation correlates to its 
various functions due to the variety of ligands present in these different cellular 
compartments. Immunolocalisation and immunoblotting analysis of 3T3 
fibroblasts revealed that galectin-3 is localised to the nucleus of proliferating 
cells, whereas in quiescent culture the protein expression is down-regulated, 
most cells lose their nuclear staining and acquire a cytoplasmic expression of 
galectin-3 (Moutsatsos et al., 1987). Immunoblotting analysis of proteins 
extracted from mitochondria, isolated from human breast cell line BT549, 
showed that galectin-3 is also localised to this organelle (Yu et al., 2002).
Galectin-3 can be externalised by various cell types including macrophages, 
kidney epithelial cells, polarised MDCK cells grown within collagen gels and 
BHK cells (Hughes, 1999; Hikita et al., 2000; Sano et al., 2003). Several other 
galectins have been found to be secreted even though they are not 
glycosylated and do not contain any signalling sequences that direct them to 
the ER-Golgi network. This indicates that they are not secreted through the 
classical pathway. In addition, non-classical pathways cannot account for the 
rapid rate of galectin-3 secretion from tumour cells. Hence an alternative 
pathway may take place. Immunocytochemical data illustrated that galectin-3 
was released from BHK cells as vesicle blebbing from the cell surface Cells 
transfected with truncated galectin-3C that has no N-terminal could not be 
secreted, indicating the involvement of the N-terminal in galectin-3 secretion 
(Hughes, 1999). Galectin-3 can be rapidly internalised by breast carcinoma 
cells via a cavaleolae-like pathway of endocytosis and the internalisation is 
inhibited by lactose. More interestingly, the study demonstrated that 
extracellular galectin-3 at a concentration approaching 100 pg/ml could 
effectively mediate endocytosis of p-1 integrins (Furtak et al., 2001).
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The functions of galectin-3
There are several functions displayed by galectin-3. All of them depend on its 
particular cellular location, its phosphorylation state and sometimes on the cell 
cycle. The four most studied functions are its regulatory role in cell adhesion, 
proliferation, apoptosis and cancer.
Galectin-3 as a modulator in cell adhesion
Many extracellular ligands were identified to interact with galectin-3, which 
triggers different activities in different cell types. Figure 4.4 shows a summary of 
some of these ligands, as seen, most of the associated functions are related to 
the modulation of adhesion to cells or to the extracellular matrix (ECM).
Galectin-3 has a high affinity towards different glycoligands. Its implication in 
cancer metastasis has sparked much research into its role in cell-cell and cell- 
matrix interactions. The lectin binds to various major ECM proteins such as 
collagen IV, laminin, elastin, fibronectin and vitronectin. It also binds various 
matrix receptors such as a1(31 integrins (lacobini et al., 2003; Ochieng et al., 
2004). Overexpression of galectin-3 in several transfected tumour cell lines 
enhanced the attachment of cells to ECM components by direct interaction and 
via increased expression of specific integrins (Matarrese et al., 2000; O'Driscoll 
et al., 2002). In contrast, incubation of tumour cells with galectin-3 reduced 
adhesion to ECM proteins such as laminin, collagen IV and fibronectin in a 
dose dependent manner. It was reported that pre-incubation of a variety of 
tumour cells with 0.8 to 3.33 pM of galectin-3 resulted in internalisation of (3-1 
integrins, which are principle receptor subunit for ECM proteins. The reduction 
of extracellular (3-1 intergrins leads to a decrease in adhesion to ECM protein 
(Ochieng et al., 1998; Furtak et al., 2001). These results suggest that galectin- 
3, like galectin- 8  (Warfield et al., 1997) acts as both pro-adhesion and anti­
adhesion.
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Table 4.1. Extracellular ligands for galectin-3 and the associated 
functions
(modified from Ochieng et al 2004)
Ligand Function associated with galectin-3 binding
Laminin Modulates cell/ECM adhesion
Collagen IV Modulates cell/ECM adhesion
Fibronectin vitronecin Modulates cell/ECM adhesion
Hensin Maintains terminal differentiation of renal epithelial 
cells
Elastin Promotes adhesion of cells to elastin
Mac-2BP (gp90) Promotes cell/cell and cell/ECM adhesion
Advanced glycosilation end 
products (AGE)
Mediates endocytosis of AGE
a ip i integrins Modulates cell/ECM adhesion
aMpi (CD11/18, Mac-1 
antigen)
Modulates cell/ECM adhesion
CD66a/CD66b (human Induces activation NADH oxidase and adhesion of
neutrophils) cells to ECM
CD98 (Jurkat cells) Induces uptake of extracellular Ca2+ and modulates 
cell/ECM adhesion
CD4+/CD8+ (T lymphocytes) Inhibits apoptosis and modulates cell/ECM adhesion
NCA-160 (human neutrophils) Induces an oxidative burst in neutrophils
Neural cell adhesion 
molecules (NCAM) MAG, L1
Modulates cell/ECM adhesion
IgE Triggers degranulation and serotonin release
Lamp-1, Lamp-2 (tumour cells) Modulates cell/cell, cell/ECM adhesion
Lipopolysaccharides (LPS) - Adhesion of pathogen organisms to host ECM and
bacteria cells
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Galectin-3 roles in proliferation
Nuclear galectin-3 is associated with the regulation of proliferation. Several in 
vitro studies showed that galectin-3 stimulates cell proliferation. Incubation of 
normal human lung fibroblast IMR-90, mesangial cells from rat glomeruli or 
isolated hepatic stellate cells with recombinant galectin-3 leads to an increase 
in cell proliferation (Inohara etal., 1998; Sasaki et al., 1999; Maeda et al.,
2003). Overexpression of galectin-3 in a human breast carcinoma cells BT549 
also enhances proliferation (Lin et al., 2002). Experiments in thyroid cells using 
gel-retardation and transient transfection assays, it demonstrated that galectin- 
3 stimulates the DNA-binding and the transcriptional activity of TTF-1, a 
transcriptional factor that plays an important role in the proliferation of thyroid 
cells (Paron et al., 2003). The study on hepatic stellate cells found that both 
galectin-1 and galectin-3 activate MAPK pathways, which are key signalling 
pathways involved in the growth factor-induced stimulation of these cells. More 
importantly, it was found that galectin-3 untilises protein kinase C and A to 
induce MEK1/2-ERK1/2 signalling pathway whereas galectin-1 does not. It 
was suggested that galectin-3 cross-links with target molecules through their (3- 
galactoside-containing glycoconjugates, which triggers proliferation (Maeda et 
al., 2003).
Galectin-3 roles in apoptosis
Over-expression of galectin-3 in T-cells, epithelial cells, macrophages and in 
breast carcinoma cells protects them from apoptosis induced by various 
apoptotic stimuli. Macrophages derived from galectin-3 null mutants were more 
susceptible to apoptosis (Hsu et al., 2000). There are two pathways of 
apoptosis, the intrinsic and the extrinsic pathway. Galectin-3 was thought to 
work by preventing the initiation of the former pathway. Confocal and 
biochemical analyses revealed that galectin-3 is enriched in mitochondria of 
apoptotic cells. Upon apoptotic stimuli, the protein translocates to the 
perinuclear membrane of mitochondria consequently blocking the release of
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cytochrome c (Yu et al., 2002). Galectin-3 contains a BH1 (NWGR) domain of 
the Bcl-2 family, a group of anti-apoptotic proteins. Mutation of this domain 
abolished the anti-apoptotic function of galectin-3 in breast carcinoma BT 549 
cells (Akahani etal., 1997). In addition, galectin-3 can directly interact with Bcl- 
2 protein in the cytoplasm (Wang et al., 2004). Also, p53-dependent apoptosis 
causes repression of galectin-3, indicating a new apoptotic pathway 
(Cecchinelli et al., 2006).
Galectin-3 roles in cancer
Galectin-3 has been widely studied in various types of cancer: kidney, breast, 
gastrointestinal, lung, ovarian, thyroid etc. Its level in the sera of some cancer 
patients is elevated approximately 5 times compared with healthy normal 
individuals (lurisci et al., 2000). It is also expressed in some affected tissues 
which often correlate with tumour progression positively (head and neck 
squamous cell carcinoma, thyroid carcinoma) or negatively (breast carcinoma, 
prostate carcinoma) depending on the types of tissue involved (Takenaka et al.,
2004). These observations lead to the recognition of galectin-3 as a 
diagnostic/prognostic marker for specific cancer types (Califice et al., 2004). In 
the case of renal cell cancer, galectin-3 is overexpressed (Young et al., 2001); 
also galectin-3 together with other makers such as cimentin, CD74 and 
parvalbumin, can be used to define individual histologic subtypes of renal 
cancer (Kopper and Timar, 2006). Further details on the role of galectin-3 on 
renal cell cancer can be found in Chapter 5.
Galectin-3 may have various roles in tumour progression: it may act as an 
adhesion molecule in aid of angiogenesis and cell-matrix interaction during 
metastasis. Its regulatory role in apoptosis may contribute to anoikis by 
preventing tumour cells from under going programmed cell death. On the other 
hand, secreted galectin-3 induces apoptosis of human T leukaemia cells line, 
thus participating in the immune escape mechanism during tumour progression 
(Fukumori et al., 2003).
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Galectin-3 null mutant mice
Two types of Galectin-3 null mutant mice were used in this thesis: one on the 
129Sv background and the other on C57BL/6j. The former was engineered by 
Dr. Poirier from the ICGM (Institut Cochin de Genetique Moleculaire) in France; 
and the latter was created by Prof. Liu and was obtained from the Consortium 
for Funtional Glycomics. Both were created by homologous recombination
Galectin-3 mutant on 129Sv
The galectin-3 gene was disrupted by deleting 3.7 kb of genomic DNA which 
removes exons II, III and IV, including the initiating codon in exon II. A 
replacement vector was prepared, it contains the mutated galectin-3 gene 
structure, a neo cassette flanked by 1.5 kb of 5’ homology corresponding to the 
BamHI-Hindlll fragment from exon I and by 6  kb of 3’ homology corresponding 
to the EcoRI-EcoRI fragment including exon V and VI. A pMC1-TK cassette 
was added to aid negative selection with gancyclovir. See figure 4.5 for a 
schematic explanation. The vector was introduced into WW6  ES cells by 
electroporation. WW6  ES cells were derived from a mixed genetic background 
(C57BL/6J,129/Sv and SJL). Transformed cell clones were selected and 
injected into blastocysts to generate chimeric animals. The animals carrying the 
mutated gene were selected based on the different gene structure using 
southern blotting; they were bred with 129 c/c females. Galectin-3 
heterozygotes were selected and inter-crossed to yield null mutant animals 
(Colnot et al., 1998). These animals were maintained on the 129Sv 
background, with four years of inbreeding prior to shipment to my lab.
Galectin-3 mutant can easily be screened by genotyping using two primer pairs, 
each corresponds to either the wildtype or the mutant alleles, giving a specific 
size of DNA fragment. The primers that are probed against the wildtype allele 
amplify a 305bp fragment from the deleted region in intron I (just before exon
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II); whereas the primers against the null mutant allele amplify a 577bp DNA 
fragment from the Neo cassette.
Figure 4.4. Galectin-3 mutant gene construct.
The figure shows the physical map of galectin-3 in genomic DNA. The 
six exons are represented by vertical bars (black or red) with roman 
numbers I to VI below them. Exons II (containing start codon ATG -  in 
red), III and IV in red were deleted in mutant galectin-3. The region 
disrupted which was 3.7 kb was replaces with a neo cassette. The vector 
contained the neo cassette flanked by the 1.5 kb and 6  kb (in blue).
Other labels: E, B and H represent restriction enzyme sites (EcoRI, 
BamHI and Hindlll). Adapted from Colnot et al 1998.
E E
I
E E 
l
3.7kb
1.5kb ATr 4------------ ► ATG
region
replaced
E 8
-H -
E H 
J—L
I I I  III IV '  V
/
• /
‘ /
• /
s i — *
*
EEE Mi H
E°H— ’-§■
VI
6kb
— 4 — Ll ------- 1------- * w t locus
VI
■f * ~ |
1 kb
targeting vector
mutated locus
76
Galectin-3 mutant on C57BL/6j
Similar to the other galectin-3 mutant, a Neo cassette was used to disrupt the 
galectin-3 gene. A replacement vector consisted of a Neo gene flanked by a 
segment from exon 4 and 5 of the galectin-3 gene and another segment from 
exon 5 and 6 . Therefore, exon 5 was interrupted by the Neo gene (see fig 4.6). 
Murine stem cells, D3, were electroporated with this vector. Transformed cells 
were selected and injected into 3.5 day old blastocysts from C57BL/6j mice and 
the injected blastocysts were implanted into pseudo-pregnant CD1 mothers. 
Male chimeric mice were bred to C57BL/6j females to produce heterozygotes, 
which were then intercrossed to generate homozygotes (Hsu et al., 2000).
Figure 4.5. Galectin-3 mutant gene construct (2).
The targeting vector was constructed by replacing the 500bp Xba\ -  
Xba\ segment at the intron 4 -  exon 5 junction with the Neo cassette 
from the pMCINeoPLA vector.
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Both galectin-3 null mutants are viable and fertile. The mutant animals appear 
generally healthy and had a normal life span, suggesting that the roles of 
galectin-3 in normal development may be redundant or that they are replaced 
by other galectins. Interestingly, double mutant galectin-1/galectin-3 null 
animals are also healthy and fertile although they were both implicated in 
embryo implantation (Colnot et al., 1998). In kidneys; galectin-3 null mutant 
animals have normal kidney function although they have 1 1 % fewer glomeruli 
compared with wildtypes, associated with kidney hypertrophy. In clearance 
experiments, urinary chloride excretion was found to be higher in the mutants, 
but there was no difference in urinary bicarbonate excretion, in glomerular 
filtration or urinary flow rates (Bichara et al., 2006).
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C h a p t e r  5: T he  r o le  o f  g a l e c t in -3 in k id n e y
DEVELOPMENT AND CYSTOGENESIS
Galectin-3 is expressed in a tightly regulated manner during kidney 
development in humans and mice; as well as in an in vitro model of 
tubulogenesis of kidney epithelial cells, MDCK (Bao and Hughes, 1995; 
Winyard etal., 1997; Bao and Hughes, 1999; Bullock etal., 2001). It is also 
found to regulate cyst growth in an in vitro model, suspension culture from 
digested cpk kidneys.
Kidney development
In mammals and birds, the kidney develops in three stages: pronephros, 
mesonephros and metanephros.
Figure 5.1. Human embryogenesis illustrates early kidney 
development.
A) The mesonephric ducts appear adjacent to pronephric tubules and 
grow caudally. B) Pronephric tubules regress and mesonephric glomeruli 
and tubules are formed. C) The ureteric bud branches from the caudal 
mesonephric duct and enters the metanephric mesenchyme. Adapted 
from Winyard 1998.
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Pronephros
The pronephros is formed early in development, embryonic day 22 in human 
and embryonic day 8  in mouse. The structure and number of nephrons varies 
between species. In mammals most of the pronephric duct degenerates but the 
caudal portion becomes part of the excretory system and is referred to the 
Wolffian duct, which later gives rise to the ureteric bud (Kuure et al., 2000).
Mesonephros
The mammalian mesonephros develops from a mesodernal region called the 
aorta-gonad-mesonephros (AGM) zone. As suggested by its name, the AGM 
region also contributes to the development of the aorta, gonads, mesonephoros 
as well as haematopoietic stem cells. Organogenesis of the mesonephros is 
based on the interaction between the mesonephric mesenchyme (MM) and the 
Wolffian/pronephric duct. It is initiated when the pronephric duct reaches the 
MM and induces adjacent mesenchymal cells to condense. The condensate 
contributes to the formation and branching of the ureteric buds that develop into 
nephrons. This takes place around E10.5 in mouse (Kuure et al., 2000; Bard, 
2002). The interaction between MM and Wolffian duct is governed by signalling 
and adhesion molecules such as WNT-11, GDNF (glial-cell-line-derived 
neurotrophic factor), integrins and proteoglycans that are heavily glycosylated 
with chains of long, linear carbohydrate polymers (Muller and Brandli, 1999).
Mammalian mesonephric nephrons consist of glomeruli-like structures and 
proximal and distal ducts. The size, distribution, functional maturity and 
developmental fate of these nephrons differ greatly between species. In 
human, mesonephric nephrons are functional excretory organs during 
embryogeneis whereas the murine mesonephros is more primitive and a non- 
secretory organ. Eventually mesonephric tubules regress and this leads to the 
complete disappearance of the organ in the female. In male embryos, some 
caudal tubules and duct remain and develop further as part of the male genitals 
(Kuure et al., 2000).
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Metanephros and the development of nephron
Nephrogenesis is very similar in the meso- and metanephros. However, it 
should be noted that in the mesonephros the tubules are formed along side the 
Wolffian duct whereas in the metanephric kidney they are organized around the 
branching ureteric tree. The metanephros starts to develop at embryonic day 
11 in mouse when the metanephric blastema appears. Similar to 
organogenesis of mesonephros, metanephros development depends on the 
reciprocal inductive interactions between mesenchymal cells and ureteric bud.
It is thought that signals from the mesenchyme initiate kidney development by 
inducing formation of the ureteric bud from the Wolffian duct. Subsequently, the 
growing ureteric bud starts to branch as a response to the mesenchymal 
signals and in return transmits signals to the mesenchymal cells, causing them 
to condense and generate pretubular aggregates around branches of the ureter 
tree.
The second stage (embryonic day 13.5 -  after birth in mouse) is the formation 
and differentiation of nephron from disorganised mesenchymal cells to highly 
organised epithelial tubule. This process can be divided into four stages: 1) 
condensation, in which groups of about 1 0 0  cells condense tightly around the 
ureteric bud to from a distinct mass. 2) Epithelialisation, in which condensed 
cells lose their mesenchymal characteristics and gain epithelial ones. At the 
end of this stage the mesenchymal cells form a small epithelial cyst complete 
with a basement membrane, cell-cell junctions and a defined cellular apical- 
basal polarity. 3) Early morphogenesis, in which the epithelial cysts invaginate 
twice to form comma and then an S-shaped bodies, one of these invagination 
sites later becoming the glomerular cleft. At about this time, blood vessel 
progenitors invade the cleft to begin construction of the vascular component of 
the glomerulus. 4) Tubule maturation, in which the specialised segments of the 
nephron differentiate.
By about embryonic day 13 in mice, the extending ducts have reached the 
periphery of the metanephros, and the mesenchymal cells spread out over the
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surface to give a rim of stem cells that both maintain duct development and 
support new nephron formation at the periphery. As time proceeds, existing, 
internal nephrons start to extend into the medulla forming the loop of Henle, 
mature and start functioning, while new, more peripheral nephrons continue to 
be induced by the ducts. 2 weeks after birth in mice and at approximately 34 
weeks of gestation in humans, the populations of blast and stromal cells 
disappear, leaving a stable functioning kidney (Bard, 1992; Lechner and 
Dressier, 1997; Kuure etal., 2000; Bard, 2002).
Galectin-3 expression in human kidney
During human kidney development, galectin-3 was detected in all stages. Using 
western blot and immunohistochemistry, galectin-3 protein was found, mainly 
apically, in mesonephric ducts and also in the distal mesonephric tubules from 
5 weeks gestation age. In the metanephros, the lectin was detected in the 
apical domains of ureteric bud branches, and there was intense expression in 
fetal medullary and papillary collecting ducts in both the cytoplasm and plasma 
membranes. Low levels of galectin-3 were detected in the cytoplasm of a 
subset of cells in adult collecting ducts; the expression overlaps that of basal 
band 3 protein, which is a marker for a-intercalated cells (Winyard et al., 1997).
Galectin-3 expression in mouse kidney
RT-PCR revealed that in mice kidneys the first galectin-3 transcripts appear 
around embryonic day 12; the expression is maximal around E16 and then 
reduced sharply after birth and is barely detectable in adult kidney. In E17, 
galectin-3 is expressed at the stems of ureteric bud branches but not at their 
growing tips. Deep in the E17 cortex, collecting ducts expressed galectin-3 with 
various subcellular locations: some with cytoplasmic or weak basal expression, 
as detected by immunohistochemistry, others with a subset of cells with intense 
cytoplasmic immunostaining. Large medullary collecting ducts displayed 
intense galectin-3 staining basally. Proximal tubules that were confirmed with a
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brush border marker -  periodic acid schiff’s reagent (PAS), had no galectin-3 
expression. And no immunostaining was detected in glomeruli. Postnatally, 
galectin-3 protein was detected in a uniform apical distribution in cortical 
tubules that were PAS negative. These galectin-3 expressing tubules are often 
adjacent to the glomeruli in the cortex, suggesting that they are distal 
convoluted tubules. Galectin-3 is also found in deep medullary collecting ducts 
and the urothelium of the renal papilla (Bullock et al., 2001; Nio et al., 2006). 
Studies carried out by my predecessor, Dr Johnson, established that galectin-3 
is widely expressed in the collecting tubules in the cortex and the medullary 
collecting tubules and in the urothelia in adult mice.
These findings suggest that galectin-3 may be involved in the early 
development of collecting tubules. Its precise functions in these tubules are 
unclear, it may play a role in regulating cell adhesion. Organ cultures where 
E11/E12 metanephroi were cultured in the presence of exogenous galectin-3 
provided evidence that galectin-3 can modulate ureteric bud branching.
Addition of galectin-3 to these whole organ cultures inhibited ureteric bud 
branching. The effect is reversible by withdrawal of galectin-3 in the medium. 
The addition of galectin-1 or mutant galectin-3, that lacks the high-affinity 
binding to extended oligosaccharides, did not perturb branching 
morphogenesis of the ureteric bud/collecting duct lineage. Moreover, the 
addition of a blocking antiserum to galectin-3 caused dilation and distortion of 
developing epithelia in E12 metanephroi cultures (Bullock et al., 2001).
Galectin-3 expression in MDCK cells
Galectin-3 is expressed in immortalised kidney epithelial cells such as mouse 
inner medullary collecting duct cells (mIMCD), baby hamster kidney cells (BHK) 
and in Madin-Darby canine kidney epithelial cells (MDCK) (Bao and Hughes, 
1995; Hughes, 1999). Studies of kidney epithelial tubulogeneis was carried out 
using MDCK cells in 3-D collagen gel cultures. In 3-D culture, MDCK cells 
develop into a cyst-like structure containing a polarised epithelium surrounding
83
a central lumen. These cysts can be induced to form tubules with hepatocyte 
growth factor (HGF). Shortly after induction, sprouting of the cysts occur and 
these processes develop into multicellular arms which branched and eventually 
formed tubular structures with a central lumen.
Prior to the induction of tubulogenesis, galectin-3 is expressed in the 
basolateral domain of the cyst-like structure, with little cytoplasmic expression. 
After the addition of HGF, galectin-3 expression in the main body of the 
sprouting cysts remains similar to that found in simple cysts developing in the 
absence of HGF: strong basolateral expression. Although the sites initiating 
extension of the multicellular tubules and the progressing tips clearly lack 
galectin-3. Additionally, galectin-3 is secreted by MDCK, BHK and IMCD cells 
via a non-classical pathway. These results support the organ culture study, 
further suggesting that galectin-3 play an important role in tubulogenesis during 
kidney development (Bao and Hughes, 1995).
The protein also exhibits an effect on the development of MDCK cysts in 
collagen gel. Galectin-3 added exogenously to the cultures exerted an 
inhibitory effect on cyst enlargement of MDCK cells in 3-D gel matrix; whereas 
anti-galectin-3 antibodies promote cyst growth (Bao and Hughes 1995).
Role of galectin-3 in terminal differentiation of intercalated 
cells and acidosis
Galectin-3 is involved in the terminal differentiation of rabbit renal intercalated 
cells, a type of kidney epithelial cell in the collecting tubules (Hikita et al., 2000). 
The cortical collecting duct of the kidney is made up of principal cells, which are 
involved in salt, water and potassium transport; and the intercalated cells, 
which made up of a third of the cells in this segment and mediate acid-base 
transport (Al Awqati and Oliver, 2002). Two functionally distinct sub-types of 
renal intercalated cells have been identified: bicarbonate (HC0 3 - ) absorbing a- 
intercalated cells and the HCO3-" secreting p-intercalated cells. The former 
expresses CP :HC0 3 ~ exchange at the baso-domain and apical H+ ATPase,
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thus it also secretes proton (H+). Whereas the p-intercalated cells express 
these markers at opposite domains, p cells can convert to the a form both in 
vivo and in vitro (Al Awqati, 2003). Conversion takes place under the influence 
of acidification of the medium or acid diet in vivo. The seeding density of 
intercalated cells also influences the phenotype: subconfluent seeding results 
in the formation of p cells whereas high density seeding results in the a 
phenotype. In both cases, the conversion requires the deposition of a protein 
called hensin at the extracellular matrix. Galectin-3 was found to be associated 
with hensin in the extracellular matrix. Purified recombinant galectin-3 is able to 
bind to hensin and polymerise it in vitro. Seeding cells at high density induces 
secretion of galectin-3 to the extracellular matrix where it bundles hensin, which 
in turn signal the cell to change its phenotype.
Galectin-3 expression in rabbit kidney is altered under metabolic acidosis. 
Under normal diet, galectin-3 expression is restricted to the a-intercalated cells 
and the principal cells, however, under acid diet, the protein expression is 
dramatically increased in the cortical collecting duct cells, particularly in p- 
intercalated cells. This result further supports the role of galectin-3 in the p cells 
adaptation (Hikita et al., 2000; Al Awqati and Oliver, 2002; Schwaderer et al., 
2006).
All these studies were carried out in rabbit, which may not represent human 
and mouse kidneys due to differences in kidney physiology and the diet of the 
animal.
Role of galectin-3 in diabetic nephropathy
Nonenzymatic glycation is implicated in the pathogenesis of the dysregulated 
tissue remodelling that characterises diabetic glomerulophaty, via the formation 
of advanced glycation end products (AGEs) and their binding to cell surface 
receptors. Galectin-3 is one of such receptors. In diabetic rats, galectin-3 can 
be detected in the glomeruli but not in the non-diabetic population. Its role in
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the development of diabetic nephropathy was further studied using galectin-3 
knockout mice that were rendered diabetic with streptozotocin. Galectin-3- 
deficient mice develop accelerated glomerulopathy compared with wild-type, as 
evidenced by more pronounced increase in proteinuria, which is associated 
with the higher AGE accumulation in kidneys (Pugliese et al., 2000; Pugliese et 
al., 2 0 0 1 ).
Galectin-3 exhibits a high binding affinity towards AGE, in addition, it was 
shown to play a role in endocytosis of AGE and modified (acetylated or 
oxidised) low density lipoproteins, LDL. The lectin appears to play a functional 
role in the removal of these harmful compounds. It was suggested that the 
upregulation of galectin-3 in diabetic milieu was due to its participation in the 
pathogenesis of diabetic nephropathy by enhancing AGE removal. Hence 
galectin-3 protects kidneys from AGE-induced tissue injury (Zhu et al., 2001; 
lacobini et al., 2003).
Galectin-3 and renal cell carcinoma
As mentioned in the Chapter 4, galectin-3 is overexpressed in renal cell 
carcinoma (RCC) (Francois et al., 1999). There are different subtypes of RCC, 
conventional RCC which is the commonest form, oncocytoma and 
chromophobe RCC. Conventional RCCs were distinguished from oncocytoma 
and chromophobe RCCs based on large scale gene expression patterns. The 
latter two displayed similar expression profiles, consistent with the 
mitochondrion-rich morphology of these tumours and the theory that both 
lesions are related histogenetically to distal nephron epithelium. On the other 
hand, conventional RCCs underexpressed mitochondrial and distal nephron 
genes. Galectin-3 expression is predominantly found in low-grade conventional 
RCCs, indolent chromophobe RCCs and benign oncocytomas. Although 
microarray study reveals that galectin-3 mRNA overexpression is specific to 
oncocytoma and chromophobe RCCs (Young et al., 2001). These results do 
not suggest the role of the galectin in RCC, however they open up a possibility
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of using galectin-3 as a marker to define individual histologic subtypes of RCC 
(Kopper and Timar, 2006).
Galectin-1 and galectin-9 in kidney.
In addition to galectin-3, both galectin-1 and galectin-9 are expressed in the 
kidney. Galectin-1 is expressed widely in the mesodemally derived cells in the 
developing mouse embryo, including kidney, where these cells are responsible 
for the development of the mesodermal mesenchyme that in turn gives rise to 
the non-ureteric tubular epithelia. No expression was detected in ureteric 
epithelia (Hughes, 2004). Experiments involving two-dimensional gel 
electrophoresis combined with mass spectrometry on juvenile cystic kidney 
(jck) mice kidneys, galectin-1 protein expressed was found to be 9-fold higher 
compared with wildtype (Valkova et al., 2005).
Galectin-9 expression in kidney, like galectin-3, is also developmentally 
regulated although in a different manner. Galectin-9 expression increases 
steadily from E12 through late embryonic development and postnatally, and 
reaches its highest and constant levels in adult kidney, whereas galectin-3 
expression is highest during development and decreases as the kidney 
matures. Galectin-9 is most prominently found in the apical domain of the 
proximal tubules. Here, the galectin act as an urate transporter/channel that is 
incorporated into the lipid bilayer. It was suggested that the opening of the 
channel may in part be regulated by extracellular glucose binding to the CRD 
domain of the galectin (Leal-Pinto etal., 2002; Hughes, 2004).
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C h a p t e r  6: T h e  e f f e c t  o f  p a c l it a x e l  o n  t h e
DEVELOPMENT OF POLYCYSTIC KIDNEYS
Currently, there are no treatments for human PKD patients. The disease leads 
to renal failure and patients at the end stage of PKD require dialysis or kidney 
transplantation. Investigators have tested various reagents in mice in the hopes 
of finding a treatment for PKD. One of these successful treatments in animals is 
paclitaxel (Taxol®) (Woo et al., 1994). Paclitaxel is a poison produced by 
endophytic fungi that reside in a variety of plants (Amos and Lowe, 1999). It is 
isolated from Taxus brevifolia (Pacific yew tree) and Taxus yannanensis. 
Semisynthesis, cellular culture production, chemical synthesis and total 
synthesis of the molecule have been reported (Nicolaou et al., 1994). It was 
first approved by the Federal Drug Administrator in the US in 1992 for treatment 
of ovarian cancer. It is now often used as chemotherapy against breast, ovarian 
and non-small lung cancer. Although it increases the toxicity profile of patients 
under treatment, it is the only reagent that on its own exhibits a relatively high 
response rate. It is often used in combination with different reagents such as 
doxorubin or cisplatin to increase the response rate in breast carcinoma 
(Maiche et al., 2000).
In this thesis, paclitaxel treatment was investigated because preliminary results 
showed that it affects the expression pattern of galectin-3 in treated cpk cysts in 
vitro and in vivo. The location of galectin-3 expression appeared to be altered in 
paclitaxel treated cells from cytoplasmic staining in untreated cystic kidney 
epithelial cells to prominent apical expression.
How does paclitaxel work?
Paclitaxel targets the microtubules although the precise mechanism of how it 
works is not yet resolved (Amos and Lowe, 1999). It is often described as a 
microtubule-stabilising drug which inhibits the completion of mitosis by 
disrupting the spindle microtubule dynamics, thus blocking cell cycle progress
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at the metaphase/anaphase transition. Cell death is caused by either aberrant 
mitosis resulting in an aneuploid G1 cell population: multinucleated cells of up 
to 11 micronuclei was found with PtKi cells under paclitaxel treatment (Jensen 
et al., 1987); or by mitotic arrest at higher concentration (Torres and Horwitz, 
1998; Yvon et al., 1999; Alexandre et al., 2006).
It was suggested that the microtubule damage caused by paclitaxel induces 
apoptosis through a JNK-dependent pathway in the early phase followed by a 
JNK-independent pathway, perhaps related to the activation of protein kinase A 
or of Raf-1 kinase, that results in phosphorylation of Bcl-2 (Blagosklonny et al.,
1999). Accumulation of hydrogen peroxide is also important in paclitaxel 
induced cell death, at least in cancer cells (Alexandre et al., 2006).
Paclitaxel stabilizes microtubules
In order to understand how paclitaxel works, we must first examine the 
structure of microtubules. Microtubules are hollow cylindrical tubes formed 
primarily by self-association of a,p-tubulin heterodimers into polymers. Each 
polymer, called protofilament, is arranged in a polar fashion and these 
protofilaments interact laterally to form microtubules. The number of 
protofilaments in each microtubule ranges from 10 to 15 (Nogales, 2000; Orr et 
al., 2003b). Microtubules are highly dynamic structures that depend on the 
balanced exchange between tubulin molecules associated with microtubules 
and a free cytoplasmic pool of tubulin (Jensen et al., 1987). In differentiated 
cells microtubules are polarised with the fast growing plus-ends, which points 
towards the basolateral surface of epithelial cells, and the slow-growing minus- 
ends, which points towards microtubule-organising centre (MTOC) located near 
the apical surface of epithelial cells (Musch, 2004).
Paclitaxel reversibly binds to the hydrophobic pocket in the central domain of (3 
tubulin, close to the microtubule loops (M-loop), which is the major lateral 
contact between adjacent protofilaments. It is believed that the binding to this
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site causes a conformational change in the M-loop that strengthens the lateral 
contacts between protofilaments and enhances microtubules stability (Amos 
and Lowe, 1999; Nogales, 2000; Or r etal., 2003).
Paclitaxel causes apoptosis
The disruption of microtubules caused by paclitaxel initiates apoptosis. 
Apoptosis can be induced via different transduction pathways: c-Jun N-terminal 
kinase (JNK) pathway and the caspase cascade triggered by the release of 
cytochrome c from the mitochondria.
Paclitaxel activates the JNK signalling pathway in a variety of human cells, and 
the activation is dependent on the interaction of the drug with microtubules 
(Wang et al., 1998).
Paclitaxel also acts directly on isolated mitochondria, causing them to release 
cytochrome c which can potentially initiate caspase activity leading to apoptosis 
(Andre et al., 2000). It was demonstrated that tubulin is localised in the 
mitochondrial membranes and that the mitochondrial tubulin interacts with the 
permeablility transition pore (PTP), which is responsible for mitochondrial 
permeabilisation. Therefore, it is possible that paclitaxel can bind to 
mitochondrial tubulin thus altering the PTP activity (Carre et al., 2002). 
Furthermore, paclitaxel induces Bcl-2 phosphorylation and degradation, which 
in turn regulates its function to control cytochrome c release (Basu and Haidar, 
1998; Brichese et al., 2002).
Paclitaxel treatment in PKD animal models
Woo et al (1994) found that at least in the primary suspension culture of cpk 
kidneys, inhibition of DNA, RNA and protein synthesis with methotrexate (10 
pg/ml), cytosine arabinoside (20 jug/ml), a-amanitin (100 ng/ml) or
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cyclohexamide (40 pg/ml) does not prevent in vitro cyst formation. Whereas 
cultures in the presence of microtubule-specific agents colchicine, vinblastine or 
paclitaxel significantly reduced cyst formed in vitro. Further, the investigators 
found that a single treatment of cpk mice with 150 pg of paclitaxel between 
postnatal day ten and twelve prolongs the lifespan of these animals to 40-50 
days old, compared with untreated animals which die between 25 and 28 days. 
Weekly paclitaxel treatment in cpk animals further prolongs their lifespan to 
over 200 days. Histological examination of paclitaxel-treated polycystic kidneys 
at up to 200 days revealed the presence of normal to slightly dilated renal 
tubules and normal glomeruli, which are absent in untreated end-stage cystic 
kidneys. Although cysts were present, they were less numerous and smaller in 
size compared with untreated 21-day-old polycystic kidneys.
The effect of other microtubule-specific agents in vivo could not be determined 
as treatment with the minimum doses of colchicine (250 nM), colcemid (200 
nM) and vinblastine (200 nM) required to disaggregate microtubules in vitro are 
lethal to 10-12 day-old polycystic cpk mice. Sub-lethal doses of these 
compounds were ineffective in prolonging the survival of cpk mice. The results 
indicate that the microtubule cytoskeleton has a central role in the 
pathogenesis of PKD in cpk mice.
The treatment was repeated in different animal models. In vitro cultures derived 
from cystic kidneys of Han:SPRD (cy/+) rats. It was found that human cysts 
fluid and epidermal growth factor both stimulated the formation of cysts 
whereas paclitaxel inhibited cystogenesis (Pey et al., 1999). However, 
contradictory outcomes were found when the same treatment was carried in 
different animals models in vivo. No beneficial effects were observed in orpk 
(Sommardahl et al., 1997), pcy mice and Han:SPRD-cy rats (Martinez et al., 
1997), suggesting that the paclitaxel effect may be specific to the cpk model.
A close examination of the published data revealed that the dosage used for 
each experiment differed greatly. The dosage used by Woo et al in the original
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cpk paper was a single dose of 30 jug/g at day 10, Sommardahl et al used 10 
pg/g/week on the orpk mice model beginning at Day 7; Martinez et al treated 2- 
to 10-week-old pcy mice with approximately 15 pg/g/week, assuming that the 
animal weigh on average 6g at week 2; and treated 7- to 10-day-old Han:SPRD 
(cy/+) rats with 0.1 to 15 pg/g/week. A summary of the dosage used is in figure 
6.1, which shows that all other models used a dosage that was at most, half the 
dosage used in the cpk mice. Hence, the inefficiency observed could be due to 
the reduced dosage used.
Table 6.1. Comparison of paclitaxel treatment in different PKD 
animals.
Studies on the effect of paclitaxel treatment against cyst growth 
suggested that paclitaxel only worked in cpk mice. However, close 
examination revealed that there is a great variation the dosage and the 
method of administration used. In particular the dosages for treating 
other animals are reduced, which may contribute to the lack of positive 
effect by paclitaxel.
PKD
model
* Cyst
development
Concentration 
used, pg/g
Method of 
administration
Reduce
cystogenesis
Cpk, mice AR, fast 30 Single dose at 
Day 10
Yes
Orpk, mice AR, fast 10 Weekly from Day 
7
No
Pcy, mice AR, slow -15 Weekly from week 
2 to 10
No
Han.SPRD- 
cy, rat
AD, fast 0.1 to 15 Weekly from day 
7 to 10
No
* AR = autosomal recessive, AD = autosomal dominant
Mechanisms of paclitaxel resistance
Paclitaxel resistance is a significant problem in cancer therapy. Several factors 
contribute to this effect and they may also contribute to paclitaxel resistance in 
some polycystic kidney disease models. Studies on several paclitaxel 
resistance cell lines such as A549 human non-small lung carcinoma, K562
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e ry th ro leukeukem ia  cell line, DU-145 prostate carcinoma cell line and KPTA5 
cells revealed that alteration of the p-tubulin gene expression contributes to the 
drug resistance. In particular mutation around or within the M-loop domain that 
results in weaker interaction between protofilaments and mutation in the 
paclitaxel binding sites in p-tubulin is responsible for the drug resistance 
(Giannakakou et al., 1997). Also the upregulation of the isotype p lll-tubulin 
expression correlates to increase paclitaxel resistance (Jaffrezou et al., 1995; 
Kavallaris et al., 1997; Ranganathan et al., 1998; Orr et al., 2003). It was 
shown that microtubules consisting of only p lll-tubulin are more unstable 
(Panda et al., 1994) and this instability is linked to paclitaxel resistance. It may 
be possible that some PKD models exhibit these traits, in particular reduced 
stability of microtubules.
Further work on cpk mice found that only certain taxanes that are able to 
promote microtubule assembly, in contrast to those that are microtubule 
inactive, can significantly prolong the life of affect animals (Woo et al., 1997). 
Paclitaxel may alter cystogenesis by suppressing proliferation of cystic epithelia 
which is up-regulated in cystic kidneys; it may also act directly on the primary 
cilia, which consist of acetylated tubulin. The disruption if microtubule caused 
by paclitaxel may affect the structure of the primary cilia.
Other potential therapies
Researchers have been trying to find potential therapeutic treatments using 
different animal models. These treatments include vasopressin V2 receptor 
(VPV2R) antagonist, epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitors, purinergic receptor P2X(7), base treatment and dietary modulation; 
all have shown to be effective in specific PKD models. For most of them, their 
effects have not yet proven to be effective to all PKD models and their mode of 
action are still unclear. Nonetheless they provided important clues into the 
mechanisms of the disease and potential treatment.
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Vasopressin V2 receptor (VPV2R) antagonist OPC31260
OPC31260, an antagonist of VPV2R, the major cAMP agonist in the collecting 
duct, has recently been shown to be an effective therapy in three animal 
models: pck rat (orthologous to human ARPKD), pcy mouse (orthologous to 
human nephronophthisis and p/cc/-/tm1Som (an orthologous to human PKD2) 
(Gattone et al., 2003; Torres et al., 2004a). cAMP levels was increased in cystic 
animals and it is present in cysts fluid. It stimulates fluid secretion in normal 
collecting ducts and isolated ADPKD cysts; it also increases proliferation of 
ADPKD cells while poses an opposite effect on normal kidney epithelial 
cells(Torres et al., 2004a). The mechanisms responsible for these changes are 
unclear, however, these results showed that by inhibiting cAMP signalling 
pathways, it is possible to delay cystogenesis.
Epidermal growth factor receptor (EGFR)
Increased level of EGFR-specific tyrosine kinase activity is observed in affected 
kidneys of several different ARPKD animal models. The activity can be blocked 
by introducing a mutant EGFR (wa2 mutation) into an ARPKD models (orpk 
mice), which exhibit a decrease EGFR tyrosine kinase activity and these double 
mutants have reduced cytogenesis (Richards et al., 1998). Experiments 
showed that administration of tyrosine kinase inhibitor, EKI-785, markedly 
reduced collecting duct cyst formation in bpk mice (Sweeney et al., 1999) 
although the same treatment did not yield any positive effects in pck rat (Torres 
et al., 2004a). Specific inhibition of EGFR binding partner HER-2, which is the 
preferred dimerisation partner, to PKD1 null heterozygous mice significantly 
inhibited the development of renal cysts (Wilson et al., 2006).
P2X(7)
P2X(7), a purinergic receptor, is expressed in the cystic epithelia in cpk mice. In 
vitro culture generated by dissociated cpk kidney in suspension culture reveals 
that a P2X(7) agonist, BzATP, reduces cystogenesis. The effect is P2X(7) 
specific as other purinergic agonists, ATP and UTP, had lesser effects; and the
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P2X(7) inhibitor, oxidised ATP abolished the BzATP-mediated effect on 
cystogenesis (Hillman et al., 2004).
Base treatment
Sodium/potassium bicarbonate or citrate markedly attenuates the development 
of kidney cysts in Han:SPRD-cy rat although it has no effect in pcy mice and 
actually accelerated PKD progression in pck rats. These conflicting results 
reflect the complexity of this disease. Different segments of the nephron may 
undergo different cystic changes in each model. The Han:SPRD-cy rat have 
cysts derived primarily from proximal tubules where as pcy mouse and pck rats 
have cysts originated in the distal tubules and collecting ducts (Tanner and 
Tanner, 2000; Guay-Woodford, 2003).
Dietary modulation
High protein diet was associated with accelerated renal cystogenesis whereas 
low protein diet was shown to attenuate disease progression in the slow 
progressive form of PKD models, pcy mouse and Han:SPRD-cy. Specific 
components within the protein diets appear to modulate PKD. Soy protein and 
flaxseed, were both shown to attenuate the development of renal cysts. In 
particular substances such as phytoestrogens, soy-derived isflavones were 
demonstrated to attribute to the beneficial effect (Tomobe et al., 1994; Ogborn 
et al., 1998; Aukema and Housini, 2001; Guay-Woodford, 2003).
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C h a p t e r  7: Hy p o t h e s e s , a im s  a n d  e x p e r im e n t a l
STRATEGIES
Hypotheses
My main hypothesis was that galectin-3 is an endogenous, negative-regulator, 
of renal cyst growth in the cpk mouse model of ARPKD.
Subsidiary hypotheses were that:
I. Galectin-3 is implicated in other PKD.
II. Galectin-3 associates with the primary cilium.
III. Galectin-3 may have a role in paclitaxel-mediated restriction of cyst 
growth in cpk mice.
Aims
There were several primary aims in this thesis:
1. Fully characterise galectin-3 expression in the cpk mouse model of ARPKD, 
and determine whether expression is also increased in other PKD.
2. Determine whether lack of galectin-3 alters cyst formation in cpk/galectin-3 
mutants.
3. Investigate galectin-3 in the primary cilium.
4. Investigate whether paclitaxel and galectin-3 modulate cystogenesis via 
common mechanisms.
Experimental strategies
Four major groups of experiments were performed:
1. Expression analysis. The expression pattern of galectin-3 was examined in 
cpk mice, and compared to other collecting duct developmental markers
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and renal galectins. Galectin-3 expression was also sought in other PKD 
including bpk, orpk, and pkd2 mutant mice, plus human ADPKD and 
ARPKD kidney tissues.
2. Breeding experiments. Galectin-3 and cpk mutants were bred to generate 
compound offspring with which to assess the effects of reduced galectin-3 
on cyst formation. The level of cystogenesis was measured by kidney/body 
weight ratio and histological analysis, and compared to determine if the lack 
of galectin-3 resulted in enhanced cyst growth.
3. Galectin-3 and primary cilia. Immuno-cyto and -histochemistry was 
performed on primary cultures of kidney epithelia from cpk mice and inner 
medullary collecting duct (IMCD) cells, cpk and normal mouse kidney 
sections, and human ARPKD and ADPKD samples. Double labelling for 
galectin-3 and either a-acetylated or y-tubulin was examined using a 
confocal microscope.
4. Paclitaxel and galectin-3. New in vivo experiments were performed to 
assess early effects of paclitaxel on general and cilial galectin-3 expression. 
Further in vitro cpk cyst culture experiments were used to determine 
whether paclitaxel and galectin-3 might act in the same or distinct pathways 
to reduce cyst formation.
Preliminary experiments were also conducted using the atomic force
microscope as a novel technique to assess ciliary structure and function.
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C h a p t e r  8: M a t e r ia l s
Animal husbandry
I studied normal mouse strains, C57BL/6j and 129Sv (Charles River mouse 
Farms, UK). Known heterozygous cpkl+ mice on C57BL/6j were obtained from 
the Jackson Laboratories (Bar Harbor, Maine, USA). Initially galectin-3 null 
mutant mice on 129Sv were obtained from Dr. Poirier from the ICGM (Institut 
Cochin de Genetique Moleculaire) in France. Later, galectin-3 null mutant mice 
on C57BL/6j were obtained from the Consortium for Functional Glycomics 
(http://www.functionalglycomics.org/static/consortium).
ARPKD affected mice are homozygous recessive (cpk/cpk), and hence are the 
F1 progeny from mating two heterozygotes. Statistically half of the litter from 
parents that carry the mutation, will be heterozygotes, one quarter will be 
affected homozygotes and one quarter, wildtype mice that do not carry the 
mutation. Mice were kept with their mothers until they were weaned at 21 days 
old. Both the Home Office, and the Institute of Child Health, Animal Welfare 
Committee, approved all studies involving animals.
Kidneys were collected, via micro-dissection, from cpk homozygous offspring 
and their littermates at 1 or 3 weeks of age, as well as from normal mouse 
strains at the same ages. All homozygous cpk mice were culled before week 4 
at which point they became severely ill. The cpk allele was also bred onto the 
129Sv background for 10 generation to yield cpk animals on a virtually pure 
129Sv background.
Galectin-3 null mutants on 129Sv (from Dr. Poirier) were bred with cpk 
heterozygotes to yield double mutants. They were also inter-bred to maintain 
the null allele on 129Sv background. Galectin-3 null mutant on C57BL/6j (from 
the Consortium for Functional Glycomics) were also bred with cpk
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heterozygotes to yield double mutants on the C57BL/6j backgroud. Details of 
these two mutants are in chapter 4.
Following micro dissection tissues for immunohistochemistry were placed into 
4% paraformaldehyde (PFA); tissues for protein and DNA analysis were placed 
into liquid nitrogen, tissues for cell culture were placed into L15 medium at 4°C 
and tissues for electron microscopy were placed into 3% gluteraldehyde.
Kidney samples of various PKD models
Kidneys from different PKD mouse models were obtained to assess galectin-3 
expression. 3 weeks old cpk mutants on Balb/c and DBA backgrounds, 3 
weeks old bpk and 1 week old orpk mutant kidneys were obtained from Prof. 
Guay-Woodford and Dr. Yoder from the University of Alabama in Birmingham; 
adult pkd2 mutant samples were kindly provided by Dr. Somlo. Human samples 
were obtained from Histopathology Department in the Institute of Child Health. 
Due to the limitation of resources, only one kidney was obtained per sample. All 
mice samples were obtained in wax block and the human samples were 
provided as histology sections.
Bpk model arose from a spontaneous mutation in an inbred colony of Balb/c 
mice and the disease is transmitted in an autosomal recessive fashion (Nauta 
et al., 1993). Renal cystogenesis in this model is very similar to that of cpk 
mice. The three-week old bpk kidney samples has severe cystic lesion, similar 
to cpk mice. Renal cysts were also presented in adult pkd-2 mutant mice 
(autosomal dominant inheritance, renal cysts develop in affected adults), with 
40% of cysts derived from the collecting tubules (Wu et al., 1998). Orpk model, 
which is another autosomal recessive PKD model, was developed as part of a 
large-scale insertional mutagenesis programme (Moyer et al. 1994). The 
TgN737 gene codes for polaris is disrupted. Most mutants die at first week of 
age therefore 1 week old orpk kidney samples were examined. Similar to cpk 
model, the severity of cystic lesion depends on the genetic background. The
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orpk samples obtained was on the FVB background, and at one week it did not 
have a gross renal cystic presentation.
Tissue culture 
Cells
mlMCD-3 cells were obtained from ATTC (Middlesex, UK), a global bioresource 
centre with catalogue number CRL-2123. These cells were derived from the 
inner medullary collecting duct from a transgenic mouse (Rauchman et al., 
1993). These cells are commonly used an in vitro model of renal collecting 
tubules.
Media
Dulbecco’s Modified Eagle Medium F12 mix (DMEM/F12) was supplied by 
Gibco BRL (Paisley, UK).
Media supplements
Sigma-Aldrich Corporation (Poole, Dorset, UK) supplied: insulin transferrin 
selenium (ITS), dimethyl sulfoxide (DMSO), human recombinant Epidermal 
Growth factor (EGF), antibiotics solution, hydrocortisone, triiodothyronine (T3) 
and paclitaxel. Gibco BRL (Paisley, UK) supplied the heat inactivated fetal calf 
serum.
Galectin-3 recombinant protein
Proteins used include: Recombinant hamster galectin-3 protein, A1-93, 
containing the C-terminal domain but lacking most of the N-terminal domain of 
full length galectin-3. A mutant protein, named SS, similar to full length galectin- 
3, except for a mutation, where residue Arg139 has been changed to serine 
(Mehul et al., 1994). The recombinant protein was generously supplied by Dr
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Colin Hughes and Suleman Bawumia, National Institute for Medical Research, 
Mill Hill, London, throughout the duration of this study.
Tissue culture plasticwares
Nunc (Roskilde, Denmark) supplied the petri dishes (30mm and 90mm), 6 well 
and 96 well plates.
Genotyping
cpk mice and galectin-3 null mutant mice were genotyped by DNA amplification 
followed by polymerase chain reaction (PCR) using specific primers. Different 
genotypes were identified by the size and pattern of DNA bands in 
electrophoretic gel.
DNA extraction
Tail tips were collected from animals to be genotyped and DNA was extracted 
from them using the DNeasy kit (Qiagen, West Sussex, UK), which consists of 
DNeasy Mini Spin Columns, two washing buffers and an elution buffer. 
Procedures were carried out in accordance with the manufacturer’s manual. 
The DNeasy kit uses advanced silica-gel-membrane technology for rapid and 
efficient isolation of total cellular DNA without phenol, chloroform, or ethanol 
precipitation. In the presence of ethanol, DNA binds to the DNeasy membrane, 
while contaminants such as protein and polysaccharides are efficiently 
removed by two wash steps. Pure DNA is then eluted in a small volume of low- 
salt buffer (provided with kit).
Polymerase chain reaction
Polymerase chain reaction were carried using HotstarTaq (Qiagen, West 
Sussex, UK) which includes buffer solution, solution Q* and magnesium 
chloride; dNTP PCR nucleotide mix (Promega, Southampton, UK), DMSO
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(Sigma-Aldrich, Poole, Dorset, UK), MilliQ water and primers (MWG-Biotech 
AG, London, UK). Further information on primers as followed). Reactions were 
performed on DNA Engine DYAD™ (GRI, Essex, UK).
* Solution Q is a PCR additive that facilitates amplification of difficult templates 
by modifying the melting behaviour of DNA, particular for those with a high 
degree of secondary structure or that are GC-rich.
Primers
Primers (MWG-Biotech AG, London, UK) were used for polymerase chain 
reaction to genotype cpk mice and galectin-3 mutant mice. 
cpk primers were 5’ TCCTCCCTCCCTATCTCTCCAT 3’ and 5'
ATCCAGCAGGCGTAGGGTCTC 3’(Hou et al., 2002). These flank the 31 bp 
deletion in exon 1 of cystin, and generate 351 or 320bp products from wildtype 
and mutant alleles respectively. Sequence provided by Prof. Guay-Woodford.
Galectin-3 genotyping for samples on the 129Sv and mixed background utilised 
two PCR reactions concurrently: galectin-3 primers were 5’
CACGAACGT CTTTT GCT CT CT GG 3’ and 5’
TGAAATACTTACCGAAAAGCTGTCTGC 3’ which produced a 305bp fragment 
only from wildtype alleles; neomycin primers were 5’
CAAGATGGATTGCACGCAGG 3’ and 5’ TATTCGGCAAGCAGGCATCGCCA 
3’ which generated a 577bp product only from the mutant, neomycin-containing 
allele. Sequence provided by Dr. Francoise Poirier.
C57BL/6j Galectin-3 genotyping utilised two individual primers, with a common 
downstream primer of 5’ CACTCTCAAAGGGGAAGGCTGACTGTC 3’; wildtype 
allele - 5’ GTAGGTGAGAGTCACAAGCTGGAGGCC 3’ which produced a 
490bp fragment; mutant allele - 5’ GGCTGACCGCTTCCTCGTGCTTTACGG 3’ 
which amplified a 300bp segment from the Neomycin gene. Sequence provided 
by Prof. FT Liu.
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DNA gel electrophoresis
Agarose gel electrophoresis was used to separate DNA fragments according to 
size. Electrophoretic graded agarose was provided by Gibco (Paisley, UK). 
Tris-Acetate-EDTA (TAE) buffer was prepared by making up a 50x stock (242g 
Tris base, 57.1ml Acetic acid and 100ml of 0.5M EDTA, all from Sigma, made 
up to 1 litre by adding ddH20  and adjust pH to 8.5). DNA samples were loaded 
on to the gel using a 6x Type 1 gel loading solution (Sigma-Aldrich, Poole, 
Dorset, UK).
Electrophoretic gels were prepared using a gel tray and the process was 
performed using a Gel tank. 1 Kilobase (Kb) DNA marker was purchased from 
Gibco BRL.
Ethidium Bromide (Sigma-Aldrich, Poole, Dorset, UK) was used to visualise 
DNA bands in electrophoresis. It binds to DNA and fluoresces readily when 
exposed to ultraviolet light.
Molecular size markers
1 Kilobase (Kb) DNA marker was purchased from Gibco (Paisley, UK).
Protein extraction and quantification
RIPA buffer plus protease inhibitors were used to extract proteins from cells 
and tissue. RIPA buffer was made up of 150mM of sodium chloride, 1% 
nonident P-40 (NP-40), 0.5% sodium deoxycholate, 1% sodium dodecyl 
sulphate (SDS) and 50mM of Tris buffer. Protein inhibitors: Aprotinin, PMSF 
and sodium orthovanadate were used together with RIPA buffer. All reagents 
provided by Sigma-Aldrich (Poole, Dorset, UK). Eppendorf vial-shaped 
homogeniser was used to homogenise cultured cells. Sonicator was used to 
lyse cell membrane further.
BCA protein assay kit was purchased from Pierce (Northumberland, UK) and 
was used to quantify protein concentration. The BCA Protein Assay is based on 
bicinchoninic acid for the colorimetric detection and quantitation of total protein.
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This method combines the well-established reduction of Cu2+ to Cu1+ by protein 
in an alkaline medium (the biuret reaction) with the highly sensitive and 
selective colorimetric detection of the cuprous cation (Cu1+) using a reagent 
containing bicinchoninic acid. The purple-coloured reaction product of this 
assay is formed by the chelation of two molecules of BCA with one cuprous ion. 
The water-soluble complex exhibits a strong absorbance at 562 nm that is 
nearly linear with increasing protein concentration over a broad working range 
(20-2000 pg/ml). The macromolecular structure of protein, the number of 
peptide bonds and the presence of four particular amino acids (cysteine, 
cystine, tryptophan and tyrosine) are reported to be responsible for colour 
formation with BCA. Protein concentrations were determined with reference to 
standards of a common protein such as bovine serum albumin (BSA).
Lipid raft extraction
Lipid raft extraction was carried out using IMCD cells. Reagents used were 
0.1% Triton X-100 (ice-cold), buffer B (50mM Tris/HCL, pH 7.4; 150mM NaCI; 
5mM sodium vanadate; 1mM PMSF; and protease inhibitor cocktail (Roche, 
East Sussex, UK), Optiprep (Axis-Shield, Norway), which is a density gradient 
medium. It is a ready made, sterile and endotoxin tested solution of iodixanol, 
5,5’-[(2-hydroxy-1-3 propanediyl)-bis(acetylamino)] bis [N,N’- 
bis(2,3dihydroxypropyl-2,4,6-triiodo-1,3-benzenecarboxamide], designed for 
the in vitro isolation of biological particles.
Other equipments used were tight-fitting Dounce homogenizer, 27-gauge 
needle, SW 50Ti centrifudge tube and L8-M ultracentrifudge (Beckman, High 
Wycombe, UK).
Mouse monoclonal anti-caveolin-1 (BD Transduction laboratories, Oxford, UK) 
was used as a marker for lipid raft.
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Western Immunoblotting
Western blotting equipment
Mini-Protean II cell gel electrophoresis tank system (including glass plates and 
metal strips), trans-blot SD semi-dry transfer cell and Polyvinylidene diflouride 
membrane (PVDF) were purchased from Bio-Rad (Hemel Hempstead, UK), 
supplied by Gibco (Paisley, UK).
Gel electrophoresis
Gibco (Paisley, UK) supplied electrophoresis graded agarose. Sigma-Aldrich 
(Poole, Dorset, UK) supplied: 30% acrylamide, ammonium persulfate, TEMED, 
and X-ray film: Kodak X-OMAT AR. 3MM chromatography paper was supplied 
by Whatmann Ltd (Maidstone, Kent, UK). Amersham Pharmacia (Chalfont 
St.Giles, Bucks, UK) supplied nitrocellulse membrane: Hybond-N.
Buffers and reagent
SDS gel-loading buffer: 2x was prepared, it consisted of 1M Tris-HCL (pH 6.8), 
4% SDS, 20% glycerol, 0.2%bromophenol blue and 200mM dithiothreitol.
The SDS in the loading dye surrounds the protein with a negative charge and 
the p-marcaptoethanol prevents the reformation of disulfide bonds. It was used 
to denature protein samples prior to electrophoresis.
Running buffer: It was prepared in 5x the working concentration. The 5x 
solution consisted of 25mM Tris, 250mM glycine (pH 8.3) and 0.1% SDS made 
up to 1 litre with distilled water.
Transfer buffer: It consisted of 48 mM Tris, 39 mM glycine, 0.037% SDS, 20% 
methanol.
Ponceau S (Sigma-Aldrich, Poole, Dorset, UK) was used to detect protein 
bands on the nitrocellulose membrane. It is a sodium salt of a diazo dye that is
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used to prepare a reversible stain of protein bands on nitrocellulose 
membranes. It stains protein bands pink which can be readily washed out with 
water.
Immunohisto/cyto-chemistry
Tissues samples were fixed, embedded and sectioned for 
immunohistochemistry; whereas cells grown on monolayer or in suspension 
culture were fixed and used for immunocytochemistry.
Equipment and chemicals
The following equipment was used: microtome, water bath, hot plates, 
microscope slides, coverslips. Reagents used were all provided by Sigma- 
Alrich: 3-aminopropyltreithoxysailane (TESPA), fluorescence mounting medium 
(DAKO), paraformaldehyde, bovine serum albumin, ethanol and histoclear.
Antibodies
Specific antibodies were used to detect antigens on tissue or cell samples. All 
antibodes were purchased from commercial companies, except anti-galectin-3 
antibodies which was produced by Dr. Hughes and Suleman Bawumia,
National Institute for Medical Research, Mill Hill, London.
The specific anti-galectin antibodies do not cross-react with other galectins, e.g. 
anti-galectin-1 antibodies do not react with galectin-3. The primary antibodies 
used during this thesis were raised against the following molecules, dilutions 
used for immunohisto/cyto-chemistry are listed:
Anti-galectin-1 goat polyclonal antibody (Cat#: AF1245, R & D Systems, UK). It 
was raised against E.co//-derived, recombinant mouse galectin-1. Galectin-1 
specific IgG was purified by affinity chromatography. This antibody was tested 
to cross-react with human galectin-1. Dilution used for immunohisto/cyto- 
chemistry 1:100
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Anti-qalectin-3 rabbit polyclonal affinity purified antibody was kindly provided by 
Dr Colin Hughes and Suleman Bawumia, National Institute for Medical 
Research, Mill Hill, London, throughout the duration of this study.
This antibody was produced in rabbit and was raised against a full length 
hamster galectin-3 protein. The protein sequence of hamster galectin-3 is 89% 
identical to that of mouse and 83% identical to that of human. This antibody 
was previously shown to detect human and mouse galectin-3 (Bao and 
Hughes, 1995; Winyard et al., 1997; Bullock etai ,  2001). Dilution used for 
immunohisto/cyto-chemistry 1:100; dilution used for western immunoblotting 
1:250
Anti-qalectin-4 goat polyclonal antibody (Cat#: sc-19286, Santa Cruz 
Biotechnology). It was raised against a peptide mapping within an internal 
region of human galectin-4. It cross-reacts with mouse and rat galectin-4. 
Dilution used for immunohisto/cyto-chemistry 1:100
Anti-qalectin-9 goat polyclonal antibody (Cat#: sc-19294, Santa Cruz 
Biotechnology). It was raised against a peptide mapping at the carboxy 
terminus of mouse galectin-9. it cross-reacted with human and rat galectin-9. 
Dilution used for immunohisto/cyto-chemistry 1:100
Anti-acetvlated tubulin monoclonal mouse antibody, (Cat#: 6-11B-1, Sigma- 
Aldrich). It was derived from the hybridoma produced by the fusion of mouse 
myeloma cells and splenocytes from an immunized mouse. Acetylated tubulin 
from the outer arm of Strongylocentrotus purpuratus (sea urchin) was used as 
the immunogen. The antibody cross-reacted with human, mouse, pig, bovine, 
rat, hamster, monkey, chicken and frog; as well as non-vertebrates protista and 
plants. Dilution used for immunohisto/cyto-chemistry 1:1000
Anti-y tubulin monoclonal mouse antibody (Cat#: GTU-88, Sigma-Aldrich). It 
was derived from the GTU-88 hybridoma produced by the fusion of mouse
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myeloma cells and splenocytes from an immunized mouse. A synthetic y- 
tubulin peptide (N-terminal amino acids 38-53) conjugated to KLH was used as 
the immunogen. The antibody cross-reacted with human, bovine, dog, hamster, 
rat, mouse, chicken and Xenopus y-tubulin. Dilution used for immunohisto/cyto- 
chemistry 1:1000
Anti-aauaoorin 2 polyclonal rabbit antibody (Cat#: 22110201, Chemicon 
International, USA). This antibody was raised against highly purified peptide 
corresponding to residues 254-271 of rat or mouse Aquaporin-2 with an 
additional N-terminal lysine and tyrosine. The antibody was shown to react with 
human, rat and mouse aquaporin-2. Dilution used for immunohisto/cyto- 
chemistry 1:300
Anti-calbindin D-28K polyclonal rabbit antibody (Cat#: 22090345, Chemicon 
International, USA). It was raised against recombinant calbindin. 
Immunoglobulin was affinity purified and recognises human, rat and mouse 
calbindin. Dilution used for immunohisto/cyto-chemistry 1:100
Anti-ret polyclonal rabbit affinity purified antibody (Cat#: R787, Immuno- 
Biological Laboratories Co, Japan). It was raised against synthetic peptide for 
C-terminal of human c-Ret. It also cross-reacts with mouse and rat. Dilution 
used for immunohisto/cyto-chemistry 1:100
PCNA (proliferating cell nuclear antigen): (Cat#: 555566, Oncogene Science, 
Massachusetts, USA): mouse monoclonal antibody (lgG2) to the PCNA that is 
expressed at high levels during S phase. The antibody is conjugated with 
biotin. Dilution used for immunohisto/cyto-chemistry 1:100.
Pre-immune serum (Sigma-Aldrich). Rabbit IgG was used as negative control.
Secondary antibodies: Secondary biotinylated antibodies which combined anti 
mouse / anti rabbit IgG were included in the ABC kit (DAKO) and secondary
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goat anti-rabbit horseradish-peroxidase (HRP) were purchased from DAKO. 
Fluorescent FITC (fluoroscein isothiocyanate) and TRITC 
(tetramethylrhodamine isothiocyanate) conjugated antibodies raised against 
rabbit and mouse IgG were purchased from Boehringer-Mannheim (Mannheim, 
Germany). Alexa Fluor Dye Series anti-rabbit, anti-mouse and anti-goat 
secondary antibodies were purchased from Molecular Probes, USA.
Specific Markers
Lectins; biotin conjugated lectins were obtained from Sigma-Aldrich. Lectins are 
proteins or glycoproteins, often derived from natural sources such as plants, 
which bind to specific carbohydrate residues. The specificities of lectins used in 
this thesis were: Arachis hypogaea (peanut) -  p-gal(1-3)galNAc and Dolichos 
biflorus -  a-galNAc. In the kidney, lectins can be used to identify different parts 
of the mature nephron. Arachis hypogaea specifically detects the collecting 
ducts and Dolichos biflorus specifically detects the ureteric bud and its 
derivatives (Holthofer, 1981 and 1984; Verani et al., 1989).
Periodic Acid- Schiff’s (PAS) reagent (Sigma-Aldrich) was used to detect 
proximal tubules in kidneys. It labels brush border of proximal tubules pink.
In situ Cell Death Detection Kit. Fluorescein (Roche) was used to detect cells 
that underwent apoptosis. This kit detects cell death base on the TUNEL- 
reaction (Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End 
Labeling). Cleavage of genomic DNA during apoptosis may yield double­
stranded, low molecular weight DNA fragments as well as single stand breaks, 
which can be identified by labelling free 3’-OH termini with modified 
nucleotides. This reaction is catalyzed by Terminal deoxynucleotidyl transerase 
(Tdt).
Haematoxvlin and eosin (Sigma-Aldrich) were used to immunostain nucleus 
and cytoplasm respectively under light microscopy.
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Propidium iodide (Sigma-Aldrich) was used to label the nucleus under 
fluorescent microscopy. It intercalates in the nucleic acid helix (both DNA and 
RNA) with a resultant increase in the fluorescence.
Detection reagents
ABComplex/HRP kit (DAKO). The avidin-biotin complex (ABC) was used to 
amplify the signal. It has proven to be an excellent and sensitive immunoassay 
technique. Avidin (reagent A), a protein found in egg white and certain bacteria, 
has an extraordinarily high binding affinity to biotin. It is a 68 kDa tetrameric 
glycoprotein composed of four identical subunits. Each subunit is glycosylated, 
and contains one binding site for biotin. Peroxidase (Reagent B) has been 
biotinylated with activated biotin. The reagent A and B were mixed together to 
increased the signal produced by the secondary antibodies; the avidin molecule 
that binds to the biotinylated secondary would have more then one peroxidase 
attached to it. And hence the signal is amplified. Peroxidase activity is then 
detected by colorimetric changes in DAB. Usage of the kit is in accordance to 
the manufacturer’s guide.
3,3-diaminobenzidine tetrahvdrocholride (DAB) buffer (DAKO) was used to 
indicate positive reaction under light microscopy. DAB is suitable for use in 
peroxidase-based immunohistochemistry. Upon oxidation, it forms an insoluble 
brown end product at the site of the target antigen.
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Microscopy
Light and fluorescent microscopy was performed on a Zeiss Axiophot 
microscope (Carl Zeiss, Oberkochen, Germany) using objective lenses of 5x, 
10x, 20x, 40x and 63x (oil immersion) magnification. Specimens were taken 
digitally using an Olympus Camedia C-3030Zoom Digital camera.
Confocal fluorescent microscopy was performed on a Leica Aristoplan 
microscope and computer confocal laser scanning system (Aristoplan-Leica, 
Heidleberg, Germany) with oil immersion objective lenses of 16x, 25x, 40x, 63x 
and 100x and software interpolation of intermediate magnifications. Images 
were saved as tagged image format (TIF) files and imported, for labelling, into 
Adobe Photoshop (Version 7.0, Adobe Systems Europe, Edinburgh, UK) or 
Microsoft Powerpoint 2000 (Microsoft Corporation, Seattle, USA). A dual­
channel confocal instrument was used which was able to produce a single 
image of expression of two different proteins.
Dr Kerrie Venner prepared cystic kidney samples for scanning electron 
microscopy in the Electron Microscopy Department, Institute of Neurology 
(UCL, London). They were then examined on a Joel 100 CX transmission 
electron microscope.
Atomic force microscope, AFM (JPK Instruments AG, Germany) was housed in 
the Bone and Mineral Centre at UCL and operated under the supervision of 
Prof. Mike Horton and Dr. Belinda Haupt. AFM detects the surface of a sample 
with such a discriminating touch that it can sometimes even distinguish 
individual atoms on the surface of a crystal such as gold (Dufrene 2001;
Charras et al., 2001). It does this by raster-scanning a small tip back and forth 
over the sample surface. The tip is on the end of a cantilever, which deflects 
when the tip encounters features on the sample surface. This deflection is 
sensed with an optical lever: a laser beam reflecting off the end of the 
cantilever onto a detector that magnifies small cantilever deflections into large 
changes in the relative intensity of the laser light on the two segments of the
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photodiode. In this way, the AFM generates a topographic map of the sample 
surface. See figure 8.1.
Figure 8.1. Simple diagram illustrating the principle of AFM.
The diagram below simply illustrates the components of an AFM. A 
cantilever is set to be in contact with the sample on the sample stage 
and it scans through the sample to give a topograph. A laser beam is 
adjusted to direct to the back of the cantilever and the beam is reflected 
to a detector. The movement of the cantilever can therefore be detected 
and measured as the beam reaches different points on the detector.
I I  Laser
detector
Cantilever
sample stage
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Statistical analysis
Microsoft Excel 2003, SPSS (Illinois, US) and MLwiN (Multilevel Modelling -  
Bristol, UK) were used to analyse data.
Chi-squared from MS Excel was used to see if the offspring followed 
Mendelian’s Law of Inheritance, by comparing observed ratio of genotypes to 
the expected ratio (e.g. 1:2:1 ratio when assessing one locus). If the chi-square 
value is less than 0.05, than the outcome does not follow Mendel’s Law of 
Inheritance.
t-test from MS Excel was used to compare two groups of samples. If the p- 
value is less than 0.05 than the difference between the two groups was 
significant.
Multilevel Modelling (MLwiN) program was used to assess inter-and intra-litter 
differences and if these differences affected the outcome of the results; and 
more importantly to determine if all the animals obtained could be analysed as 
one big group without adjusting to their littermates and parents. Many kinds of 
data, including observational data collected in the biological sciences, have a 
hierarchical or clustered structure. For example, animal studies of inheritance 
deal with a natural hierarchy where offspring are grouped within families. 
Offspring from the same parents tend to be more alike in their physical and 
mental characteristics than individuals chosen at random from the population at 
large.
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C h a p t e r  9: M e th o d s
Generation of cpk, galectin-3 double null mutants
Initially, galectin-3 null mutants were obtained from our collaborator Dr. Poirier. 
These mutants were on the 129Sv background. They were crossed with cpk 
heterozygotes (on C57BL/6j background) to yield F1; from which double 
heterozygotes (cpk +/- galectin-3 +/-) were selected by genotyping and 
intercrossed to yield offspring, some of which were cystic with various galectin- 
3 genotypes. To obtain double mutants on a pure background, cpk allele was 
backcrossed 10 times to 129Sv animals, to give a genetic background 
difference of less than less than 0.2%. Double heterozygotes on the 129Sv 
background were intercrossed to yield double mutants. Because of 
confounders described later, galectin-3 mutants on the C57BL/6j were imported 
and they were bred with cpk heterozygotes; as above, double heterozygotes 
were selected and intercrossed to yield double mutants on the pure C57BL/6j 
background. For the study of cystogenesis in animal with different galectin-3 
genotypes, all animals were sacrificed at 1 week because we predicted that 
galectin-3 null mutant would have accelerated cyst growth. Their body and 
kidney weights recorded. The kidney/body weigh ratio was use as an indicator 
of cytogenesis. For each sample, the body weight was recorded before cervical 
dislocation; a tail tip was saved for DNA extraction and genotyping; the left 
kidney was carefully dissected out and stored on ice before weighing then 
stored at -70°C; the right kidney was dissected out and placed immediately in 
4% paraformaldehyde (PFA -  supplemented with calcium chloride and 
magnesium chloride) to preserve the kidney morphology structure, prior to 
sample embedment.
Cystic index of cortical cysts in kidneys.
A cystic index score was developed to quantify the cortical cystic level of each 
sample and to compare subtle differences in cystogenesis between cystic mice 
with different galectin-3 genotype. This scheme grades cortical cysts as follows:
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0 - no cysts; 1 - mildly dilated tubules/ducts only; 2 - occasional moderately 
dilated ducts and cysts; 3 -  more frequent or larger cysts, or cysts extending to 
the edge of the cortex but with relatively well preserved architecture; 4 - 
frequent large cysts disrupting cortical architecture. Three sections were 
prepared from the mid section and outer quarters of each kidney and reacted 
with DBA, counterstained with PAS (see later on methods for 
immunhistochemistry); these were then photographed by a blinded observer, 
and scored by three blinded observers to generate a mean cortical cyst score 
for each sample.
Cell culture
Inner Medullary Collecting Ducts cells (IMCD3)
IMCD3 were used to assess the localisation of galectin-3 and other proteins 
such as acetylated tubulin. This immortalised cell line is derived from adult 
mouse kidney. They were preserved as frozen stock in liquid nitrogen. Prior to 
experiment these cells were thawed and plated into fresh medium.
Maintenance of cell culture
Aseptic technique was employed to ensure no contamination. All procedures 
were carried out in a sterile laminar flow hood. IMCD3 cells were grown in 
tissue culture flask in a 37°C incubator. Medium and PBS were warmed up to 
37°C before use. To feed these cells, first the old medium was extracted 
carefully, and then the cells were washed three times with room temperature 
PBS by adding 3 to 5ml then gently shake the flask from side to side. The PBS 
was then discarded and fresh medium was added.
IMCD3 cells have to be split once they reach confluent growth, which took 2 to 
3 days. The cells were split into 2 or 3 portions and each portion was plated 
into a new flask. Before splitting, the cells were washed with PBS three times 
as described above, and then they were dislodged by adding trypsin-EDTA
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solution, 1 ml to a 25 cm2 flask and 3 ml to a 75 cm2 flask. The flask was then 
shaken gently sideways for no more then 30 seconds, followed by removal of 
all trypsin-EDTA solution and incubation at 37°C until cells are floating. This 
usually takes around 5 minutes. After checking that all the cells were dislodged 
under a microscope, they were collected in fresh medium into a falcon tube, 
and then centrifuged at 2000 rpm for 5 minutes. The supernatant was 
discarded and the cells were resuspended in 30 or 45 ml of fresh medium, this 
volume depends on the size of culture flask used. One third of the medium with 
suspended cells was plated into a culture flask.
Freezing and thawing cells
Immortalised cells can be preserved in liquid nitrogen. It is best to freeze cells 
when they were growing rapidly and just before reaching confluence. For 
monolayer culture, the cells were always fed a day before freezing. The cells 
were washed with PBS twice, followed by removal of the solution. Then they 
were dislodged using trypsin-EDTA as described above and then resuspended 
in 1 ml of 10 % DMSO in fetal calf serum. The cells were frozen down slowly by 
putting in a polystyrene box in -70°C overnight. Finally the frozen cells were 
transferred into liquid nitrogen.
To thaw the stock, the frozen cells were warmed up quickly by putting into a 
37°C water bath. The thawed stock was then added dropwise to 10 ml of warm 
medium in a 25 cm2 culture flask. The cells were added slowly to avoid osmotic 
shock. The cells were allowed to adhere for approximately 8 hours then the 
medium was changed to get rid of all DMSO which is toxic to cells.
Primary culture
Primary cultures of kidneys from cpk mice were carried out to grow collecting 
duct epithelial cells, as an in vitro model of cpk epithelial cells. In suspension, 
these cells form cysts within 24 hours (Woo et ai. 1994). Whereas cultures from 
non-cystic kidneys did not form cysts after 24 hours. Primary cultures of normal 
kidney were also carried out in order to grow normal epithelial cells in vitro.
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Three-dimensional suspension culture of cpk cyst
Suspension cultures were used to grow cysts in vitro. These cells came from 3- 
week old cpk -I- kidneys. The pair of kidneys was dissociated to give partially 
digested kidney cells, which were then cultured in suspension. The cultures 
were incubated for 24 hours (Woo et al., 1994). For experiments involving the 
addition of taxol and/or galectin-3, these reagents were added before 
incubation. After 24 hours, the plate was assessed and at least 12 random 
fields were photographed. The photos were then evaluated for cyst number and 
size using computer software, Scion or ImageJ.
Details of experimental procedures are as follows.
Kidney dissociation:
3 week old cpk cystic animals were sacrificed and their kidneys were dissected 
and placed into ice-cold L15 medium with antibiotics. All subsequent 
procedures were performed in a tissue culture hood using aseptic techniques. 
The kidneys were gently cut by scalpels to release cyst fluid which was 
discarded. Then the tissue were cut into small pieces <2mm3, which were 
transferred into 7ml of DMEM:F12 supplemented medium (see material), with 
10mg/ml collagenase, 200mg/ml of dispase and 10mg/ml of DNase I. These 
enzymes dissociate cells to virtually a single cell dispersion and degrade 
released DNA, which contributes to cell clumping. The mixture was left for 30 
minutes in a 37°C water bath with occasional shaking. Afterward, the 
suspension was spun at 2000 rpm for 5 minutes, and the supernatant 
discarded.
Plating cells:
The pellet was resuspended in 14ml of fresh DMEM:F12 supplemented 
medium by pipetting up and down. It was then left to settle for 2 minutes to 
allow large aggregates and tubules to settle to the bottom, afterward the top 12 
ml containing single cells, small aggregates and tubule fragments was removed 
to a fresh tube. Next the number of viable cells was counted under a
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haemacytometer. Viable cells were determined by mixing 10pl of tryphan blue 
with 10pil of cell suspension. Dead cells are permeable to the tryphan blue, and 
hence appear blue. The optimal plating cell density was 5 x 105 cells per ml. 
When required, the cell suspension was diluted to obtain the plating density. 
2ml of cell suspension was plated on each well of a 6 well plate that was 
coated with 1% agar in cultured medium; the agar gel was used to stop cells 
from adhering to the plastic surface of the cultured plates. The cultures were 
incubated at 37°C in a moisture saturated incubator in 5% CO2 and air for 24 
hours (Woo et al., 1994; Hillman et al., 2004). The supplements added to the 
medium encouraged the growth of epithelial cells.
Culture assessment:
After incubation, cell growth was terminated by addition of 1ml of 4% 
paraformaldehyde in PBS with 1mM CaCb and 1.5mM of MgC^. Calcium and 
magnesium prevent microtubule depolymerisation, which was useful when 
assessing microtubule organisation (e.g. acetylated tubulin in primary cilia). 
This step also fixed the cells for immunocytochemistry.
The plates were gently shaken to disperse the cells evenly across each well. 
After the cells had settled to the bottom, twelve random fields per wells were 
photographed using a digital camera attached to the microscope. The pictures 
were analysed using computer software, Scion or ImageJ, to determine the 
mean number and size of cysts per well.
Epithelial monolayer using cpk cells
Monolayers of cpk mutant cells were extracted from cystic kidneys and cpk 
wildtype and heterozygotes kidney cells were extracted from the medulla of 
non-cystic kidneys. These cells were grown to assess the localisation of 
galectin-3 and other protein (such as acetylated tubulin) by 
immunocytochemistry. The procedure employed here was very similar to that 
used in 3-D cyst culture. Instead of plating the cell on agar-coated plates, the 
dissociated cells were plated on glass cover slips or chamber slides to form
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monolayers. For the growth of non-cystic kidney epithelia, only the medulla was 
cultured. The cortex was carefully cut out before partial digestion of the 
medulla. Due to the smaller size of these samples, they were incubated in the 
dissociation enzymes (collagenase, dispase and Dnase 1) for 20 minutes only 
instead of 30 minutes. The plating density of cells was 5 x 105 cells/ml.
Culture assessment:
The assessment of these monolayers are different to the 3-D cyst cultures:
All monolayers were plated using DMEM/F12 medium with 5% serum and 
supplements until cells were adhered to the bottom. This usually took 24 hours, 
then the medium was changed to serum-free to discourage the growth of 
fibroblasts. Once islands of epithelial cells were grown, the serum free medium 
was changed everyday. Prior to the addition of fresh serum-free medium with 
supplements, the cells were washed twice with PBS to get rid of all the non­
adherent cells and allow the continuous growth of the epithelial monolayer. 
Relatively big colonies of epithelial cells appeared after five days in culture, 
which at that stage they were fixed and immuno-stained. The cultures were 
kept for no more then 10 days as by that stage, a mixed population of cultures 
were seen and were beginning to be overgrown by fibroblasts.
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Genotyping
The cpk and galectin-3 genotypes of animals were determined. It was carried 
out by Polymerase Chain Reaction (PCR) using specific primers flanking the 
locus of interest. DNA was extracted from samples. After PCR, the genotype of 
an individual was determined by the size of the fragment and/or the presence 
or absence of fragments showed on an electrophoretic gel (see figure 9.1).
Figure 9.1. Patterns of DNA bands on electrophoretic gel indicating 
different genotypes.
Genotyping were carried out by PCR and the genotype of samples was 
distinguished by the size of DNA fragment obtained. Below pictures of 
two electrophorectic gels show the correlation between the size of DNA 
fragment and the cpk genotypes and galectin-3 genotypes from 
the129Sv mutant.
cpk genotypes
V.:.. 351 bp
« 320bp
1. 2. 3.
galectin-3 genotypes
577bp
305bp
1. Wildtype
2. Null mutant
3. Heterozygous
DNA extraction
DNA was extracted from the tail tip of the animals, around 0.3 mm tail tip of 4 
weeks old mice or 0.5 mm tail tip of culled, pre-weaned mice were cut and 
stored in -20°C. All extractions were carried out using the DNeasy kit (Qiagen) 
and based on the protocol supplied with the kit. In some cases where tail tips 
were not available, ~ 25 mg of animal tissues were used instead.
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Polymerase Chain Reaction
PCR was used to amplify DNA fragments that were size-specific to a particular 
sub-type of the cpk or galectin-3 loci. The primers used were specifically 
designed (see Materials for sequence).
Both cpk genotyping and galectin-3 genotyping were optimised by varying the 
primer concentration and dNTP concentration to determine maximum yield. 
Also the annealing temperature was optimised by running the reaction in a 
temperature gradient. The PCR reaction was initiated by incubating at 95°C for 
15 minutes to activate the HotstartTaq polymerase.
For cpk genotyping, the reaction mix consisted of 41.6 pi of MilliQ water, 0.4 pi 
of dNTP, 0.4 pi of each primer, 100-500 ng of DNA, 1 unit of HotstartTaq 
polymerase, 1 pi of DMSO, 5 pi of buffer solution provided with the enzyme. 
And for galectin-3 genotype, the reaction mix was made up of 13.6 pi of milliQ 
water, 0.6 pi of dNTP, 0.4 pi of each primer, 100-500ng of DNA, 1 unit of 
HotstartTaq polymerase, 5 pi of solution Q provided with the enzyme kit, extra 
1 mM of MgCb, 2.5 pi of buffer solution provided.
The first step of the cycle was DNA denaturing at 94°C for 30 seconds; 
followed by annealing for 30 seconds at 64°C for cpk genotyping and 57°C for 
galectin-3 genotyping; then DNA replication was carried out at 72°C for 5 
minutes. This cycle was repeated 30 times and was terminated by incubating at 
72°C for 7 minutes to allow complete elongation of DNA fragments, followed by 
incubation at 4°C for storage.
DNA Electrophoresis
Agarose gel electrophoresis was used to separate DNA fragments according to 
size. This method is based on the fact that DNA molecules are negatively 
charged and that fragments of linear DNA migrate through agarose gels with a 
mobility that is inversely proportional to the logio of their molecular weight.
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Therefore the shorter the DNA fragment the further it runs through the gel. For 
this experiment, 1.5% agarose gel was used to separate DNA fragments 
produced by cpk genotyping and 1% agarose gel was used to separate DNA 
fragments yielded by galectin-3 genotyping. The higher concentration used for 
cpk genotyping was due to the smaller difference between the two DNA 
fragments produced by the wildtype and null allele.
To make up a 1.5% gel or 1%, 1.5 g or 1g of agarose was dissolved in 100 ml 
of TAE buffer by microwaving at full power, 0.5 pg/ml of ethidium bromide 
solution was added as the agarose cooled to reduce the risk of ethidium 
bromide, which is an active carcinogen, from vaporising. It was then poured into 
a casting tray and the comb was inserted. The gel was allowed to set for 
around 30 minutes. Once set, the comb was carefully removed and the tray 
was placed in an electrophoresis apparatus, which was filled with enough TAE 
buffer to cover the gel. 7 to 10 pi of the DNA sample containing 1x blue loading 
dye was loaded into the wells. The gel was run at up to 100 volts and required 
a minimum of 45 minutes running time, according to the size of the fragment. 
The DNA fragments were visualised and photographed under UV light.
Protein extraction
Protein was extracted from cultured cells and kidneys for immunoblotting. RIPA 
buffer (150 mM sodium chloride, 1% nonident P-40, 0.5% sodium 
deoxycholate, 1% sodium dodecyl sulphate and 50 mM Tris buffer pH 8.0) plus 
protease inhibitors (66 pg/ml of aprotinin, 100 pg/ml of PMSF and 1 mM of 
sodium orthovanadate) were use to lyse cells and prevent protein degradation. 
RIPA buffer was stored at 4°C and protease inhibitors were added fresh to the 
buffer just before use.
Ceil homogenisation
Cultured cells
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Medium was aspirated from culture flasks and the culture was washed twice 
with PBS. 500 pi of ice cold RIPA buffer with protease inhibitors was added to 
the culture flask, using a cell scraper, cells were scraped off the flask and were 
transferred to a 1.5 ml eppendorf tube on ice. The cells, still on ice, were 
treated with intermittent sonication.
Kidney samples
Proteins were extracted from one or three weeks old normal and cystic kidneys. 
For three weeks old cystic kidneys, cyst fluid was first removed by gently 
pressing the kidneys with a scalpel. The fluid was collected and stored at -70°C 
for later use. Using two scalpels the kidneys were diced on a sterile plastic Petri 
dish in RIPA buffer with protease inhibitors; 700 pi was used for normal and 
one week old cystic kidneys, 1.5 ml was used for three weeks old cystic 
kidneys. The kidneys were cut into small pieces <2mm3 and together with RIPA 
buffer was transferred into either a 1.5 ml eppendorf tube or a 2 ml eppendorf 
tube. The samples were placed on ice and were homogenised using a plastic 
homogenator specifically used with eppendorf to break the tissues down 
further, followed by sonication.
Sonication
Homogenised samples were sonicated to ensure all cell membranes were 
lysed. The probe was washed with distilled water before use. Samples were 
placed on ice during the process and were sonicated by placing the probe in 
solution. The samples were intermittently sonicated for no more than 5 seconds 
per stroke to avoid overheating which leads to the breakdown of the protein. 
Approximately 5 strokes were applied for each sample or until the solution went 
frothy.
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Protein collection
The samples were certrifuged at 13000 rpm at 4°C for 30 minutes. Supernatant 
which contained protein was transferred to a fresh eppendorf and stored at -70 
°C.
Protein quantification
Protein was quantified using a BCA (bicinchoninic acid) protein assay kit. 
Procedures carried out following the manufacturer guide. Protein samples were 
quantified using a 96 well ELISA plate
Preparation of BSA standards and working reagent
2 mg/ml of BSA was provided with the kit and was used to prepare a standard 
curve of known dilution: 2000 pg/ml, 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 
pg/ml, 25 pg/ml and 0 pg/ml. BSA protein was diluted with PBS. Working 
reagents were prepared by mixing the two reagents provided (50 parts of A 
plus 1 part of B). 200 pi of working reagent was required for each sample, 
hence the total volume of working reagent required was calculated by 
multiplying 200 pi the number of tester samples plus 7 (the number of standard) 
plus 2 (spare).
Sample incubation and detection
Two hundred pi per sample or standard of working reagent was added into a 
96-well plate. 25 pi of each sample or standard was added to the working 
reagent. The order and position of the samples was recorded for later 
reference. The plate was covered and mixed gently before incubation at 37°C 
for 30 minutes. After which the plate was cooled and the absorbance was 
measured at 560 nm on a plate reader.
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Determination of protein concentration
First the standard concentration was plotted with MS Excel, with the 
absorbance (y-axis) versus the know protein concentration (x-axis). Using MS 
Excel, equation that showed the slope of the graph and the y-intercept was 
shown, e.g. y = 0.0003x + 0.0589. Using the equation, the protein 
concentration (value x) of each unknown samples was determined by 
substituting y with the absorbance.
Lipid raft extraction
Lipid raft extraction and fractionation was carried out in IMCD cells in order to 
assess the presence of galectin-3 in lipid rafts.
Lipid raft is a more ordered domain within the lipid bilayer, containing a high 
degree of tightly packed lipid acyl side chains. It is insoluble in cold detergent 
(1% Triton) thus making it feasible to be isolated. Due to its high lipid content, it 
floats to the top of a sucrose gradient during ultracentrifugation. In this thesis, 
commercially available Optiprep was used instead of sucrose.
Confluent IMCD cells were harvested in cold PBS with a cell scrapper and 
pelleted by centrifugation at 3000rpm for 5 minutes. The cell pellet was 
resuspended in 1% triton X-100 in cold buffer B (see Material for constituents) 
and incubated for 30 minutes on ice. The cells were then homogenised with 10 
strokes of a tight-fitting Dounce homogenizer followed by 3 passages through a 
27-gauge needle. The homogenates were adjusted to 35% Optiprep and 600pl 
the solution was placed at the bottom of a SW 50Ti centrifudge tube beneath a 
discontinuous gradient (0% to 35%) of Optiprep. There were a total of three 
layers: the bottom layer was the cell homogenates/ 35% Optiprep, the middle 
layer was 2400 pi of 30% Optiprep and the top layer was 700 pi of buffer B. 
Each layer was added slowly along the side of the tube to avoid mixing. Dilution 
was made with buffer B. The tube was then weighed and a second centrifuge 
tube was adjusted to the same weight. It was very important to have the two 
tube to the exact same weights as they have to balance each other during the
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ultracentrifugation. The two tubes were carefully placed into the appropriate 
tube holders which were then securely placed into a Beckmann SW 50Ti rotor. 
The samples were centrifuged at 200,000 x g for four hours at 4°C. Afterward, 
the content in the tube was divided into ten fractions; starting from the top 
370 pi was carefully pipetted out. The interface between the top and the middle 
layer (fraction 3) contained lipid raft proteins. The ten fractions were then used 
for western blot analysis (see below), a marker was loaded to the first fraction 
due to space limitation on the gel, which only contains 10 wells. Western 
blotting was carried out using antibodies against galectin-3 to determine which 
fractions the protein could be found; and anti-caveolin-1 as a marker for lipid 
raft.
Western Immunoblotting
Western blot analysis was used to detect the presence of a particular protein in 
a mixture of any number of proteins while giving information on the size of the 
protein. This method depends on the use of a specific antibody directed against 
a desired protein. Process in brief: proteins were extracted from tissue or 
cultured cells; the proteins were then separated using SDS-polyacrylamide gel 
electrophoresis, which separates the proteins by size; protein bands were 
transferred to a nitrocellulose membrane; specific proteins were detected by 
incubating the membrane with specific antibodies and detection reagents.
Details of procedures are as follows:
Setting up gel apparatus
For this equipment, two gels need to be run together whether they contain any 
samples or not, therefore two sets of glass plates are needed.
Electrophoresis glass plates and racks were washed in distilled water then with 
70% ethanol and dried completely. The glass plates and metal strips were 
assembled in the rack in the correct orientation (large glass first, then metal 
strips on each side and the smaller glass placed on top). The metal strips were
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pushed to the side and bottom and the rack were tightened. The racks were 
then clicked into apparatus stand. 70% ethanol were poured in between the 
glass slides to ensure no leakage, after that, all solution were poured out and 
the glass slides were dried with 3MM paper.
Preparation of gels
Resolving gel
Twelve % resolving gels were used in this study. Fifteen ml of resolving gels 
were prepared each time to make up two gels. It consisted of 4.9 ml of distilled 
water, 6 ml of 30% acrylamide mix, 3.8 ml of 1.5M Tris pH 8.8, 0.15ml of 10% 
SDS 0.15 ml of 10% ammonium persulfate (made up fresh) and 6pl of TEMED 
(added last as it caused polymerisation). Using a pipette, 7 ml of resolving gel 
was poured slowly in between each set of the glass plates. On top of resolving 
gel water-saturated butanol (50% butanol and 50% distilled water, left overnight 
to separate into two distinct layers) was added, which removed any air bubbles 
which inhibits polymerisation and will ensure a flat gel meniscus. It took 
approximately 40 minutes to an hour for the gel to set; this was checked by 
observing the remaining gel which was not used. Once set, butanol was poured 
off and the area above the gel was washed with distilled watered and dried with 
3MM paper, being careful not to damage the resolving gel.
Stacking gel and combs
Ten ml of 5% stacking gel was prepared for each set-up. It consisted of 6.8 ml 
of distilled water, 1.7 ml of 30% acrylamide mix, 1.25 ml of 1.0 M Tris pH 6.8,
0.1 ml of 10% SDS 0.1 ml of 10% ammonium persulfate and 10 jul of TEMED. 
Stacking gel was carefully pipetted on top of the resolving gel to the top of the 
glass plate. Combs were placed into the stacking gel by first putting one side 
over the metal strip at the side and then gently glided the comb into the gel. 
Care was taken to ensure no trapped air bubbles. It took approximately 1 hour 
for the stacking gel to set, this again was checked by observing the unused
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stacking gel. The gel was either prepared for immediate use or made up the 
night before, wrapped in cling film and stored at 4°C.
Combs were removed from the gels, which together with the racks were 
transferred into a holder and were placed vertically into an electrophoresis tank. 
Running buffer (see chapter 7: Materials for details) was poured into the centre 
of the holder, in the area between the two gels and outside the holder in the 
tank. Checks were carried out to ensure that there were no leaks and no air 
bubbles in wells.
Protein denaturing
Forty to 50 pg of protein sample was loaded into 1.5 ml eppendorf tube and an 
equal volume of 2x electrophoresis buffer was added to each sample. The 
samples were then heated to 95°C for 5 minutes to denature the proteins and 
unfold them completely and were placed on ice afterward for another 5 
minutes. Denatured protein samples were stored in -70°C for future use or kept 
on ice for loading in the same day.
Sample loading and electrophoresis
Twenty to 40 pi of denatured protein samples were loaded into the wells. Care 
was taken to ensure no spillage of samples into adjacent wells. The dense 
sample solution will sink in buffer solution and sits onto the gel surface, forming 
a sharply defined layer. 12 pi of marker was loaded to allow comparison of 
protein bands later. Unused wells were filled with an equivalent volume of blank 
sample buffer.
The electrophoresis apparatus was connected to the power pack in the correct 
orientation. 140 mV was applied to the apparatus for 40 minutes for detecting 
galectin-3: by this point the protein travelled to the middle of the stacking gel.
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Electroblotting
Semi-dry electroblotting was used to transfer proteins from the gel to a 
nitrocellulose membrane. The electrophoretic apparatus was carefully 
dismantled and the two glass plates were separated carefully without breaking 
the gel, which was transferred to distilled water for a quick rinse before 
immersing it in transfer buffer (see chapter 7: Materials for details). 6 pieces of 
3MM paper and a protein transfer nitrocellulose membrane (Hybond C) were 
cut to slightly bigger than the gel. They were all placed in transfer buffer before 
use. On the semi-dry transfer apparatus, three pieces of 3MM paper were 
placed first, followed by the membrane and the gel. Before a new layer was put 
on top of the last one, air bubbles were removed by rolling a pipette over the 
papers/ membrane. This was done because air bubbles would stop the current 
from going across the gel. Sellafilm was placed around the outside of the gel so 
that electric current was run efficiently through the gel to the membrane. On top 
of the gel, three more layers of 3MM papers, again using a pipette to eliminate 
air bubbles. The lid was placed on securely and the transfer took place at 12V 
for 60 minutes. After this step the apparatus was dissembled, the membrane 
was inspected for adequate transfer by checking the transfer of marker. No 
component of the marker should be left on the gel. Experimental details and 
marker bands were marked on the membrane. The membrane was placed in 
PBS.
Staining with Ponceau S solution
The membrane was immersed in Ponceau S solution for 1 minute, then washed 
with distilled water. For most cases, a smear of protein bands were observed. 
These band patterns were photographed for later reference. The membrane 
was then washed with distilled water using a rotating platform until all Ponceau 
S staining was washed off. After that, the membrane was carefully placed into a 
50 ml falcon tube with PBS.
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Blocking non-specific binding directly to the membrane
Some antibodies can directly bind to the membrane, therefore available site 
was blocked to eliminate non-specific false positive reaction. This was done 
using a blocking solution (5% skim milk, 0.3% Bovine Serum Albumin and 0.2% 
Tween-20), which was usually prepared fresh and can be kept at 4°C for 3 
days. The membrane was immersed in blocking solution and was placed on a 
rotating mixer for a minimum of 30 minutes at room temperature, although 
membranes were often blocked for overnight at 4°C because of time-limit.
Incubation with antibodies
Primary antibody was diluted in blocking solution, the dilution used for each 
antibody is listed in chapter 7: Materials. 5 ml of this solution was prepared per 
membrane. Blocking solution was poured out of the falcon tube and primary 
antibody was added. For the detection of galectin-3, anti-galectin-3 antibody 
was incubated at room temperature for 2 hours. After the reaction, the 
membrane was washed three times in PBS-0.2% Tween for 15 minutes each 
then incubated with blocking solution again for 20 minutes in room temperature. 
Secondary antibody (again diluted in blocking solution) was incubated for 30 
minutes at room temperature. After that, the membrane was washed three 
times with PBS-0.2% Tween for 15 minutes each and once in PBS for 15 
minutes.
Signal detection
Luminol ECL reagent was used to detect signal. The two solutions (A+B) were 
mixed by adding an equal volume of each into a 15 ml falcon tube. Prepare 2 
ml of working solution for each blot. The membrane was carefully removed from 
the tube and was placed face up to dry. ECL was added directly onto the 
membrane and was incubated for 1 minute. ECL solution was poured off and 
the membrane was placed in a developing cassette in between two clear 
plastic sheets. The following steps were carried out in the dark room to avoid 
exposing the X-ray films. In the dark, an X-ray film was placed in the cassette
on top of the membrane. One corner of the film was cut to mark the orientation 
of the film and the film was place to the edges of the cassette so that the film 
and membrane could be aligned after development. The film was exposed to 
the membrane for various length of time, usually starting with 30 seconds. And 
based on that initial result, exposure time was adjusted to increase or decrease 
the signals. The HRP reaction only lasts for 1 hour maximum. After exposure, 
the film was developed then it was aligned to the membrane and the marker 
bands were marked on the film.
Immunohisto/cyto-chemistry
Immunohistochemistry and immunocytochemistry were carried out to detect the 
presence of specific antigens in tissues. In brief, fixed tissue or cells on a 
microscope slide reacted with a primary antibody specific to the protein of 
interest. The preparation was then treated with a secondary antibody that was 
coupled to the enzyme, horseradish perosidase (HRP) and was directed 
against the primary antibody. It was then treated with a chromogenic substrate 
(DAB) which reacted to HRP. A positive reaction was indicated by the 
development of a colour which signified the presence of the protein. 
Alternatively, the secondary antibody was directly coupled to a fluorofluor which 
was visualised under a fluorescent microscope or a confocal microscope. 
Microscopic examination revealed the presence of labelling, and hence of the 
specific protein to be detected.
Immunohistochemistry was carried out on mouse tissues unless otherwise 
stated.
Details of experimental procedures are as followed:
Repetition of samples
For most samples examined, at least 3 individuals from the same group were 
examined unless otherwise stated.
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Tissue fixation
Kidneys and sometimes other tissues were harvested and were put 
immediately into 4% paraformaldehyde (PFA) for 1 to 24 hours to preserve the 
tissue morphology and to confer chemical stability on the tissue by covalently 
cross-linking adjacent amino acids. For immunocytochemistry, cells grow in 
monolayer or in suspension were fixed with 4% PFA with calcium and 
magnesium for 20 minutes. The ions were added to maintain microtubule 
stability especially when detecting primary cilia.
Tissue embedment
Tissues were embedded in wax in order to preserve them permanently as 
specimen blocks and to obtain sections for immunohistochemistry. Fixed 
samples were washed twice with PBS. They were then dehydrated through an 
increasing ethanol gradient at room temperature: 30%, 50%, 70%, 85%, 95% 
and 100% twice. The solutions were changed every 30 minutes. Next the 
samples were immersed in Histoclear, twice for 30 minutes each, followed by a 
1:1 Histocleanwax at 60°C for 1 hour. The samples were then submerged into 
wax three times for 30 minutes each at 60°C. Samples were then transferred to 
a mould, where they were oriented and the wax was allowed to set.
Sectioning
Sections of 3 -  5pm in thickness were cut using a microtome. These sections 
were floated on a 45°C water bath to allow the tissue to un-crease. The 
sections were then picked up on either electrostatic glass slides or on glass 
slides that were treated with TESPA (aminopropyltriethoxysilane), which form a 
strong adhesion to the tissue. Slides were dried at 37°C overnight and stored at 
room temperature.
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Rehydration and pre-treatment
Sections were first dewaxed and rehydrated. The slides were placed in a rack 
and sequentially passed through Histoclear twice for 5 minutes each to fully 
dewax the tissues. Then the sections were passed through a graded ethanol 
series of 100% twice, 90%, 80%, 70% and 50% either for 5 minutes each or 
several seconds with agitation, followed by washing in running tap water.
The next step was to permeablise the cells to improve antibody penetration. 
This was achieved by microwaving the sections, which was reported to cause 
antigen unmasking (Shi et al. 1991). A pressure cooker was filled with citric 
buffer (2.1g Citric Acid in 1 litre milliRo water, adjusted to pH 6.0 with sodium 
hydroxide). The buffer was heated up by microwaving in full power for 5 
minutes. Then the hydrated slides were transferred into the buffer and 
microwaved at full power for another 5 to 6 minutes depending on the number 
and type of specimens. Slides were then left to cool by adding running tap 
water before washing in two short dips of MilliRo water followed by immersing 
in PBS/Tween, twice, for 5 minutes each. A wax ring was drawn surrounding 
each section to prevent spillage of solution in subsequent steps.
Blocking steps
The following two steps were designed to reduce background caused by 
endogenous peroxidase and non-specific binding. Before using horseradish 
peroxidise (HRP) in immunohistochemistry it was necessary to quench any 
endogenous peroxidase that was present in the tissue sections. In particular in 
kidney proximal tubules where a detectable level of peroxidase was present. 
Quenching was achieved by immersing slides in 3% hydrogen peroxide(H202) 
in PBS-0.1% tween-20 for 15 minutes in room temperature and then washed 
three times in PBS for 5 minutes each.
Non-specific binding was eliminated by incubating the slides in 5% fetal calf 
serum in PBS or 1% bovine serum albumin for 30 minutes in room temperature. 
At the same time, a humid chamber was prepared with PBS-soaked tissues. 
Blocking solution was tapped off prior to the addition of primary antibodies.
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Primary antibodies
The dilution of the primary antibodies differ from 1:50 to 1:1000 in blocking 
solution depending on the antibodies used, optimum concentration was 
determined in preliminary experiment where varying concentrations (1:50, 
1:100, 1:200, 1:500 and 1:1000) were used. This reaction took place in a humid 
chamber either overnight at 4°C or at 37°C for 1 hour. After incubation, the 
slides were washed three times with PBS-Tween, 5 minutes each. The 
concentration of each antibodies used can be found in chapter 7: Materials.
Secondary antibodies
For light microscopy analysis, the signal was amplified with the commercial 
avidin-biotin conjugate (ABC) kit. The biotinylated secondary antibodies were 
applied in 1:100 or 1:200 dilution depending on the antibodies and samples, for 
30 minutes at room temperature. Followed by washing with PBS/Tween for 
three times 5 minutes each.
For fluorescent immunohistochemistry, fluorescent secondary antibodies were 
added directly onto primary antibodies, usually in 1:100 dilution for 1 hour room 
temperature or at 4°C overnight. These slides were then washed three times in 
PBS/Tween for 5 minutes each and were ready for mounting.
Avidin Biotin Complex/ ABComplex-HRP kit
ABComplex/HRP (mixture of reagent A and B) is applied to the samples after 
excess secondary antibodies were washed off. The samples were incubated 
with the ABComplex/HRP for 20-30 minutes, followed by washing with 
PBS/Tween 3 times.
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Detection
3,3-diaminobenzidine tetrahydrocholride (DAB) solution was used to produce a 
coloured end product. It was directly applied onto the sections. Colour 
development was monitored either microscopically or directly by naked eye. 
Development was terminated when a brown colour developed by placing the 
slides in running water for 5 mintues. The time for colour development was kept 
constant when assessing different samples with the same antibodies, so 
immunostaining intensities can be directly compared.
Counterstaining
Counterstaining was performed to define the anatomy/histology of samples and 
help identify cells that expressed the antigen of interest and its location. 
Dolichos bilforus agglutinin (DBA) was commonly used to identify collecting 
tubule or the origin from it in kidney samples. Haematoxylin and/or eosin were 
usually used; the former stains nuclei dark purple and the latter stains 
cytoplasm pink. And for some kidney samples, periodic acid -  Schiff’s (PAS) 
reagent was performed before haematoxylin, it stains brush border of kidney 
proximal tubules pink. For samples that were counterstained with PAS, no 
eosin staining was carried. For fluorescent staining, some samples were 
counterstained with propidium iodide, which stains the nucleus red.
Following describe the procedures involved in carrying out these 
counterstainings.
Dolichos bilforus agglutinin (DBA), lectin
For staining collecting ducts, the slides were incubated in 1:100 dilution of 
biotinylated Dolichos bilforus agglutinin (DBA) for 30 minutes in room 
temperature or in 4°C overnight. Wash the samples 3 times in PBS for 5 
minutes. The biotin was detected by incubation in streptavidin-peroxidase mix 
(A/B solution from the ABC kit) for 30 minutes in room temperature, followed by 
washing in PBS for 5 minutes. The samples were again washed 3 time in PBS 
followed by immersing in DAB solution, which produces a brown precipitate
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through reacting with the A/B mixture and this reaction can be monitor by the 
naked eye or microscopically. The colour was usually developed between 1 
and 5 minutes, after that the slides were washed in running tap water. The time 
for colour development was kept constant when assessing different samples, 
therefore immunostaining intensities could be directly compared.
Haematoxylin/ eosin
The slides were submerged in reagent for 30 seconds to 2 minutes in room 
temperature, depending on the concentration of the reagent. Then washed in 
running for 10 minutes.
Periodic Acid Schiff’s (PAS) reagent
PAS reagents were stored at 4°C. They were allowed to warm up to room 
temperature before use. The staining was carried in a fume hood at room 
temperature. Slides were immersed in periodic acid solution for 5 minutes.
They were then rinsed several times in distilled water, followed by immersing in 
Schiffs reagent for 15 minutes and washing in running tap water for 5 minutes.
Propidium Iodide
Propidium iodide is commonly used as a red-fluorescent marker that binds to 
DNA. It is applied onto section in 1:5000 dilutions for 5 minutes at room 
temperature. Followed by washing with PBS/Tween 3 times for 5 minutes each.
Dehydration and mounting
Slides were dehydrated by passing through solutions of increasing ethanol 
concentrations from 50%, 70%, 80%, 90% and 100% twice either 1 minutes 
each or several seconds with vigorous agitation, then the slides were 
submerged in Histoclear twice for 5 minutes each. After drying the slides were
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mounted in DPX solution and covered with glass coverslips. They were stored 
away and were observed using a light microscope.
Slides stained with fluorescent antibodies did not require to be dehydrated. 
These slides were mounted using fluorescence mounting medium and the 
glass coverslips were sealed with nail vanish, which held the coverslips and 
avoided mixing of the glycerol and the oil when used oiled lens. They were then 
stored in the dark at 4°C and were examined within three to five days.
Negative control
Negative controls were used to evaluate non-specific immunostaining and allow 
better interpretation of specific immunostaining at the antigen site. All slides 
had a section that was not reacted with any primary antibodies, instead PBS- 
Tween was used. This allowed assessment of background levels. In some 
cases, primary antibody was preabsorbed with an excess (10:1 weight/weight) 
of immunising peptide before applying to sections; that pre-immune antibodies 
were applied. This allowed assessment of the specificity of each antibody.
Double staining using fluorescent antibodies
In most fluorescent immunochemistry, two different isotopes were stained 
together, i.e. in looking at the localisation of galectin-3 and y-tubulin and 
determine whether the two proteins are expressed at the same location. In this 
case, the two primary antibodies used were derived from two different types of 
animal, hence, rabbit anti-galectin-3 antibodies and mouse anti-y-tubulin 
antibodies. And the two secondary antibodies were conjugated to different 
fluorescent marker, goat anti-rabbit-FITC (green) and goat anti-mouse-TRITC 
(red). These slides were examined using the confocal microscopy and the 
images were processed with a computer programme called Leica Confocal 
Software (LCS).
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Determination of proliferative index on histological samples
A PCNA antibody was used as a marker for proliferating cells.
Kidney histological samples were immunostained with antibodies against PCNA 
for 1 hour at 37 °C and they were counter-stained with haematoxylin. After 
mounting, they were examined and counted blind using light microscopy. For 
each sample 20 cysts, approximately 600 cystic epithelial cells were counted 
per sample. Proliferative Index (PI) was measured as a percentage of PCNA 
positive cells over the total number of cystic epithelial cells. All samples were 
processed at the same time to ensure consistency in signal intensity.
Determination of apoptotic index on histological samples
Apoptotic cells were detected using the In Situ Cell Death Detection kit, 
Fluorescein, which is based on the TUNEL technology. Reaction was carried 
out according to manufacturer’s protocol. The kidney sections were treated with 
trypsin (30 minutes at 37°C) before the labelling with TUNEL reaction mixture 
(1 hour at 37°C), then the samples were counterstained with propidium iodide. 
Each sample was photographed using a confocal microscopy with a 40X lens.
At least 10 fields were taken for each kidney, for which the number of positive 
apoptotic cystic epithelial cells and the total number of cystic epithelial cells in 
each data point were counted. Approximately 700 cystic epithelial cells were 
counted per sample. Apoptotic index was expressed as a percentage of 
apoptotic bodies over the total number of cystic epithelial cells counted.
Immuno-staining for the presence of extracellular galectin-3 in primary 
cilia.
The sub-cellular localisation of galectin-3, in particular in primary cilia, was 
assessed by immunocytochemistry of non-permeablised IMCD cells. The 
primary antibodies (anti-galectin-3) were incubated to live cells, as fixation 
caused a slight permeablisation (as previously tested). IMCD cells were grown 
to confluency in 4 wells chamber slides and were allowed to ciliate. Prior to
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immunoreaction with anti-galectin-3 antibodies, the cells were gently washed 
with room temperature PBS three times then they were cooled to 4°C. Primary 
antibodies were added to the samples and were incubated at 4°C for two 
hours. The samples were then washed five times with PBS and fluorescent 
secondary antibodies (anti-rabbit) were added and incubated at 4°C for one 
hour; followed by 5 washes with PBS. The samples which were immunostained 
for extracellular galectin-3 were then fixed using 4% PFA for 20 minutes. The 
purpose of this experiment was to detect extracellular galectin-3 on the primary 
cilia, therefore the organelle were marked out using anti-acetylated tubulin 
antibodies. For this, the cells were permeablised with 0.5% Triton for 10 
minutes so that the antibodies could gain assess to the tubulin structure of the 
primary cilia. The samples were then incubated with anti-acetylated tubulin 
antibody for 1 hour at room temperature, followed by three washes with PBS- 
Tween and incubation with fluorescent secondary antibodies (anti-mouse). The 
samples were then washed three times with PBS-Tween. Excess solution was 
poured off and the samples were mounted with fluorescence mounting 
medium; covered with glass coverslips and sealed with nail vanish. The 
samples were then examined under a confocal microscope.
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Quantification of galectin-3 expression in renal epithelial cells
The expression of galectin-3 in normal collecting tubules and in cystic epithelial 
cells were compared, in order to determine any difference in the level of 
expression. The expression level was reflected by the immunostaining intensity 
following immunofluorescence staining. The intensity was quantified using the 
Leica Confocal Software (LCS). Cystic and normal kidney samples were 
immunostained for galectin-3 at the same time using the same concentration to 
ensure consistency. At least 10 frames per samples were recorded using the 
same intensity of laser beams under the confocal microscope. The intensity of 
galectin-3 expression was measured by tracing the epithelia; the expression 
profile of the trace, which represented cystic epithelia or normal tubule, was 
automatically generated by the LCS.
The profile showed the mean, maximum and minimum amplitude of a given 
trace. The amplitude reflected the immunostaining intensity, thus mean 
amplitude was a measurement of the mean galectin-3 expression among a 
group of cells marked out by the trace and the maximum amplitude was the 
level of expression of the most intensely stained point. The trace line (ROI in 
figure 9.2) was manually drawn on the computer image by tracing a tubule or 
cyst. The mean and maximum amplitude was use to compare the level of 
galectin-3 expression.
It is worth noting that this is a very crude method for determining the level of 
expression and that it did not take into account the amount of secreted protein.
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Figure 9.2. Illustration of staining quantification using Leica Lite 
software.
A) shows the traces of immuno-stained cysts for measurement. The five 
traces were represented as R01 to R05, in different colour. B) is a 
graphic representation of the immunostaining intensity of the five traces 
in A. Each trace was represented by a colour. C) shows the 
measurements of the traces in A. The amplitude reflected the 
immunostaining intensity, thus mean amplitude was a measurement of 
the mean galectin-3 expression among a group of cells marked out by 
the trace and the maximum amplitude was the level of expression of the 
most intensely stained point. The mean and maximum amplitude was 
use to compare the level of galectin-3 expression.
A B
H r-V      ■ ■ ■ i r r* ■■ ■ i t— 1 i '■ i i )
56 *30 196 *53 258 990 399
ROM ROI 2 ROI 3 ROI 4 ROI 5
Length 277.20 pm 243.31 pm 381.45 pm 86.00 pm 43.39 pm
Mean Amplitude 121.47 124.77 125.45 125.19 172.73
Max. Amplitude 255 255 250 255 254
Min. Amplitude 12 4 5 0 0
Average
Deviation 43.53 47.69 44.98 48.28 54.42
Standard
Deviation 54.58 58.01 54.44 58.03 61.59
Variance 2979.36 3364.82 2963.91 3367.74 3792.83
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Microscopy
Atomic force microscopy
Atomic force microscope (AFM) works were carried out in this thesis in order to 
find a novel approach to study primary cilium in culture.
The works were carried out in collaboration with Prof. Mike Horton and Dr. 
Belinda Haupt at the Bone and Mineral Centre at UCL. IMCD cells were 
cultured to confluency and were fixed with 4% PFA. For the examination of 
dried samples, the cells were washed three times with distilled water after 
fixation to avoid the build up of salt crystals, which can be detected by the 
cantilever of the AFM and interfere with the image outcome. For wet 
examination, the samples were incubated in PBS after fixation. A wax ring was 
drawn around the samples to hold the PBS while the cantilever scanned across 
the cells.
Topographs were obtained that showed the size and shape of primary cilia on 
the surface of the cells.
Scanning electron microscopy
Scanning electron microscopy, SEM, was used to observe primary cilia in cystic 
kidneys. The work was carried out in collaboration with Dr. Kerrie Venner. 3 
weeks old cpk kidneys were dissected and immediately placed in 3% 
glutaraldehyde/0.1M sodium cacodylate/5mM calcium chloride and were given 
to Dr. Venner for further processing. The samples were manually chipped into 
2-3mm pieces under liquid nitrogen and then passed through distilled water, 
and 1% Osmium Tetroxide to 100% ethanol. Critical point drying was then 
performed and samples mounted on aluminium stubs before overnight vacuum 
drying. They were then gold coated and imaged with a Jeol JSM-35CF 
scanning electron microscope
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Statistical analysis
For the in vivo study of cystogenesis in animals with various galectin-3 
genotypes, large amounts of data were obtained (approximately 200 per group 
of experiment). Data recording, sorting, analyses and graph preparations were 
all carried out using MS Excel. Multilevel Modelling (MLwiN) program was used 
to assess inter- and intra-litter differences.
Error bars presented in results represent standard error (SE).
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C h a p t e r  10 : R e s u l t s
The results of this thesis are organised into four groups: expression of galectin- 
3 in kidneys of cpk and other PKD models; effects of galectin-3 mutations on 
cystogenesis in viVo; expression of galectin-3 on the primary cilium of renal 
epithelial cells and the effect of paclitaxel on the cystogenesis of cpk mice. All 
these results support the hypothesis that galectin-3 is important to the 
development of renal cysts, and more importantly these results suggest that 
galectin-3 suppresses cystogenesis and may act via the primary cilium.
E x p r e s s io n  o f  g a l e c t in -3 in c p k  k id n e y s
Galectin-3 is normally expressed in the collecting tubules of the kidneys. It was 
previously reported to be up-regulated in human renal cystic disease. The 
protein is also implicated in renal development in a strictly regulated fashion 
(Winyard et al 1997, Bullock et al 2001). Here the expression of galectin-3 in a 
PKD model, cpk mouse, is investigated.
Persistent expression of galectin-3 in the renal cystic epithelia 
of cpk mice
Examination of several (n > 5) normal adult kidney tissue showed that galectin- 
3 expression occured in the collecting tubules in the cortex (fig. 10.1 A). These 
expression patterns overlapped with that of DBA (black arrows fig. 10.1B) and 
not with PAS (pink arrows in fig. 10.1 A), which indicated that galectin-3 was 
expressed in the collecting tubules and not proximal tubules. The protein was 
also expressed in the urothelium of the renal pelvis (* in fig. 10.1C). Cystic 
kidney samples of cpk mutant on B57BL/6j background at 1 week and 3 weeks 
were examined. In both age, galectin-3 was found in almost all cystic epithelia 
(fig. 10.1D, 1F, 3A -3D) derived from the collecting tubules as confirmed by 
DBA staining (fig. 10.1E). These results agree with those previously observed, 
confirming the expression of galectin-3 in collecting tubules of normal kidney
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and in human cystic epithelia (Winyard et al., 1997; Bullock et al., 2001). As a 
negative control, the antibody staining was performed on galectin-3 null mutant 
samples which showed no positive signal (fig. 10.1G).
Galectin-3 exhibited a predominantly cytoplasmic expression 
in both normal and cystic samples.
Intracellular expression of the galectin-3 in normal and cystic samples was 
carried out by immunoflorescent staining and confocal microscopy.
Examination revealed that galectin-3 was expressed in the cytoplasm of the 
epithelial cells, with a small proportion of cells expressing the protein apically in 
both normal and cystic samples (white arrows in fig. 10.2C and 10.3C). The 
intensity of cytoplasmic staining varied between cells and was barely detectable 
in a small number of cells (fig. 10.3B). Negative control was performed using 
pre-immune rabbit IgG on cystic kidney sample (fig. 10.3E) which gave no 
positive signal.
Using western blot analysis, secreted galectin-3 was detected in the cyst fluid 
of 3 weeks old cpk kidneys of 2 samples taken from different animals. Both 
galectin-3 monomer (30kD) and dimer (60kD) were detected. Cysts fluid was 
obtained by cutting the kidney in half and gently squeezing the samples, a 
process that released approximately 1 ml of cyst fluid per kidney. The cyst fluid 
was used undiluted and untreated as samples for immuno-blotting for the 
detection of galectin-3. Negative control of western blot analysis was performed 
using preabsorbed antibodies and postive control was used where recombinant 
galectin-3 was used (fig. 10.3F).
145
Cpk,gel-3 null /£&1-3
* « r-
Normal/ Gal-3
cp/c^Gal-
Normal/ Gal Normal,
Figure 10.1. Expression of galectin-3 in 3 week old normal and cpk 
kidneys.
Galectin-3 expression in kidney samples. In normal kidneys, galectin-3 
was expressed in the collecting tubules in the cortex (A, black arrows), in 
the medulla (C) and in the urothelium (*  in C). In cystic kidneys, 
galectin-3 is expressed in the cystic epithelia (D and F). Immunostaining 
on gal-3 null mutant samples confirmed the specificity of the antibodies 
(G). Collecting tubule origin was confirmed by Dolichos bilforus 
agglutinin (DBA) (B and E). Pink arrows in A indicate proximal tubules 
stained with periodic acid Schiffs reagent (PAS), which gave a pink 
signal and they did not express galectin-3. F shows that galectin-3 was 
expressed cytoplasmically. Scale bars = 50 mm
cpk/ G a l ^ ^
146
Figure 10.2. Expression of galectin-3 in normal adult kidneys.
A to D below show the expression of galectin-3 in normal adult mouse 
kidneys, of different magnitude (A with the lowest magnification and D 
with the highest). A strong cytoplasmic expression can be seen in all 
figures. Galectin-3 was detected in the collecting tubules and in the 
urothelium (*  in A). Galectin-3 was expressed cytoplasmically in the 
majority of cells that express the protein, except a small subtype that 
express the protein apically (white arrow in C). Negative control of anti- 
galectin-3 antibodies was carried out using pre-immune rabbit antibodies 
in figure 10.3E. Only anti-galectin-3 antibodies were applied and no 
nuclear markers were use. Scale bars = 20 mm
Figure 10.3. Expression of galectin-3 in 3 week old cpk kidneys and 
cyst fluid.
Fluorescent immunohistochemistry of cpk kidneys (A -  E) and western 
blot analysis of cyst fluid (F). A -  E show galectin-3 expression in 
different samples and of various magnifications. No nuclear immunostain 
was carried out in these samples. Majority of cystic epithelial cells 
express galectin-3 in the cytoplasmic domain, though a subset of cells 
expressed the protein apically only (white arrow in C). E is a negative 
control using pre-immune rabbit IgG on a cpk sample. Scale bars = 10 
mm.
r. J I' :
B
148
Figure 10.3. (continue)
Western blot analysis (F) of the cyst fluid of two different samples (1 and 
2). These samples were undiluted prior to loading, thus of unknown 
concentration. Negative control using pre-immune antibodies (3) and a 
positive control using recombinant galectin-3 (4) is also shown in F. All 
samples and controls were run in the same blot thus the positive control 
was used as a size marker. Lane 1 and 2 contained positive protein 
bands (both monomer and dimer galectin-3) at the same positions to that 
of the positive control (lane 4).
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Figure 10.3. (continue)
Western blot analysis (F) of the cyst fluid of two different samples (1 and
2). These samples were undiluted prior to loading, thus of unknown 
concentration. Negative control using pre-immune antibodies (3) and a 
positive control using recombinant galectin-3 (4) is also shown in F. All 
samples and controls were run in the same blot thus the positive control 
was used as a size marker. Lane 1 and 2 contained positive protein 
bands (both monomer and dimer galectin-3) at the same positions to that 
of the positive control (lane 4).
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Expression of other collecting duct markers in cystic kidneys 
compared with galectin-3.
Galectin-3 upregulation in cysts might simply represent non-specific re­
expression of early ureteric markers as these epithelia dedifferentiate towards a 
more embryonic phenotype. Hence, we investigated expression of other 
developmental markers, including ret, aquaporin-2 and calbindin. Strikingly 
similar expression patterns were observed for galectin-3, ret and aquaporin-2 in 
normal kidneys, with positive immunoreactivity restricted to collecting ducts 
(Fig. 10.4). Calbindin expression was more widespread, including some distal 
tubule segments (Fig. 10.4D). The distribution pattern of galectin-3 was unique 
in cystic kidneys: none of the other markers reiterated the pattern of prominent 
galectin-3 immunoreactivity across the whole range of cyst sizes; ret and 
calbindin immunostaining, for example, was inverse to cyst size (i.e. strong 
signal in tubules and small cysts, but little or no staining in large cysts); 
aquaporin-2 immunoreactivity was detected in some larger cysts but it was not 
as widely expressed in all cysts as galectin-3 was (Fig. 10. 4G).
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Figure 10.4. Expression of different collecting tubule markers in
normal and cystic kidneys.
All samples from 3 week old mice. A-D: phenotypically-normal kidneys; 
E-H: cystic kidneys. Immunostaining is for galectin-3 (gal-3), ret (ret) 
aquaporin-2 (aq-2) and calbindin d28k (calb). All counterstained with 
PAS. A -  C, Similar distribution of immunoreactive galectin-3, ret and 
aquaporin-2 in collecting ducts (arrowed) in normal kidneys. D, more 
widespread calbindin expression in distal tubules as well as collecting 
ducts. E, prominent cytoplasmic galectin-3 expression in collecting 
ducts/cyst of all sizes, from small undilated tubules through to large 
cysts. F, ret immunoreactivity in smaller tubules (arrowed) but reduced 
signal in larger cysts, with some having virtually no staining (*). G, 
aquaporin-2 was expressed in some cysts (arrowed), although others 
were negative (*). H, intense calbindin immunostaining of tubules and 
small cysts but reduced intensity in larger cysts (*). Scale bars = 50 mm.
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Expression of galectin-1 and galectin-9 in cystic kidneys 
compared with galectin-3
Both galectin-1 and galectin-9 are normally expressed in developing and 
mature kidneys; galectin-1 is predominantly located in the connective tissues 
and galectin-9 is expressed mainly in the proximal tubules (Hughes, 2004). 
Expression of the two galectins was examined in the kidneys of normal and cpk 
mice, as well as in galectin-3 null mutant kidneys, by immunohistochemistry 
using the light microscope and the confocal microscope.
In both normal and cystic kidneys (fig 10.5), galectin-1 was found exclusively in 
interstitial cells between epithelial cells, exhibiting strong cytoplasmic 
expression. No epithelial cells in both normal and cpk kidney samples were 
found positively stained with anti-galectin-1 antibody (fig 10.5A, C, E and G). As 
for galectin-9, it was mainly found in the apical domain of proximal tubules in 
both normal and cystic epithelia (fig.10.6B), although it was expressed in the 
rare collecting tubule epithelial cells in the cytoplasmic domain (black arrows in 
fig 10.5B, D, F and H).
Co-immunostaining using antibodies against galectin-3 (rabbit anti-galectin-3 
antibodies) and galectin-9 (goat anti-galectin-9 antibodies) revealed that the 
expression of the two galectin-3 appeared to overlap each other in the apical 
domain of non-cystic samples (fig 10.6A -  F); while the expressions of galectin- 
3 and galectin-9 in cystic samples were mutually exclusive (white arrows in fig 
10.6G -I).
The expression patterns of galectin-1 and galectin-9 were similar in both 
galectin-3 wildtype and null mutant kidneys (fig 10.5E -  H) compared with 
galectin-3 wildtypes.
153
Figure 10.5. Expression of galectin-1 and galectin-9 in normal and
cystic kidneys.
A -  D are three week old normal kidneys and E -  H are 3 weeks old cpk 
kidneys. Samples were immunostained with antibodies against galectin- 
1 (A, C, E, G) or galectin-9 (arrowed in B, D, F, H). The genotypes of 
each samples are indicated on the left. Galectin-3 null mutant samples 
are in C, D, G and H, which have the same expression pattern as 
galectin-3 widetype samples. Scale bars = 30 mm
Galectin-1
+/+ +/+
Galectin-9
+ /+  -/-
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Figure 10.6. Co-localisation of galectin-3 and galectin-9 in normal
and cystic kidneys.
A -  F are 3 week old normal kidneys and G -  I are 3 week old cpk 
kidneys. All samples were immunostained with antibodies against both 
galectin-3 and galectin-9 and examined using a confocal microscopy. 
Co-localisation of the two galectins in normal collecting ducts were 
observed in the cortex and the medulla (C and F). In cystic kidneys, 
most epithelial cells expressed galectin-3 (G) with a few cells that did not 
express it (white arrows in G -  I), galectin-9 was instead expressed in 
these cells that lack galectin-3. Scale bars = 20 mm
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Semi-quantification of gaiectin-3 expression in cystic and
normal kidneys.
Attempts were made to quantify the level of galectin-3 expression in normal 
tubule epithelia and in cpk cystic epithelia. Using immuno-blotting, my 
predecessor Dr. Tanya Johnson detected that the total amount of galectin-3 
protein expressed in cystic kidneys was much higher than in normal kidneys. 
However, she did not show that individual cystic epithelial cells expressed more 
galectin-3 compared with normal epithelial cells.
Using the Leica Confocal Software (LCS) and immunofluorescence, the 
intensity of galectin-3 immuno-staining was measured and quantified. Six 
samples of normal and five of cystic kidneys were immuno-stained for galectin- 
3 and accessed using the confocal microscope. All samples were processed at 
the same time to ensure consistency. Approximately 15 normal tubules/cysts 
were photographed at the same magnification (x40), excitation power (843 
voltage) and offset (2%). Representative images are shown in figure 10.7. At 
least 20 normal tubules/cysts were examined for each sample and their staining 
intensities were quantified and compared. Refer to Chapter 9: Methods, figure 
9.2 for an illustration of staining quantification.
In normal collecting tubular cells, the mean amplitude was 92 and the maximum 
was 200. In cystic epithelial cells, the mean amplitude was 94 and the 
maximum was 222 (fig 10.8). The differences in mean and maximum amplitude 
between normal and cystic sample was biologically non-significant, (p-values 
0.87 for mean amplitude and 0.10 for maximum amplitude).
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Figure 10.7. Representative images of kidney sections used for 
semi-quantification.
All samples were processed together to ensure equal exposure to anti- 
galectin-3 antibodies and other reagents; in addition, the images were 
taken using the same setting. Thus comparison of immuno-staining 
intensity can be compared. The four images below were randomly 
selected. A and B were sections taken from normal kidneys whereas C 
and D were from cpk kidneys. Note the different staining intensity 
between sections and also within the same section (white arrows in D). 
Cy = cysts and scale bars = 40 pm.
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Figure 10.8. Comparison of the mean and maximum level of 
galectin-3 expression in normal tubular cells and cystic epithelial 
cells.
A is a summary of the mean amplitude (mean staining intensity) 
comparing normal and cystic epithelia whereas B is a summary of the 
maximum amplitude (highest staining intensity).
Mean Amplitude B Max. Amplitude
i  I
Normal Cystic
E 150 
<
I
*
Normal Cystic
Mean 92.3 94.1 Mean 199.9 222.4
SE 6.57 9.85 SE 9.21 7.20
Lower ci 79.4 74.8 Lower ci 181.8 208.2
Upper ci 105.2 113.4 Upper ci 217.9 236.5
n 6 5 n 6 5
It is important to acknowledge that this protocol did not measure the total 
protein expression as it only allows the measurement of cytoplasmic galectin-3 
expression, ignoring the secreted protein. It was shown that galectin-3 was 
secreted into the cyst fluid which was detected by immuno-blotting (fig 10.3F).
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High level of galectin-3 expression in renal cystic epithelia of 
various PKD samples.
The focus of this expression study is on the cpk model as this was the chosen 
model for the study of ARPKD development. However, the phenotypes of cpk 
animals depend on the background of the animals, implying the presence of 
important modifier genes (ref, Guay-Woodford and Woo et al 1997). Therefore 
cpk samples from three different backgrounds (C57BL/6j, Balb/c and DBA) 
were examined. Various otherPKD kidney samples of different PKD mouse 
models and human samples were examined for the expression of galectin-3. 
These samples include pkd2, bpk and orpk mutant mouse; human samples 
included ARPKD and ADPKD samples. All mouse samples were of 3 week of 
age except orpk which was 1 week old, as this mutant dies before Day14.
Examination of galectin-3 expression in cpk mice of different 
backgrounds.
Galectin-3 expression in cpk models on different backgrounds were compared. 
It was previously shown that galectin-3 was widely expressed in cpk mouse in 
the B57BL/6j background, its natural and the most characterised background. 
Kidneys from 3 week old cpk mice on the Balb/c background were assessed. 
Renal cytogenesis in this background is very similar to that of C57BL/6j 
background: the 3 week old cpk Balb/c kidney was almost entirely filled with 
collecting duct cysts. Immunohistochemistry of the cpk Balb/c kidney revealed 
that the majority of cysts expressed galectin-3 cytoplasmically (figure 10.9B).
The 3 week old cpk kidney in DBA background did not exhibit renal cystic 
lesion. Immunohistochemistry analysis showed that galectin-3 was expressed 
in the collecting tubules in the cortex and the medulla of the kidney. No renal 
cysts were found in these samples. The expression pattern of galectin-3 was 
very similar to that of normal kidney (fig 10.9C).
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Examination of galectin-3 expression in different PKD models showed 
that galectin-3 was expressed in the cystic epithelial of all samples.
Immunohistrochemistry examination of the 3 week old samples of the pkd2 and 
bpk mutant showed that, similar to cpk kidney, galectin-3 was widely expressed 
in cystic epithelia (fig 10.10A-D).
The orpk samples obtained was on the FVB background, and at one week did 
not have a gross renal cystic presentation. Immunohistorchemistry showed that 
galectin-3 was expressed in the few cysts present in the orpk kidney (fig 10.10 
E and F).
Lastly, examination of human samples: ARPKD and ADPKD, revealed that 
galectin-3 was also cytoplasmically expressed in these cystic epithelial cells (fig 
10.10 G-J).
In both orpk and ADPKD samples: not all cysts express galectin-3 as indicated 
with * in fig 10.1 OF and 10.10G, these cysts may not be derived from collecting 
tubules.
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Figure 10.9. Expression of galectin-3 in cpk models on three
different backgrounds (B57BL/6j, Balb/c and DBA).
All kidney samples were of three week old cpk null mutants, cpk mutants 
on both the B57BL/6j (A) and Balb/c (B) backgrounds were severely 
cystic at three weeks, however on the DBA (C) background, no cysts 
were.present. Instead a small number of dilated tubules were found 
expressing galectin-3. Scale bars = 80 mm.
cpk, B57BU6J
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Figure 10.10. Expression of galectin-3 in cystic epithelia of various 
PKD models.
Galectin-3 expression on various PKD samples. A, C, E, G and H are of 
lower magnification. Galectin-3 expression was found in cystic epithelial 
cells of all samples examined. A and B are PkD-2 heterozygote, which 
gives>rise to PKD; C and D are from bpk model; E and F are from orpk 
model; G to J are human PKD samples (AD and AR). All samples 
expressed galectin-3 in the cystic epithelia. * in F and G indicate cyst 
that did not express galectin-3. They may represent cysts of a non­
collecting tubules origin. Only a one kidney was examined per sample 
due to limitation in resources. Scale bars = 80 mm.
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Summary of findings of galectin-3 expression on cystic
epithelia:
• Galectin-3 was found to be widely expressed in renal cystic epithelia of 
cpk mutant mice. It exhibited a predominantly cytoplasmic expression in 
these cells.
• The expression of galectin-3 was compared with other developmental 
collecting tubule proteins (ret, aquaporin-2 and calbindin) and found 
galectin-3 was different from the others and the wide expression 
observed was not simply a non-specific re-expression of early ureteric 
markers as these epithelia dedifferentiate towards a more embryonic 
phenotype.
• The expression of galectin-3 was compared with galectin-1 and galectin- 
9, the two galectins expressed in the kidney. Neither galectin-1 nor -9 
have the same expression pattern of galectin-3 in cystic epithelia. 
Assessment in galectin-3 null mutant kidneys found that two galectins 
were not widely expressed in the cystic epithelial cells: galectin-1 was 
absent and galectin-9 was only expressed in a small number of cystic 
epithelial cells; therefore it was unlikely that they could compensate for 
the lack of galectin-3 in these samples.
• Lastly, the expression of galectin-3 was assessed in a limited number of 
other PKD samples and found that in all samples examined (Pkd2, Bpk, 
Orpk, human ADPKD and human ADPKD kidney samples), galectin-3 
was widely expressed in the cystic epithelia.
Next the function of galectin-3 was investigated in vivo by introducing galectin-3 
null mutant allele to the cpk mutant. The effects of the lack of galectin-3 in 
cystogenesis were examined.
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E f f e c t s  o f  g a l e c t in -3 m u t a t io n  o n  c y s t o g e n e s is
in  vivo
Previous findings of the widespread expression of galectin-3 in cystic epithelia 
did not show that protein is able to modulate cystogenesis. Previous in vitro 
study using cpk suspension cultures showed that the addition of galectin-3 to 
the culture medium significantly reduced the number of cysts formed after 24 
hours (Johnson, 2001). To further investigate the effect of galectin-3 on cyst 
growth, we examined the cpk mouse model, to determine the effect of reducing 
the expression of galectin-3 in these mice.
The effect of galectin-3 on renal cyst development was investigated in vivo by 
generating double mutant, galectin-3 and cpk null. Galectin-3 null mutant mice 
(129Sv background) were bred with cpk heterozygous (C57BL/6j), then the F1 
double heterozygous (Galectin-3 +/-, cpk +/-) were genotyped by PCR. They 
were crossed to generate F2 which had 9 possible genotypic outcomes 
following the Mendelian’s Laws of Inheritance according to either the cpk or the 
galectin-3 genotypes (see fig. 10.11 and 10.12 below). 24 litters were 
generated in the F2 generation, yielding a total of 266 animals. No post-natal 
death was recorded in these samples. All animals were sacrificed at 1 week, 
when renal cysts were still developing and there was an adequate level of renal 
activity. The absolute kidney to body weight ratio (K/B ratio) was calculated and 
used as an indicator of the severity of cystogenesis in the kidneys. This is 
based on the fact that cyst growth results in kidney enlargement, hence, the 
more severe the cystic kidney disease, the heavier the kidney.
Western blotting was used to quantify the amount of galectin-3 in these 1 week 
old cystic samples with various galectin-3 genotypes. However, no galectin-3 
protein bands were detected in all samples due to the very low amount of 
galectin-3 presence in 1 week old kidneys.
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Frequency test (chi-square) on the ratio of the genotype 
outcome.
Frequency test was carried out in the initial 8 litters collected, a total of 93 
samples. The number of samples in each genotype group is summarised in 
table 10.1 and 10.2 below. Chi-square test was performed on these samples to 
determine if the ratio of the genotype outcome was as expected, following the 
Mendelian’s Laws of Inheritance.
The transmissions of cpk and galectin-3 loci were analysed separately as well 
as clustered into nine groups (various galectin-3 and cpk genotypes) The chi- 
square values of the three tests carried were 0.26, 0.39 and 0.69 (see table 
10.1 and 10.2) which is above the 0.05 significant value, therefore, there were 
no significant difference between the actual and the expected frequency.
Table 10.1. Frequency test 1 and 2.
Genotype
Observed
number
Observed 
Frequency %
Expected
Number
Expected
frequency
%
Chi-square
test
Cpk +/+ 30 32 23.25 25
Cpk +/- 43 46 46.5 50
Cpk -1- 20 22 23.25 25
Total: 93 100 93 100 0.26
gal-3 +/+ 21 23 23.25 25
gal-3 +/- 53 57 46.5 50
gal-3 -/- 19 20 23.25 25
Total: 93 100 93 100 0.39
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Table 10.2. Frequency test 3
Genotype
Observed
number
Observed 
frequency %
Expected
Number
Expected 
frequency %
Chi-square
test
cp/c+/+, gal-3 +/+ 7 7.53 6 6.25
cpk+l+, gal-3 +/- 15 16.13 12 12.5
cpk+/+, gal-3 -/- 8 8.60 6 6.25
cpk+/-, gal-3 +/+ 10 10.75 12 12.5
cpk+/-, gal-3 +/- 26 27.96 23 25
cpk+/-, gal-3 -/- 7 7.53 12 12.5
cpk-/-, gal-3 +/+ 4 4.30 6 6.25
cpk-/-, gal-3 +/- 12 12.90 12 12.5
cpk-/-, gal-3 -/- 4 4.30 6 6.25
Total: 93 100 93 100 0.69
After the confirmation that both loci were inherited as expected, galectin-3 
genotyping was performed only in cystic animals. This was to save resources 
and time, cpk locus was confirmed using the PCR genotyping method.
Inter- and intra-litter variability did not affect the kidney/body 
weight ratio, as assessed by Multi-level modelling
Multi-level modelling was employed to confirm that there was no variation in the 
K/B ratio between animals in the same litter and between animals of different 
litters. Hence all animals were analysed together as one group, without 
adjusting to its litter of origin.
Reduced galectin-3 gene expression accelerated cystogenesis
61 animals were phenotypically and genotypically confirmed to be cystic, out of 
which there were 15 galectin-3 wildtypes, 35 galectin-3 heterozygotes and 11 
galectin-3 null mutants.
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In terms of kidney weight, non-cystic kidneys weighed on average 0.025g (left 
kidney only); mean kidney weight of cystic galectin-3 wildtype was 0.046g and 
that of both cystic galectin-3 heterozygotes and galectin-3 null mutants was 
0.065g. Compared with cystic galectin-3 wildtype, cystic galectin-3 
heterozygotes and galectin-3 null mutants had an 41% increase (p-value = 
0.023 and 0.076) in single kidney weight (fig. 10.11).
No significant difference was found in body weight when comparing cystic 
(mean body weight = 3.86g) to non-cystic samples (mean body weight =
4.15g), t-test determined a p-value of 0.062. The mean body weight of all 
animals was 4.05g. Among cystic animals, galectin-3 genotypes did not affect 
the body weight of the animals (fig.10.12).
Non-cystic animals at 1 week had a mean K/B ratio of 0.60%; that of cystic 
animals with a normal expression of galectin-3 rose up to 1.18%. This K/B ratio 
in cystic galectin-3 heterozygotes and cystic galectin-3 null mutants increased 
to 1.69% and 1.72% respectively (fig. 10.13). Galectin-3 heterozygotes and 
galectin-3 null mutants had an increase in K/B ratio of 43% (p-value = 0.030) 
and 46% (p-value = 0.016) compared with cystic galectin-3 wildtype animals, as 
determined using t-test (table 10.3).
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Figure 10.11. Summary of kidney weight.
Mean kidney weights of different genotypes. Significant difference was 
indicated by *. c.i. represents 95% confidence interval.
*
0 .0 8  
0 .0 7  
0 .0 6  
0 .0 5  
o> 0 .0 4  
0 .0 3  
0.02 
0.01 
0.00 111111
cpk + /+ + /+ + /+ + /- + /- + /- -/- - /- - /-
Gal-3 + /+ + /- - /- + /+ + /- -/- + /+ + /- - / -
Mean (g) 0.023 0.023 0.025 0.025 0.025 0.027 0.046 0.065 0.065
Lower ci 0.021 0.022 0.021 0.023 0.023 0.024 0.034 0.056 0.049
Upper ci 0.026 0.024 0.029 0.027 0.027 0.030 0.058 0.074 0.081
n 7 15 8 10 26 7 15 35 11
Figure 10.12. Summary of body weight
Mean kidney weights of different genotypes. No significantly differences 
were found.
cpk + /+ + /+ + /+ + /- + /- + /- - / - - / - - / -
Gal-3 + /+ + /- -/- + /+ + /- - / - + /+ + /- - / -
Mean (g) 3.786 4.123 3.963 4.370 4.288 4.350 3.803 4.067 3.718
Lower ci 3.525 3.853 3.589 3.966 4.061 3.957 3.293 3.734 3.420
Upper ci 4.046 4.394 4.336 4.774 4.516 4.743 4.314 4.400 4.017
n 7 15 8 10 26 7 15 35 11
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Figure 10.13. Summary of kidney/body weight (K/B) ratio.
Mean K/B ratio of different genotypes. Significant difference was 
indicated by *.
2.5
1.5
0.5 I I I I I I
cpk + /+ + /+ + /+ + /- + /- + /- -/- - /- -/-
Gal-3 + /+ + /- - /- + /+ + /- -/- + /+ + /- -/-
Mean (%) 0.621 0.566 0.628 0.576 0.579 0.624 1.179 1.695 1.723
Lower ci 0.532 0.525 0.565 0.533 0.549 0.554 0.944 1.418 1.364
Upper ci 0.709 0.608 0.692 0.620 0.609 0.695 1.415 1.971 2.083
n 7 15 8 10 26 7 15 35 11
Table 10.3. Summary of K/B ratio of cpk animals with various 
galectin-3 genotypes.
The p-values were obtained in comparison with cpk -/- gal-3 +/+.
Genotype No. Mean K/B 
ratio
Increase 
compared with 
Gal-3 +/+
95% c.i. p-value
Ga/-3 +/+ 15 1.18% 0.94%,
1,42%
Gal-3 +/- 35 1.69% 43% 1.42%,
1.97%
0.030
Ga/-3 -/- 11 1.72% 46% 1.36%,
2.08%
0.016
170
Comparison of proliferation and apoptosis in cystic samples 
with various galectin-3 genotypes
Galectin-3 was known to affect cell proliferation and apoptosis (Inohara et a!., 
1998;Yu et al., 2002). It was interesting to note the similarity of outcome 
between galectin-3 heterozygotes and galectin-3 null mutants. The levels of 
proliferation and apoptosis were assessed in the cystic sample with three 
different galectin-3 genotypes, in the hopes that these tests may provide an 
explanation for this phenomenon.
Proliferative and apoptotic Index were determined in the 1 week old cystic 
animals generated. 8 cystic samples were randomly selected from each 
galectin-3 genotypes: Gal-3 +/+ Gal-3 +/- and Gal-3 -/-, hence, a total of 24 
samples were assessed. Not all samples assessed due to the labour intensive 
nature of these tests and 8 samples per groups were sufficient for an adequate 
statistical analysis.
Proliferative cells were identified by immunohistochemistry using biotin labelled 
antibody against PCNA, proliferating cell nuclear antigen (fig. 10.14A). 
Apoptotic cells were detected using the In Situ Cell Death Detection kit, 
Fluorescein, which is based on the TUNEL technology (fig.10.14B).
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Figure 10.14. Immunostaining of proliferating cells and apoptotic
cells in 3 week old cpk kidneys.
Proliferating cells were stained brown using anti-PCNA antibodies (A); 
whereas cells undergoing apoptosis was identified using the TUNEL 
method which gave a fluorescent green signal (arrow in B). A was co­
stained with haematoxylin and B with propidium iodide in order to 
visualise the nucleus of all cystic epithelial cells. Scale bars = 50 mm.
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Proliferative index
Galectin-3 has been found to stimulate cell proliferation in fibroblasts and 
mesangial cells (Inohara etal., 1998; Sasaki et al., 1999). The effect of 
galectin-3 expression on proliferation in cystic kidney epithelial cells was 
investigated. Proliferating cells were identified using PCNA antibodies. 
Proliferative index (PI) was expressed as a percentage of PCNA positive cells 
over the total number of cystic epithelial cells counted.
PI for all cystic samples ranged from 44% to 96%. When the samples were 
sorted according to their galectin-3 genotypes, it was found that galectin-3 
heterozygotes had a significantly higher PI of 88%, compared with galectin-3 
wildtypes 68% (p-value = 0.002) and galectin-3 null mutants 78% (p-value = 
0.038). No significant differences were found between galectin-3 wildtypes and 
galectin-3 null mutants. See figure 10.15.
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Figure 10.15. Proliferative Index of cystic epithelial cells.
The percentage of PCNA positive cells over the total number of cystic 
epithelial cells counted. Galectin-3 heterozygotes had significantly more 
proliferating cells.
100
80
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Genotype Gal-3 +/+ Gal-3 +/- Gal-3 -I-
MEAN
Proliferative Index (PI) 67.75% 88.21% 78.13%
Lower ci 59.37 82.36 71.79
Upper ci 76.13 94.06 84.47
n 8 8 8
Apoptotic index
Apoptotic cells were detected using the In Situ Cell Death Detection kit, 
Fluorescein, which is based on the TUNEL technology. Apoptotic index was 
expressed as a percentage of apoptotic bodies over the total number of cystic 
epithelial cells counted (see fig. 10.16).
Figure 10.16. Apoptotic Index of cystic epithelial cells.
Percentage of apoptotic bodies over the total number of cystic epithelial 
cells counted. No significant differences were found.
i M
Genotype Gal-3 +/+ Gal-3 +/- Gal-3 -I-
MEAN
Apoptotic Index (Al) 0.31% 0.33% 0.25%
Lower ci 0.07 0.11 0.16
Upper ci 0.55 0.55 0.34
n 8 8 8
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Apoptosis was consistenly detected in cystic samples but at a low level. The Al 
ranged from 0% to 0.9% in all cystic samples examined with a mean Al across 
all samples of 0.030%. When samples were sorted to their galectin-3 
genotypes, no significant difference was found between each genotype.
Kidney morphology of cystic samples
Cystic kidney sections (randomly selected 8 samples from each of the three 
galectin-3 genotypes) were prepared and were stained with haematoxylin and 
eosin and labelled with DBA to reveal their morphology and identify their 
collecting ducts origin. Brief analysis of these histological samples was carried 
out in which two sections from each samples were examined under a light 
microscope. Among these cystic animals, subtle differences between galectin-3 
wildtype, heterozygotes and null mutants were observed in the cortical region, 
where the latter two had more cystic lesions (figure 10.17). The degree of cystic 
lesions in the cortex was examined and was given a score range from 1 to 5, 
the bigger the number the more cysts there were in that region. The score for 
galectin-3 wildtype was 11/40, that of galectin-3 heterozygotes was 24/40 and 
in galectin-3 null mutants was 23/40. It appeared that galectin-3 heterozygotes 
and null mutants had more cortical cysts compared with galectin-3 wildtypes. 
This result concurs with the kidney/body weight ratio which revealed that 
galectin-3 heterozygotes and null mutants had a more severe cystic disease. A 
more thorough examination of the histology was carried out on the pure 
background (C57BL/6j) as this set of samples came from a mixed genetic 
background (129Sv x C57BL/6j) which may affect the variability of the outcome.
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Figure 10.17. Histology of cystic kidneys with various galectin-3 
genotypes.
Histology of cpk kidney at 1 week showing the cortex of the kidney. The 
three images were representative of their genotypes: A) gal-3 wildtype, 
B) gal-3 heterozygotes and C) gal-3 null mutants. All sections were 
stained with haematoxylin, eosin and labelled with DBA, which is a 
marker for collecting tubules. Scale bars = 200 mm.
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Effects of galectin-3 mutation on cystogenesis in vivo: analysis 
using double mutants on a pure background
The previous set of in vivo data was obtained from F2 animals with a mixed 
background. The cpk mutation arose spontaneously on the C57BL/6j 
background and the galectin-3 mutants available at the time were on a 129Sv 
background. Although a significant difference was found between cystic 
animals with different galectin-3 genotypes and that multilevel modelling 
analysis showed that there were no significant variation between litters from 
different parents, one must be cautious when interpreting the data as the 
control animals were genetically different from the others. It was due to this 
reason that we have decided to repeat the experiments on a pure background. 
At the beginning of this study, the cpk allele was backcrossed onto the 129Sv 
background to yield double knockout mice on that background. At year 3 of the 
study, galectin-3 mutants on the C57BL/6j were obtained from the Consortium 
for Functional Glycomics; these mice were crossed with C57BL/6j cpk 
heterozygotes to yield double knockout on the C57BL/6j background.
Cytogenesis of cpk galectin-3 null animals on 129Sv 
background (previously uncharacterised)
The cpk allele has previously backcrossed onto different backgrounds such as 
Balb/c, CAST, CD-1 and DBA, for the study of various phenotypic outcomes 
(Guay-Woodford et al., 2000). In this study, the cpk null allele was backcrossed 
onto the 129Sv background for the first time as far as we are aware. The cpk 
null allele was backcrossed onto the 129Sv background for 10 generations. 
After which, the cpk heterozygotes (129Sv) were bred with galectin-3 null 
mutants (129Sv). F1 double heterozygotes were selected by genotyping using 
tail tips for DNA extraction and were used to generate F2, which contained the 
double mutants used for data analysis.
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Sample collection, processing and assessment were performed as before. 34 
litters were collected giving a total of 181 animals born, though only 171 were 
available for analysis due to early death.
A few unexpected factors occurred in this set of experiment, which affected the 
analysis of the results and the assessment of cystogenesis:
1) Ten animals died before day 7 a death rate of 5.5%. The cause of death was 
not known. The number of animals per litter was recorded at birth and the litters 
were checked daily and counted, and missing animals were noted. DNA was 
extracted from samples of the 7 post-natal deaths, but no samples were 
available for 3 samples. Table 10.4 shows a summary of these samples.
2) F2 generation did not follow the Mendelian’s Law of Inheritance, as there 
were significantly less galectin-3 null mutants. It is possible that galectin-3 null 
mutants died in utero, therefore the samples obtained were not a 
representative of the true cystic galectin-3 null mutants population;
3) Pancreatic cysts of various sizes occured in some cpk samples and the 
degree of severity did not correlate with galectin-3 genotypes.
Details of these unexpected factors are explained below:
Premature death
Ten mice (5.5%) died before Day 7, when the samples were collected. DNA 
were available from 7 out of these 10 samples: 6 out of 7 were genotyped and 
shown to be cpk null mutants with various galectin-3 genotypes and one was 
cpk +/+, gal-3 -I- (see Table 10.4); half of these samples died at birth.
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Table 10.4. Summary of animals that died before day 7.
10 animals died before day 7. 3 of them had no DNA available, the 
reminding 7 were genotyped and their genotypes are stated in the table 
below. No correlations were found between genotypes and the animals 
that died.
Sample Age died 
(Day)
Genotypes
1 0 cpk -/-, gal-3 +/+
2 2 cpk -/-, gal-3 +/+
3 6 cpk -/-, gal-3 +/-
4 0 cpk -/-, gal-3 +/-
5 0 cpk -/-, gal-3 +/-
6 0 cpk -/-, gal-3 -/-
7 0 cpk +/+, gal-3 -/-
8 1 No DNA
9 2 No DNA
10 2 No DNA
A significantly lower number of galectin-3 null mutants indicated by the 
frequency test (chi-square).
One hundred and seventy one samples (excluding the 10 that died before day 
7) were analysed using the frequency test, chi-square, to determine if the 
samples follow the Mendelian’s Law of Inheritance. When the samples were 
grouped into 9 groups according to the cpk and galectin-3 loci, there was no 
significant difference between the observed frequency and the expected 
frequency, although the value, 0.079, was very close to being biologically 
significant (table 10.5). To inspect this further, the samples were grouped 
according to either their cpk genotype or galectin-3 genotype; frequency tests 
(table 10.6) were preformed on this new grouping. Chi-square test on data 
grouped according to the cpk genotype gave a p-value of 0.239, indicating that 
the cpk allele was inherited as expected. However the test on data grouped by 
galectin-3 genotype gave a p-value of 0.008, indicating that the galectin-3 allele 
did not follow the expected pattern of inheritance. .
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Table 10.5. Frequency test on sample on the 129Sv background 
grouped by their cpk and galectin-3 genotypes.
Genotype
Observed
number
Observed 
frequency %
Expected
Number
Expected 
frequency %Chi-square test
cpk+/+, gal-3 +/+ 11 6.43 10.69 6.25
cpk+/+, gal-3 +/- 23 13.45 21.38 12.5
cpk+/+, gal-3 -/- 8 4.68 10.69 6.25
cpk+/-, gal-3 +/+ 19 11.11 21.38 12.5
cpk+l-, gal-3 +/- 61 35.67 42.75 25
cpk+/-, gal-3-/- 15 8.77 21.38 12.5
cpk-/-, gal-3 +/+ 7 4.09 10.69 6.25
cpk-/-, gal-3 +/- 21 12.28 21.38 12.5
cpk-/-, gal-3 -/- 6 3.51 10.69 6.25
Total: 171 100 171 100 0.079
Table 10.6. Frequency test on samples on 129Sv background 
grouped by either cpk or galectin-3 genotypes.
Genotype
Observed
number
Observed 
frequency %
Expected
Number
Expected 
frequency %
Chi-square
test
Cpk +/+ 42 24.56 42.75 25
Cpk +/- 95 55.56 85.5 50
Cpk -/- 34 19.88 42.75 25
Total: 171 100 171 100 0.239
gal-3 +/+ 37 21.64 42.75 25
gal-3 +/- 105 61.40 85.5 50
gal-3 -/- 29 16.96 42.75 25
Total: 171 100 171 100 0.008
It was suspected that there were less galectin-3 null mutants than expected. To 
confirm this, frequency test was carried out where the data was grouped into 
two: galectin-3 null mutants vs all others. The p-value obtained was 0.015, thus 
verifying that there were less galectin-3 null mutants (table 10.7).
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Table 10.7. Frequency test to confirm that there were less galectin-3
null mutants.
Genotype
Observed
number
Observed 
frequency %
Expected
Number
Expected 
frequency %
Chi-square
test
Gal-3 +/+ and Gal-3 +/- 142 83.04 128.25 75
Gal-3 -/- 29 16.96 42.75 25
Total: 171 100 171 100 0.015
In conclusion from these frequency tests, there were significantly less galectin- 
3 null mutants than expected from Mendelian’s Law of Inheritence among the 
F2 generation.
Cpk animals on the 129Sv developed pancreatic cysts of various sizes.
Out of the 171 F2 samples generated at day 7, 34 cystic samples were 
collected. Among the cystic samples, there were 7 galectin-3 wildtypes, 21 
galectin-3 heterozygotes and 6 galectin-3 null mutants. 22 out of 34 cystic 
animals exhibited pancreatic lesions, 7 had very enlarged cystic pancreases, 
which were over double the size of the animal’s stomach. The severity of 
pancreatic cysts was graded from 0 to 3, 0 = no pancreas lesion observed, 1 = 
gross dilation of pancreatic ducts, 2 = presence of multiple cysts in the 
pancreas and 3 = much enlarged cystic pancreas (fig. 10.19A). Among cystic 
animals, a mean pancreatic cysts score was generated for each galectin-3 
genotype. The mean pancreatic cysts score for galectin-3 homozygotes was 
1.43; galectin-3 heterozygotes were 1.57 and that of galectin-3 null mutants 
was 1.17. No significant difference was found between each genotype (fig. 
10.18). Therefore, the severity of pancreatic cysts was not affected by galectin- 
3 expression. No pancreatic cysts were observed in cpk mutants on the 
B57BL/6j background and the cpk B57BL/6j x galectin-3 129Sv mixed 
background.
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Figure 10.18. The correlation between the severity of pancreatic
cysts and galectin-3 genotypes.
The severity of pancreatic cysts was scored and the scores were group 
according to galectin-3 genotypes. No correlations were found between 
the severity of pancreatic cysts and galectin-3 genotypes.
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Figure 10.19. Pancreatic cysts in cpk mutants on the 129Sv 
background
A grossly enlarged pancreas can be seen in A before it was dissected 
out and B was of the same pancreas after carefully dissected out and 
placed in 4% PFA. C and D are low power view of two different cpk 
pancreases. E is a high magnification of a normal pancreas, compared 
with F, a cpk mutant with presentation of pancreatic cysts in the ductal 
tubules. C to F were all stained with haematoxylin and eosin. Scale bars 
= 100 mm.
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Cytogenesis of cpk galectin-3 null animals on C57BL/6j 
background
Towards the end of my study, we successfully obtained galectin-3 C57BL/6j 
null mutant mice from the Consortium for Functional Glycomics and bred them 
with cpk C57BL/6j heterozygotes to yield double heterozygotes animals; the 
offspring were then inter-crossed to yield F2 which contained cpk mice with 
various galectin-3 genotypes on a pure C57BL/6j background.
108 F2 samples were collected and their genotypes followed the expected 
Mendel’s law (see frequency test at table 10.8). Most of the sample collection 
was carried out by Dr. Eugenia Dahm-Vicker.
Table 10.8. Frequency test on samples on the pure C57BL/6j
background grouped by their cpk and galectin-3 genotypes.
Genotype
Observed
number
Observed 
frequency %
Expected
Number
Expected 
frequency % Chi-square test
cpk+/+, gal-3 +/+ 8 7.41 6.75 6.25
cpk+/+, gal-3 +/- 9 8.33 13.5 12.5
cpk+/+, gal-3 -/- 3 2.78 6.75 6.25
cpk+/~, gal-3 +/+ 19 17.59 13.5 12.5
cpk+/-, gal-3 +/- 27 25.00 27 25
cpk+l-, gal-3 -/- 17 15.74 13.5 12.5
cpk-/-, gal-3 +/+ 8 7.41 6.75 6.25
cpk-/-, gal-3 +/- 11 10.19 13.5 12.5
cpk-/-, gal-3 -/- 6 5.56 6.75 6.25
Total: 108 100 108 100 0.46
25 were genotyped to be cpk mutants, from which 8 were galectin-3 wildtype,
11 were galectin-3 heterozygotes and 6 were galectin-3 null mutants. The 
absolute kidney weights among cystic animals exhibited no significant 
difference (galectin-3 wildtype 30mg, galectin-3 heterozygotes 38mg and 
galectin-3 null-mutant 34mg, p-value > 0.07), see figure 10.20. The K/B ratios 
were: galectin-3 wildtype 0.79%, galectin-3 heterozygotes 0.94% and galectin-3 
null-mutant 0.92%, although it appears that heterozygotes and null mutants had
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greater K/B ratios no significance differences were found (p-values compared 
with wildtype are 0.10 and 0.12), see figure 10.21.
Figure 10.20. Summary of kidney weight
Mean kidney weight of cystic animals of different galectin-3 genotypes. 
No significant differences were found.
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Figure 10.21. Summary of kidney/body weight ratio
Mean K/B ratio of cystic animals of different galectin-3 genotypes. No 
significant differences were found.
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Examination of kidney histology revealed that galectin-3 null mutants had 
more cortical cysts.
Kidney histology of all cystic samples was examined; all cystic mice had 
prominent meduallary cysts but there was a qualitative impression of more 
cortical cysts in the galectin-3 null-mutants. A scoring system (0 -  4) was 
developed to assess the degree of cyst growth (see figure 10.22). Utilising a 
twice-blinded approach (photographs and scoring), clear differences was 
detected: galectin-3 null mutants had a cortical cyst score of 2.83, compared to 
2.01 in galectin-3 wildtypes (p-value = 0.01) and 1.92 in galectin-3 
heterozygous (p-value = 0.002), a highly significant difference.
Figure 10.22. Summary of cystic index indicating the degree of cyst 
growth in the cortex.
Mean cystic index reveals that galectin-3 null mutants had significantly 
more cysts in the cortex. *  *
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Figure 10.23. Representation of different cortical cystic index score.
Below four pictures represent the four different cortical cystic score, A -  
score 4, B -  score 3 , C -  score 2 and D -  score 1. Scoring depends on 
the number and size of cysts in the cortical region. All sections were 
reacted with DBA and stained with haematoxylin and eosin. Three 
sections were taken per samples and all sections were scored by three 
blind observers to obtain a mean score per sample. Scale bars = 300 
pm.
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Summary of findings from the in vivo studies:
• Galectin-3 null mutants and heterozygotes cpk mice had higher 
kidney/body weight ratio at Day 7 compared with galectin-3 wildtypes 
cpk mice, amongst animals on mixed genetics background C57BL/6j x 
129Sv.
• Galectin-3 null mutant cpk mice had more cortical cysts compared with 
Galectin-3 heterozygotes and galectin-3 wildtype cpk mice amongst 
animals one pure genetics background C57BL/6j.
• There were significantly less galectin-3 null mutant animals on the 129Sv 
Sv background.
• 22 out of 34 cpk mice on 129Sv background developed enlarged, 
multicystic pancreas. The appearance of pancreatic cysts did not 
correlate to galectin-3 genotype.
From the results from the C57BL/6j pure background suggests that galectin-3 
null mutants had more cortical cysts compared with galectin-3 wildtypes and 
heterozygotes. Although the cystic index did not show significant increase in 
cysts growth in galectin-3 heterozygotes, the finding supports the results 
obtained using the mixed background that galectin-3 null mutants had 
accelerated cystogenesis.
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Ex p r e s s io n  o f  g a l e c t in -3  o n  t h e  p r im a r y  c il iu m  o f
RENAL EPITHELIAL CELLS
As mentioned earlier, research into the development of PKD has been focusing 
on an organelle called the primary cilium. Primary cilia can be found in most 
mammalian cells, it is derived from the mother centriole and it is a flagella-like 
structure that occurs singly in differentiated cells. Many important proteins that 
are associated with PKD are localised to this structure, e.g. PC-1, PC-2, 
fibrocystin, cystin. As galectin-3 was proposed to be important to the 
development of renal cysts, its localisation on the primary cilia was 
investigated.
Galectin-3 localisation on the primary cilium
Immunofluorescence was employed to detect the co-localisation of galectin-3 
and acetylated tubulin, which identified ciliary structure. Confocal microscopy 
was used to detect the dual signals expressed by the two different antibodies. 
Various samples were tested: primary cultures of normal and cpk kidneys and 
IMCD monolayers (fig. 10.24); human ARPKD and ADPKD samples (fig 10.25); 
3D cultured cysts from cpk kidneys (fig 10.26). Primary cilia developed in 
monolayer culture when the cells reached full confluency and were 
differentiated, and they were found in renal epithelial cells in the kidney 
samples.
Primary cilia were found in all monolayer cell cultures and human ARPKD and 
ADPKD kidneys examined. Galectin-3 was found localised to the organelle in 
all samples. The expression pattern varied slightly between primary cilia within 
the total cell population or kidney sample. Galectin-3 was mostly expressed at 
the shaft of the primary cilium in a discontinuous manner. Expression at the 
basal body and on the tip of the primary cilia was sometimes observed. No 
differences were found on the general expression pattern between cystic, non- 
cystic samples and of ARPDK and ADPKD samples.
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Examination of 3D cysts was more difficult due to technical issues and no 
obvious co-localisation of galectin-3 was found on the primary cilium. These 
cells were only cultured for 24 hours (compared with 4 days for monolayer 
culture); the primary cilia were relatively shorter which may signify that the 
organelle was not fully developed. The immunocytochemistry of these samples 
were carried out in suspension and then fixed to poly-L-lysine coated slides for 
examination. Although the fixation was adequate to hold the cysts in place, it 
was not strong enough to prevent small movement of the cysts. Therefore no 
high resolution lens was used for those samples as they require direct contact 
with the cover slip via the oil interphase, which in turns disturbed the stability of 
the cysts.
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Figure 10.24. Galectin-3 localisation on the primary cilia of cultured 
cells.
Galectin-3 localisation on the primary cilia of diverse cultured cells: First 
row (A -  C) is a primary culture of normal kidney epithelial cells; second 
and third rows are from primary culture of cpk kidney epithelial cells and 
the last row is from IMCD cells, which is an established kidney epithelial 
cell line. Each row shows the same picture with just galectin-3 
expression (green), acetylated a-tubulin expression (red). Co-localisation 
can be seen in the last column (merged) in yellow. In all samples 
examined, galectin-3 was localised on the primary cilia. Scale bars = 5 
mm.
Galectin-3 Acetylated a-tubulin Merged
Figure 10.25. Galectin-3 on the primary cilia of kidney sections.
Galectin-3 localisation in kidney samples. First (A-C) and second (D-F) 
rows are normal mouse kidney collecting tubules and cpk cystic 
epithelia; third (G-l) and forth (J-L) rows are cystic epithelia of human 
ARPKD and ADPKD samples. Galectin-3 expression in green, 
acetylated tubulin in red and co-localisation of the two proteins are 
shown in yellow (merged column). Galectin-3 was detected in primary 
cilia of all samples examined. Negative control (M-O) using cpk, gal-3 
null mutant shows no galectin-3 expression. Scale bars = 5 mm.
Galectin-3 Acetylated a-tubulin Merged
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Figure 10.26. Primary cilia on 3D cultured cysts.
Primary culture of 3D cyst from cpk kidneys. A and B are of the same 
cyst taken with a light microscopy with and without fluorescence showing 
galectin-3 expression. C -  F are of the same cyst: C is an enlarged 
portion of F (dashed box), showing a number of very short primary cilia 
on the outside of the cyst (white arrows). G -  I showed the same cell 
from a cyst with a cilium on the outside (white arrows). Galectin-3 
expression in green, acetylated a-tubulin in red and co-localisation of the 
two proteins are shown in yellow (merged column). Very subtle galectin- 
3 expression was seen in I (white arrow), however, it was not a common 
observation because of technical issues. Scale bars A-C = 5 mm, D-F = 
50 mm, G-l = 2 mm.
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Galectin-3 Acetylated a-tubulin Merged
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Galectin-3 localisation on the outside of the primary cilia.
Galectin-3 is a secreted protein and it was found in cyst fluid (fig 10.3F). Its 
localisation on the outside of the primary cilia was assessed on IMCD cells. A 
stable cell line was used instead of a primary culture due to the technical 
difficulty of this experiment. Immuno-detection of extracellular galectin-3 was 
performed on non-permeablised cells. The live cells were cooled down to 4 °C 
and immunostaining of galectin-3 was carried out in this condition, as fixatives 
might cause slight permeablisation. Protocol detail is in chapter 8: Methods.
Figure 10.27 clearly shows that galectin-3 is localised to the outside of primary 
cilia.
Figure 10.27. Extracellular galectin-3 localisation on the primary 
cilia.
Extracellular galectin-3 expression on the primary cilium of IMCD cells. 
Galectin-3 expression in green, acetylated tubulin in red and co­
localisation of the two proteins are shown in yellow (merged). D-F: 
negative control using pre-immune rabbit antibodies instead of anti- 
galectin-3 antibodies. Scale bars = 3 mm.
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Galectin-3 localisation on the centrosome of IMCD cells
While assessing galectin-3 localisation on the primary cilia of IMCD cells, 
galectin-3 was occasionally found localised at the spindle poles of dividing cells 
(fig.10.28A -  C). It was speculated that the protein was expressed on the 
centrosome. To confirm this observation, anti-y tubulin antibodies were used. It 
is specifically expressed in the centrioles, and was therefore used as a marker 
for centrosome. As observed in figure 10.28A -  F, galectin-3 was found around 
the centrioles, hence in the peri-centriolar material.
Figure 10.28. Expression of galectin-3 in the centrosome.
Expression of galectin-3 on the centrosome of IMCD cells. All samples 
were immunostained with anti-galectin-3 antibodies (green); A -  C were 
immunostained with anti-acetylated tubulin (red) and D -  F were 
immunostained with anti-g-tubulin (red). A -  C indicate a dividing cell, 
which the acetylated a-tubulin was a marker for the chromosomal 
material. Galectin-3 was expressed in the spindle pole of dividing cells 
(C) and to the peri-centriolar material (F). Scale bars A-C = 5 mm, D-F =
0.1 mm.
Galectin-3 Acetylated a-tubulin Merged
Galectin-3 y-tubulin Merged
C om parison  o f prim ary c ilia  in ga lec tin -3  w ild typ e  and galectin  
3 knockou t cystic  kidneys.
The primary ciliary structures of galectin-3 wildtypes and galectin-3 knockout 
cystic kidneys were examined. At least three samples were examined in each 
group. Assessments were done using confocal microscopy and scanning 
electro-microscopy. Neither assessment showed any observable differences in 
appearance between the two groups of samples (fig 10.29).
Figure 10.29. Primary cilia in galectin-3 wildtype and knockout 
cystic kidneys.
Primary cilia in cystic galectin-3 wildtype and knockout samples. A, C 
and E are from cpk -/-, gal-3 +/+ kidneys; B, D and F are from cpk -/-, 
gal-3 -I- kidneys. A and B are confocal images immunostained for 
galectin-3 (green) and acetylated a-tubulin (red), which identify the 
structure of primary cilia. C -  F are scanning electro-microscope images. 
Comparison of these images shows that there are no obvious structural 
different between galectin-3 wildtype and null mutant samples. Scale 
bars = 5 mm.
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Galectin-3 may be a lipid raft protein
Cystin is present in the lipid raft of IMCD cells (Yang et al., 2004); galectin-4 is 
a well established lipid raft associated protein in intestinal epithelial cells 
(Danielsen and Hansen, 2006). Therefore I hypothesised that galectin-3 could 
also be found in the lipid raft compartment of renal epithelial cells.
Lipid raft extraction was carried out using IMCD cells to determine if galectin-3 
was in the raft fraction. Lipid rafts were extracted in cold 0.1% Triton; proteins 
associated with the rafts were insoluble under this condition. The cell 
homogenates were then mixed and adjusted to a density gradient solution and 
centrifuged at 200,000 x g for four hours. Afterwards the content containing 
fractionated cell components was divided into ten fractions and western blot 
analysis was carried out. Antibodies against galectin-3 and caveolin-1 were 
used; the latter is a marker for lipid rafts. Further details of this process can be 
found in Chapter 9: Methods.
Referring to figure 10.30, fractions 3 to 5 were most enriched with raft proteins, 
as indicated by caveolin-1. Galectin-3 was found in these three fractions in 
relatively high concentration, although it was also found in high concentration in 
fraction 9 and 10, which were the cytoplasmic proteins fractions. This result 
suggests that galectin-3 is a raft-associated protein at least in IMCD cells.
Attempts were made to isolate lipid raft from cystic kidney but failed due to 
technical difficulty.
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Figure 10.30. Western blot analysis showing that galectin-3 was
associated with the lipid raft fraction.
Western blot analysis showed that galectin-3 (30kDa) is found together 
with caveolin-1 (22kDa) in fraction 3 to 5. Marker was loaded in fraction
1. Galectin-3 was found in all fractions from 3 to 10, although the highest 
concentration was in factions 3, 9 and 10. It was expected to see 
galectin-3 in the last two fractions as galectin-3 is a cytoplasmic protein. 
The high concentration of the protein in fraction 3, 4 and 5 indicate that it 
is a lipid raft-associated protein. Caveolin-1 was used as a raft-marker 
and also to confirm that the fractionation was a success as no caveolin-1 
was found in the non-raft fractions (9 and 10). The sizes of marker were 
indicated on the left.
Fraction 1 2 3  4 5 6 7 8  9 1 0
Marker Rafts
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Attempt to repeat the perfusion study which triggers calcium 
influx in ciliated renal epithelial cells
A few studies have successfully shown that the bending of primary cilia, either 
by direct contact or by introducing flow on the surface of the cell, leads to 
calcium influx (Praetorius and Spring, 2003; Nauli et al., 2003; Liu et al., 2005; 
Shiba et al., 2005).
Therefore I performed experiments to determine whether altering galectin-3 
concentration had a functional effect on the mechanical response of primary 
cilia to calcium influx. Firstly I attempted to set up a perfusion study so I could 
pass a constant flow rate over cultured cells which would then bend the primary 
cilia and triggers a calcium influx response. Then I would repeat the experiment 
with galectin-3 null cells (taken from the medulla of galectin-3 null kidneys); and 
compare the response rate and the strength of calcium influx with that of 
normal renal epithelial cells. Finally, I planned to repeat the experiment with 
primary cultures of cpk renal epithelial cells, with the addition of galectin-3 in 
medium and determine if the exogenous galectin-3 alter the rate and strength 
of response of calcium influx compared with cells treated with media alone.
In order to carry out this experiment, one must be able to achieve the 
appropriate flow rate. Previous experiments on the bending of primary cilia 
were carried out under a flow rate of 8 pi sec'1 for a period of 10 minutes in a 
custom built perfusion chamber (16mm long x 3 mm deep and 3 mm wide) 
(Praetorius and Spring, 2001). No equipments were available in my laboratory 
for this flow rate experiment, therefore two different research groups were 
contacted and after several trials, I could not achieve the desired flow rate due 
to the absence of the custom built perfusion chamber. Instead, our attention 
changed to finding a way to physically bend the organelle. To do that, a very 
fine instrument is required that can tap the tip of the cilia without contacting the 
cell surface. Atomic force microscope (AFM) is able to provide that; it is 
sometimes described as a scanning machine that uses a very fine tip at the
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end of its cantilever to scan the surface of any samples, including live biological 
cells, and gives a image based on the topograph of the sample (Trache and 
Meininger, 2005).
Examination of the primary cilia using an atomic force 
microscope.
AFM was used in an attempt to examine and to manipulate the structure of the 
primary cilium. It is a highly sensitive device that is used to assess the 
topography of substances, both biological or non-biological. It can also be used 
to give quantitative analysis of the samples, e.g. the presence of microvilli on 
cell surface and the degree of roughness of the surface (Poole et al., 2004).
AFM is based on the use of a scanning cantilever with a tip that is in contact 
with the sample; for my experiments the idea was to develop a system in which 
the tip can be used to bend the primary cilium in live cell; and incorporate the 
AFM imaging system with fluorescent microscopy to assess calcium influx in 
cells upon stimulation of the primary cilium. My collaborator Professor Horton 
already had an AFM machine that was intergrated with a fluorescent 
microscope.
To test the system, quick-dried IMCD cells were used as a sample and primary 
cilia were detected and imaged using the AFM (fig 10.31 and 10.32). As it was 
planned for the system to run on live cells, it was important to be able to detect 
the primary cilium in liquid phase. AFM was used to image IMCD cells in PBS 
(fig 10.31). Although it was successful in imaging the wet sample, we were 
unable to get a good image of the primary cilia. Several attempts were made, 
but due to the sensitivity of the cantilever to temperature change and the lack of 
rigidity of wet cells, it was difficult to achieve a stable engagement between the 
tip of the cantilever and the cilia. The difference in cell morphology between 
dried and wet cells can be compared (fig. 10.31). The latter were fuller with a
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smoother appearance of the cell surface. The problem with the sensitivity of the 
cantilever to temperature is being investigated. It can be eliminated by using a 
specially designed chamber that controls the temperature and humidity of the 
samples. This chamber is currently being optimised for use; preliminary results 
showed that the primary cilia in liquid phase could be imaged using this 
chamber (personal communication with Dr. Haupt).
Referring to figure 10.31 and 10.32: in each frame, two images were produced, 
a height image (left) and an amplitude image (right). The former is a 
topographical image; the latter refers to the alternating voltage that is applied to 
the piezo (an adjustable platform where the sample was placed). A voltage is 
applied to the piezo to adjust its height in response to the heights of the 
sample, so that the amplitude of the cantilever oscillation remains constant. In 
other words, the signal was created by the changes on the surface of the 
sample: the bigger the change the greater the voltage. Therefore the contrast in 
the image reflects the changes on the sample.
Presence of primary cilia was confirmed by immunofluorescence which showed 
that the organelle was fully developed in confluent IMCD culture prior to AFM 
imaging (Fig 10.31B). Primary cilia were detected on dried IMCD cells. AFM 
image showed that it is a hair-like structure on the surface of IMCD cells; the tip 
of the cilia was fatter than its stalk, as observed using the confocal microscope. 
In addition, a bulky structure which appeared to be the basal body was 
detected in the AFM images (fig 10.32K and O). The primary cilia were 
between 2 and 4 pm in these dried IMCD cells. The shortened length compared 
to the average 5 pm observed indicated that the samples had shrunk, possibly 
by drying.
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Figure 10.31. AFM imaging of dried and wet IMCD cells.
A) phase contrast image of the cantilever over IMCD cells. B) An exact 
same frame as A, immunofluorescent image of IMCD cells showing fully 
developed primary cilia labelled with acetylated a-tubulin (green). C -  F) 
AFM imaging of dried (C, D) and wet (E, F) IMCD cells. C and E are 
height images; and D and F are amplitude image
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Figure 10.32. AFM imaging of primary cilia in dried IMCD cells.
All images on the left are height images, whereas those on the right are 
amplitude images. Each cell was represented in four images (A -  D, E -  
H, I -  L and M -  P), thus four different primary cilia were shown. White 
boxes in B, F, J and N are where the primary cilia were and was 
subsequently enlarged in the following images. White circles in height 
images C, G, K and O indicated the basal bodies of each primary cilia, 
revealing a shape of the two centrioles.
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Figure 10.32 continued.
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Summary of findings from the studies on primary cilia:
• Galectin-3 was expressed on renal primary cilia of cystic and non- 
cystic kidney samples (cp/c, human AD-, ARPKD and normal mouse 
kidneys) and in cells cultures (cpk primary cultures and IMCD cells).
• The protein was found on the outside of the organelle, although some 
of the protein may also be expressed intracellularly in the primary 
cilium.
• Galectin-3 was expressed in the centrosome of IMCD cells.
• Galectin-3 was found in the lipid raft fraction.
• Although no functional data were presented, efforts were made to carry 
out the calcium influx study using AFM.
• Successfully detected primary cilia on dried IMCD cultures.
So far, I have described the wide expression of galectin-3 in cystic kidney 
epithelial cells; galectin-3 null mutants had accelerated cystogenesis and that 
galectin-3 is localised to the primary cilia. This following section describes the 
work continued from my predecessor, Dr. Johnson, into the role of galectin-3 
in the effect of paclitaxel in suppressing cyst growth.
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T h e  e f f e c t  o f  p a c l it a x e l  o n  t h e  c y s t o g e n e s is  o f
CPK  MICE.
It was previously reported that paclitaxel, a drug that amongst other actions 
stabilises microtubules, has a very significant effect on the development of 
renal cystic disease in cpk mice in that it greatly prolongs the lifespan of these 
animals (Woo et al 1997). The effect of paclitaxel on the expression patterns 
of galectin-3 in normal and cpk mice was investigated by Dr. Tanya Johnson. 
Like the original study carried out by Woo et al, cpk mice were treated with a 
single dose (150 pg) of paclitaxel at day 10 and the animal were sacrificed at 
day 21 for analyses. Immunohistochemistry was used to determine that in 
paclitaxel treated cystic kidney epithelial cells, galectin-3 was expressed 
apically instead of the cytoplasmic expression in untreated cystic kidneys. In 
addition, Dr. Johnson demonstrated, using in vitro 3D cyst culture system, 
that paclitaxel treated cyst culture had more galectin-3 protein in the medium 
compared with vehicle treated (DMSO) culture, as detected with 
immunoblotting, indicating that paclitaxel enhanced the secretion of galectin- 
3.
In this thesis, the samples obtained by Dr. Johnson were reanalysed for the 
galectin-3 expression pattern and primary cilia were examined. In addition, a 
new set of paclitaxel treatment was carried out on cpk mice; again a single 
administration of 150 pg at day 10 and the animals were sacrificed at day 11, 
a much earlier time-point compared with at day 21 in previous experiment. 
Kidneys from these animals were dissected out and their galectin-3 
expression pattern was examined by immunohistochemistry.
The in vitro cyst culture was also repeated: paclitaxel (50 pM) and galectin-3 
(30 pg/ml) reduced the number of cyst formed in culture when added 
separately (Woo et al. 1994). Also, paclitaxel enhanced the secretion of
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galectin-3 (Johnson, 2001). The increased extracellular level of galectin-3 
may in turn reduce cystogenesis. I was interested to determine if the two 
reagents act on different pathways or if they have a synergistic effect on each 
other. In both cases, one would expect to see a greater reduction in 
cystogenesis when the two reagents were added. To test that, the two 
reagents were added together to the culture medium.
Expression pattern of galectin-3 in paclitaxel treated cpk 
kidneys.
Cpk mice were treated with a single dose of 150 pg paclitaxel in DMSO at day 
10 and kidneys were collected at day 11 (one day after treatment) and day 
21; the latter were samples prepared by Dr. Johnson. Immunohistochemistry 
was performed on these kidney samples.
Galectin-3 expression was relocalised to the apical surface of cystic kidneys 
in paclitaxel treated cpk kidneys, compared with a pre-dominantly cytoplasmic 
expression in vehicle (DMSO) treated and untreated samples (fig. 10.33). The 
presence of primary cilia was also examined in these samples; paclitaxel is a 
well known microtubule stabiliser, therefore it was of interest to see if it acts 
on cystic epithelial cells by structurally changing the primary cilium. In 
addition, galectin-3 was localised to the primary cilia in normal and cpk 
kidneys; thus the localisation of galectin-3 on the organelle was also 
assessed in these samples.
Anti-galectin-3 antibodies were used to assess the localisation of galectin-3 in 
paclitaxel treated samples; and anti-acetylated a-tubulin antibodies were used 
to assess the presence of primary cilia.
As previously described in cpk kidney, the majority of cystic epithelial cells 
expressed galectin-3 in the cytoplasmic domain. In paclitaxel treated samples 
(both day 21 and day 11), galectin-3 was found predominantly in the apical
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domain. This observation was more prominent in the day 11 samples. 
Primary cilia were present in all samples (treated and untreated), no 
difference were observed using the confocal microscope. Galectin-3 was 
found on the primary cilia of treated and untreated samples (fig 10.33). 
Therefore, paclitaxel had no effect on the structure of primary cilia and on 
galectin-3 localisation to the organelle in vivo.
Figure 10.33. Galectin-3 and primary cilia expression in paclitaxel 
treated and untreated cpk kidneys.
Galectin-3 and primary cilia expression on cpk kidney samples: 
untreated and single dose paclitaxel treated. Galectin-3 protein was 
expressed in green and primary cilia was expressed in red. 
Colocalisation of galectin-3 on the cilia was shown in yellow. Only the 
merged pictures are shown. In untreated kidney, galectin-3 was widely 
expressed in the cytoplasmic domain of the cystic epithelia; whereas in 
paclitaxel treated samples, either at day 21 or 11, a predominantly 
apical expression of galectin-3 was detected. Scale bars = 10 mm.
B 1 C
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The effect of paclitaxel and galectin-3 on cystogenesis of in 
vitro cyst cultures.
3 week old cpk kidneys were partially digested and the cells were used to 
prepare primary cultures in suspension. Cystogenesis was measured by the 
number of cysts formed and the mean cyst size after 24 hours in culture.
The number of cysts formed after 24 hours in different conditions is 
summarised in the figure 10.34. Control was where the medium had no 
additional galectin-3 or paclitaxel added and it was used as a standard point 
(100%). All other values were measured against the control in a form of 
percentage. Compared with control, the addition of galectin-3, paclitaxel or 
both together significantly reduced the number of cysts formed by 21%, 52% 
and 62% respectively. Paclitaxel had a greater effect in reducing cyst 
formation then galectin-3 (p-value = 0.019). By adding the two reagents 
together, there were no significant differences when compared with adding 
paclitaxel alone (p-value = 0.438), although a significant difference is seen 
when comparing adding both reagents together versus galectin-3 only. This 
may suggest that either the two reagents work on the same pathway or a 
maximum effect was already achieved, therefore no cumulative effects were 
observed.
Mean cyst size were also calculated for all samples and they are summarised 
in figure 10.35. These values were compared. No significant differences were 
found between them; hence the addition of galectin-3, paclitaxel or both did 
not affect the size of cyst formed after 24 hours in suspension culture.
These results suggest that both galectin-3 and paclitaxel affect cytogenesis 
perhaps not by restricting cyst growth as the size of cysts were not affected; 
rather the reagents may act by inhibiting the formation of cysts at the 
beginning, hence a reduced number of cysts formed in culture.
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Figure 10.34. Addition of paclitaxel and galectin-3 to in vitro cyst 
culture: effect on cyst number.
Treatment with paclitaxel and galectin-3 sigificantly reduced the 
number of cyst formed after 24 hours, compared with control. No 
significant difference was found between adding paclitaxel alone and 
adding both paclitaxel and galectin-3 together. Hence no cumulative 
effects were detected.
100
80
60
40
20
p-value = 0.438
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MEAN
cyst number (%) 100 79 48 38
Upper ci NA 82 68 54
Lower ci NA 75 28 21
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with control
NA 0.000004 0.001 0.00006
n 5 5 5 5
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Figure 10.35. Addition of paclitaxel and galectin-3 to in vitro cyst 
culture: effect on cyst size.
Treatment with paclitaxel and galectin-3 had no significant effects on 
cyst size.
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Control +
Gal-3
+
Paclitaxel
+
Gal-3 and 
Paclitaxel
MEAN
cyst size (%) 2502 2757 2341 2671
Upper ci 2815 3113 2773 3327
Lower ci 2188 2400 1909 2015
p-value compared 
with control
NA 0.32 0.57 0.66
n 5 5 5 5
Summary of findings from the paclitaxel treated cpk mice:
• Paclitaxel treated cpk animals exhibited relocalisation of galectin-3 in 
the cystic epithelia, from cytoplasmic expression to apical expression. 
The change in expression was observed in cpk animals at one day and 
11 days after treatment.
• Addition of galectin-3 and paclitaxel separately to cpk cyst cultures 
reduced the number of cysts formed after 24 hours but did not affect 
the size of cysts.
• Addition of galectin-3 and paclitaxel together did not have an enhanced 
effect on cyst number compared with adding paclitaxel alone, hence 
there are not cumulative effects.
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C h a p t e r  1 1 : D is c u s s io n
Autosomal Recessive Polycystic Kidney Disease (ARPKD) is an inherited 
disease that causes cyst formation in kidneys as well as ductal malformation 
in the liver. Clinically, the disease presents in new born patients or in young 
children. Advances in medical care and pre-natal diagnosis have dramatically 
reduced the neonatal mortality rate, though this may be partly due to 
increased number of abortions before this stage. Approximately 50% of 
surviving individuals progress to end-stage renal disease (ESRD) within the 
first decade of life. They represent 5% - 8% of all individuals requiring renal 
replacement therapy in childhood (dialysis and/or kidney transplantation) 
(Sweeney, Jr. and Avner, 2006).
In 2002, several groups (Xiong et al., 2002; Ward et al., 2002; Onuchic et al.,
2002) successfully identified mutations in PKHD1 as causative for ARPKD in 
humans. It is one of the largest disease causing genes to date in the human 
genome (Onuchic et al., 2002), with a complicated transcription profile that is 
predicted to have multiple variants of the transcribed protein -  fibrocystin. The 
PKHD1 gene consists of at least 86 exons (12,222 bp) with a longest 
continuous open reading frame of 67 exons, spanning approximately 472kb of 
genomic DNA. The combination of the large size of this gene and the 
variability of the disease has made the investigation of the pathophysiology 
and the molecular mechanisms of the disease very difficult. ARPKD belongs 
to a group of polycystic kidney diseases (PKD) which share many similarities 
especially the characterisation of their renal cystic epithelia. Thus studies of 
other PKD may provide vital information about cystogenesis of renal cysts in 
ARPKD.
Galectin-3 was previously implicated in cystogenesis in an in vitro model 
using Madin Darby canine kidney (MDCK) cells and partial digestion of cystic
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kidneys taken from the cpk model, a phenotypic ARPKD mouse model. In 
these experiments, addition of galectin-3 retards cystogenesis by restricting 
cyst growth either in size (MDCK cells) or in number (cpk primary culture). 
The experiments in this thesis were designed to further evaluate the effect of 
this protein on the development of renal cysts. Based on the studies on in 
vitro cyst cultures, the hypothesis is that galectin-3 retards cystogenesis.
I investigated the role of galectin-3 in the development of ARPKD using the 
cpk mouse model. Kidney cyst development in this model closely resembles 
that of human ARPKD. Also studies were carried out in kidney epithelial cell 
lines and in kidney samples from other PKD models. Through this study, I 
was able to identify the importance of galectin-3 in reducing renal cyst growth 
in vitro and in vivo; galectin-3 was also found on the primary cilium, an 
organelle that has a very important functional role in the pathogenesis of 
PKD. Additionally, I have begun to investigate a new technique (Atomic Force 
Microscopy - AFM) that may be used to study the primary cilia. I believe that 
this study of galectin-3 on the development of ARPKD has added valuable 
information on cystogenesis on a molecular level.
G a l e c t in -3  w a s  f o u n d  w id e l y  e x p r e s s e d  in  t h e  
CYSTIC EPITHELIA OF CPK MICE AND OTHER PKD 
MODELS.
The expression of galectin-3 in cystic kidneys was first detected by my 
supervisor, Dr. Winyard; he found that galectin-3 protein is expressed in the 
dysplastic kidneys and in human ARPKD samples (Winyard et al., 1997). 
Later Dr. Johnson (a previous PhD student studying this project), using in situ 
hybridisation, described an up-regulation of galectin-3 mRNA in the cpk cystic 
epithelial cells compared with epithelial cells in normal kidneys.
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In this thesis, I confirmed that galectin-3 protein was detected, using 
immunohistochemistry, in the majority of cystic epithelial cells of cpk samples. 
The protein was predominantly expressed in the cytoplasm. The protein was 
also detected in cyst fluid by western blot, suggesting that the protein was 
secreted.
One of the early concepts about PKD is that epithelial cells dedifferentiate 
towards embryonic state. Hence, the wide expression of galectin-3 in cystic 
kidneys can merely be caused by the dedifferentiation of epithelial cells to a 
more embryonic phenotype. Therefore, the expression patterns of other 
collecting tubules proteins expressed during development (ret, aquaporin-2 
and calbindin d28) were examined using immunohistochemistry on 3 week 
old cpk kidneys. As described in results, none of these markers reiterated the 
expression pattern of galectin-3 which was detected across a whole range of 
cyst sizes; hence, galectin-3 expression in cystic epithelial cells is unlikely to 
be due solely to the dedifferentiation of these cells.
The expression of galectin-1 and galectin-9, two other prominent galectins 
found in the kidneys, were also investigated. This was carried out in order to 
determine if they are also over-expressed in cystic epithelia and if they may 
compensate for the lack of galectin-3 in the null mutants. One common 
feature between galectins is the presence of a common carbohydrate- 
recognition domain (CRD); many of the functions of galectins are brought 
about by the CRD and some galectins do share the same functions (the role 
of galectin-1 and -3 in pre-mRNA splicing (Park et al., 2001).
Neither galectin-1 nor galectin-9 had the same expression pattern as galectin- 
3. Galectin-1 protein was not detected in any epithelial cells in the kidneys 
(normal and cystic) and galectin-9 was only detected in a small subset of 
collecting tubule epithelial cells in both normal and cystic kidneys. The 
expression pattern of these galectins remained the same in galectin-3 null
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mutants; hence, they do not appear to compensate for the lack of galectin-3 
in these animals. As we did not examine all known galectins, it is possible that 
other ones are expressed in the collecting tubules and could be up-regulated 
in galectin-3 null mutants. Very recently, galectin-7 was found in hamster 
kidney (Saussez et al., 2006). Results from null mutants suggest that 
galectin-3 role during normal development is redundant although a 11% 
reduction in the number of nephrons was observed in galectin-3 null mutant 
mice (Bichara et al., 2006) and its function is perhaps more important in 
response to cell damage. Several galectins are expressed as part of the 
immune system or as repair mechanisms: galectin-3 in activated 
macrophages, galectin-3 and -7 in re-epithelialisation and galectin-11 in 
infected gastrointestinal tissue (Dunphy et al., 2000; Cao et al., 2002; Sharma 
et al., 2004).
The in situ hybridisation assessing the expression of galectin-3 mRNA, work 
carried out by Dr. Johnson, appeared to show that galectin-3 is up-regulated 
in cystic epithelial cells compared with normal collecting tubule epithelial cells. 
This was reflected by the more intense signal in the cpk samples. Although it 
showed a positive result, the method used was not quantitative, however, 
hence one cannot conclude that galectin-3 expression is definitely 
upregulated in cystic epithelial cell compared with normal. Previous western 
blot analysis shows that the protein is upregulated in the whole organ but that 
may not reflect an upregulation in individual cells due to a higher presence of 
collecting tubules as cysts in cystic kidneys. This problem may be corrected 
by using a marker that is only expressed in collecting tubules, such as DBA 
(dolichos bifloros agglutinin). In theory, the most direct way to quantify the 
level of protein expression would be to use western immunoblot of epithelial 
cells; however, they cannot be readily isolated from the kidneys in sufficient 
quantity.
I attempted to quantify the expression level of galectin-3 by measuring the 
immunostaining intensity, using a confocal microscope with same settings to
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image all samples, which were examined with Leica software that quantified 
staining intensity. Several 3 week old normal and cpk kidneys were assessed 
and a mean level of cytoplasmic expression of the protein was determined. 
Although no significant difference was found, I cannot conclude that the 
protein expression level was the same in normal and cystic samples. This is 
because galectin-3 was detected in cyst fluid, which added to the total 
amount of protein expressed in the cystic kidney. The quantifying method 
used only measured cytoplasmic expression of galectin-3 and not the total 
amount of protein expressed or subcellular distribution. Due to lack of 
confirmation that the protein is upregulated, the expression galectin-3 in cystic 
samples was described as widely expressed rather than up-regulated. 
Although I did not manage to show a specific up-regulation of galectin-3 
expression in individual cystic epithelial cells, the expression of galectin-3 is 
more prominent across all range of cysts when compared with the expression 
pattern of other collecting tubule markers.
The expression of galectin-3 was examined in other PKD samples: cpk 
mutants on balbc and DBA backgrounds; Pkd2ws25/~, a genotypic ADPKD 
model; Bpk and Orpk, both are ARPKD models; and human samples of 
ADPKD and ARPKD. Galectin-3 protein was found widely expressed in all 
these samples, suggesting that the role of galectin-3 in cystogenesis is not 
restricted to the cpk model.
What is the role of galectin-3 in the cystic epithelia?
Setting aside my original hypothesis, the expression of galectin-3 in cystic 
epithelia may represent one of three phenomenons:
1) Galectin-3 may enhance cyst development; the protein may play a role 
in the progression of cyst expansion by modulating proliferation and cell 
adhesion. Overexpressions of proteins such as EGFR and P2X(7), and
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the second messenger cAMP in cystic epithelia lead to cyst development. 
Moreover, antagonists against these proteins appear to reduce 
cystogenesis (Sweeney, Jr. and Avner, 1998; Hillman et al., 2004; Torres 
et al., 2004b; Wilson et al., 2006), therefore it may be logical to think that 
galectin-3 acts in the same way.
2) Galectin-3 may suppress cyst development. The protein may be 
expressed as a response to the distressed cells, thus its expression may 
ameliorate the condition. Galectin-3 is known to be expressed in various 
cell types in the immune system as part of the immune responses, where 
it participates in the activation and differentiation of immune cells (Chen et 
al., 2005). Here, the protein is expressed in response to 
pathophysiological changes and it acts as a defence mechanism. MDCK 
cell culture in 3D Matrigel revealed that exogenous galectin-3 inhibits the 
enlargement of these MDCK cysts (Bao and Hughes, 1995), supporting 
the theory that the expression of galectin-3 in cystic epithelia suppresses 
cystogenesis. Examples of the protective role of galectin-3 can be found in 
glomerulopathy. Galectin-3 is not normally expressed at the glomerular/ 
mesangial level, but is overexpressed in diabetic individuals. Galectin-3 
null mutant mice developed accelerated diabetic glomerulopathy, 
suggesting that the lectin exerts a protective effect over tissue injury in 
vivo (Pugliese et al., 2001). In addition, galectin-3 null mutant mice show 
accelerated AGE (advanced glycation end products) -  induced glomerular 
injury (lacobini et al., 2004).
3) It plays no part in cystogenesis. Galectin-3 null mutant mice show only 
minor differences in body function and development. The same 
redundancy may apply to its role in cystogenesis. Its expression may be a 
reponse to the changes in the environment. It is known that galectin-3 
expression is induced during metabolic acidosis (Schwaderer et al., 2006), 
so it may be altered because of this.
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Based on the MDCK work carried out by Bao et al, I hypothesised that 
galectin-3 does play a role in cystogenesis and that it retards cyst 
development in kidneys.
Previous in vitro work shows that, in agreement with out hypothesis, addition 
of galectin-3 to culture medium retards cystogenesis. We hypothesised that a 
reduction of galectin-3 would have an opposite effect, thus galectin-3 null 
mice would have accelerated cyst growth (fig.11.1).
Figure 11.1. Diagrammatic illustration on the hypothesis of the
role of galectin-3 on cyst development.
Hypothesis of the role of galectin-3 during renal cyst development. 
Addition of galectin-3 (left) retards cysts growth, which was supported 
by the in vitro data: exogenous galectin-3 reduced the number of cyst 
form in the cpk 3D cyst culture (Johnson 2001). Reduction of galectin-3 
enhances cysts development, as observed in the in vivo data: galectin- 
3 null mutant had accelerated cyst growth in one week old cpk mice. 
Galectin-3 null mutants had accelerated cyst growth in vivo.
Addition of Galectin-3 Reduction of Galectin-3
Retards cysts development 
In vitro culture
Enhances cysts development 
In vivo study
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We hypothesised that cytogenesis is enhanced in galectin-3 null mice, 
therefore we decided to assess these animals at Day 7. Cpk mutants were 
bred with galectin-3 null mutants to generate cystic animals with the three 
different galectin-3 genotypes. Cystogenesis in these animals at Day 7 were 
determined and compared using the kidney/body weight (K/B) ratio. The 
experiment was initially carried out on a mixed C57BL/6j x 129Sv 
backgrounds, due to the availability of galectin-3 null mutants on 129Sv at the 
start of this study. Nearer the end of the study, the galectin-3 null mutants on 
C57BL/6j became available. Thus double mutants were obtained on both the 
pure 129Sv by repeated backcrosses and C57BL/6j backgrounds.
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S t u d y  o f  t h e  d o u b l e  m u t a n t s  o n  a  m ix e d  g e n e t ic  
BACKGROUND.
From the first set of experiments (on mixed background): in results cystic 
animals, galectin-3 null mutants (K/B ratio: 1.72%) and heterozygotes (K/B 
ratio: 1.69%) were significantly more cystic compared with wildtypes (K/B 
ratio: 1.18%). Suggesting that a reduction in galectin-3 expression caused 
accelerated cyst growth in cpk kidneys. This result supported the hypothesis 
that galectin-3 retards cystogenesis, therefore when galectin-3 is removed 
from cysts, the rate of cystogenesis was much greater.
The similarity in K/B ratio between galectin-3 heterozygotes and 
galectin-3 null mutant cystic mice.
Galectin-3 heterozygotes and null mutants shared a very similar K/B ratio. 
They exhibited a 43% and 46% increase in K/B ratio respectively compared 
with galectin-3 wildtypes. According to the hypothesis, one would expect 
either only the null mutants had accelerated cystogenesis or that there would 
be a significant difference between the null mutants and the heterozygotes; 
the former would be the most cystic group, hence the degree of cystogenesis 
would increase in proportion to the reduction of galectin-3 expression. But 
why did the heterozygotes had the same outcome as the null mutants?
It was recently found that galectin-3 null mutant mice had 10% fewer 
glomeruli (Bichara et al., 2006). This may contribute to the reduction in 
cystogenesis in null mutants. Less glomeruli means less nephrons and less 
collecting tubules, which are the origins for cyst growth. Therefore, a 
reduction in the number of glomeruli may lead to less cysts being developed. 
The lower than expected K/B ratio in null mutants observed may be explained 
by this phenomenon. However, the multi-functions of galectin-3 may mean 
that the level of the protein and its location may affect cyst growth differently.
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Therefore, it is important to investigate the difference in cellular activity 
between galectin-3 heterozygotes and galectin-3 null mutants.
I performed proliferation and apoptosis studies on the cystic epithelial cells by 
immunohistochemistry. Proliferative index (PI) and apoptotic index (Al) were 
generated by counting the number of positively immunostained cystic 
epithelial cells over the number of total epithelial cells. Results from blinded 
counts showed that galectin-3 heterozygotes had a significantly higher rate of 
proliferation compared with galectin-3 wildtypes and galectin-3 null mutants; 
whereas no significant differences were found between the wildtypes and null 
mutants. No differences were found in the apoptotic index amongst all 
galectin-3 genotypes.
The PI values obtained here are much higher than those previously reported: 
10.5% in human ARPKD samples (Nadasdy et al., 1995). This may be due to 
several factors:
1) Different samples: cpk is a rapidly progressive form of PKD where affected 
individuals reaches end stage renal failure at around week 4 of age; therefore 
a higher rate of proliferation was obtained compared with samples taken from 
human ARPKD.
2) Different methods: although PCNA was used for the previous study in 
human ARPKD, the experimental procedure was different in term of 
incubation time, in particular in the detection step which generated the 
positive signal; the longer the incubation period, the stronger the signal.
3) Different investigators: there are various degree of “brownness” of the 
positively stained nuclei. The various degrees of intensity may reflect the 
stages of cells in the cell cycle. PCNA is not immediately degraded after 
mitosis, therefore cells that have just completed the cell cycle may still be 
positively stained although the level of protein expression is much lower. For 
this experiment, I counted all positively stained nuclei irrespective of their 
staining intensity.
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Galectin-3 is implicated in regulating cell cycle, both proliferation and 
apoptosis. However, the exact mechanisms for these functions are unclear, 
making the interpretation of the results obtained here very difficult. Apoptosis 
was not affected by the expression of galectin-3 at least not in the cystic 
epithelia, although there may be a difference in tissues surrounding the 
epithelia. In terms of the effect on proliferation, it was surprising to find out 
that only galectin-3 heterozygotes had a higher rate of proliferation. The 
higher proliferation rate in heterozygotes might contribute to the greater than 
expected cyst development in this group compared with galectin-3 null 
mutants. The PI result suggests that lack of galectin-3 reduced proliferation in 
cystic epithelial cells, thus suppressed cyst growth. Therefore the level of 
galectin-3 may be important in inducing proliferation, in which a low level is 
required to induce proliferation. It is clear from the results that null mutants 
had the same level of cysts growth as heterozygotes, thus proliferation does 
not solely govern cyst expansion. Galectin-3 may act on other cellular 
process such as altering adhesion, which in turns regulate cystogenesis.
It is difficult to elucidate a hypothesis of what galectin-3 roles is on the 
proliferation of cystic epithelia. Firstly, one should evaluate the level of 
galectin-3 protein expression in galectin-3 heterozygotes cystic epithelia 
compared with that of galectin-3 wildtypes, in order to assess the difference in 
the quantity of galectin-3 expressed. I attempted that using western blotting 
but no signal was detected at one week old kidneys as the expression was 
not high enough. And if the concentration of galectin-3 is important, then one 
could investigate the effect of differing the concentration of galectin-3 in vitro 
using a cystic renal epithelia cell line, e.g. primary culture of cpk monolayer, 
and how that may effect the rate of proliferation and cystogenesis. Another 
factor affecting the outcome may be sub-cellular localisation; extracellular 
galectin-3 may have a different role than cytoplasmic and nuclear galectin-3. 
Therefore it is perhaps important to investigate the localisation of galectin-3 in
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the galectin-3 heterozygotes and null mutants and relate it to the rate of 
proliferation and degree of cystogenesis.
The mixed genetic background of the animals.
Although the animals on the mixed background presented a significant 
difference in the K/B ratio among cystic animals with different galectin-3 
genotype, one may see this result as preliminary due to the mixed 
background, hence a genetic confounder may affect the experiment. 
Nonetheless, the differences were significant and they represent a vast 41% 
increase in K/B ratio in galectin-3 heterozygote and galectin-3 null mutants 
when compared with galectin-3 wildtypes. It was always the intention to 
backcross the double mutants onto a pure genetic background for detailed 
analyses, however that required at least 6 backcrosses, to yield a relatively 
pure genetic background with less than 2% difference. The cpk allele was 
eventually backcrossed 10 generations onto the 129Sv background, which 
gave a less than 0.2% difference in genetic background. This backcrossing 
work alone took over 2 years; which is why the double heterozygotes (cpk +/- 
and gal3 +I-) on the mixed background were interbred to yield offspring in 
order to obtain samples for my preliminary analysis.
Nearer the end of the study, we obtained galectin-3 null mutants on C57BL/6j 
and they were bred with cpk mice.
Study of the double mutants on the 129Sv genetic 
background.
The cpk null allele was successfully bred onto the 129Sv background and the 
experiment yielding cpk animals with various galectin-3 genotypes was 
repeated, generating 34 litters and 181 animals. Cpk mutants have not been 
previously characterised on this particular background. A few unexpected 
factors lead to the termination of analysis of these data:
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1) 181 animals were born, out of which 10 (5.5%) died before day 7. Such 
early death was not observed in the previous set of experiments 
(mixed background) and rarely seen in cpk animals on its natural 
C57BL/6j background.
2) The F2 generation did not follow Mendelian’s Law of Inheritance, 
because there were significantly less galectin-3 null mutants. This 
implies that the samples obtained may be skewed as the samples did 
not include the true galectin-3 null mutant population.
3) Very large pancreatic cysts were seen in some cystic samples and the 
degree of pancreatic lesion did not correlate with galectin-3 genotypes. 
The size of the pancreatic cysts greatly increased the body weight of 
the affected samples and thus skewed the K/B ratio.
These outcomes are likely to be caused by specific alleles on the 129Sv 
background. They have greatly affected the assessment of the effect of 
galectin-3 expression on cystogenesis. The expression of certain alleles may 
lead to in utero death of galectin-3 null mutant, or it may affect implantation of 
null mutants as the protein is implicated in that process (Colnot et a i, 1998). 
Animals that died before day 7 did not correlate with the galectin-3 genotypes 
although most samples genotyped were cpk -I- (6 out of 7). This may reflect a 
correlation with an allele or a group of alleles that affect the survival of the cpk 
animals; death could be due to lack of kidney function or most likely the gross 
pancreatic lesions.
Development of the pancreas is sometimes affected in PKD models. 
Pancreatic cysts are found in orpk and Pkd2 mice (Cano et al., 2004); dilated 
pancreatic ducts are found in orpk mice. However the severity of pancreatic 
lesion was mild in comparison to that observed in cpk animals on 129Sv.
Due to the lack of correlation of galectin-3 genotypes to the death rate and 
pancreatic cyst, these samples were not analysed further. Instead attention
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was turned to the same experiments but on the pure C57BL/6j. One may still 
use this cpk model on 129Sv in future for the study of underlying genes that 
govern the different phenotypic outcomes, in particular the occurrence and 
severity of pancreatic cysts. This model can also be used to study the role of 
cystin (protein encoded by cpk) in the development of pancreatic lesions.
Study of the double mutants on a pure, B57BL/6j, genetic 
background.
Nearer the end of the study, galectin-3 mutants on C57/6j were imported and 
the in vivo analysis of double mutants on this background has begun. Double 
heterozygous (cpk+/-, gal-3+/-) were generated and crossed to yield 108 
offspring for analysis. No significant difference of K/B ratio was found but 
analysis of the cortical region of the cystic kidney samples showed that 
galectin-3 null mutants had a significantly higher cortical cystic index, which 
reflects the size and number of cysts as observed in histological sections, 
compared with galectin-3 heterozygotes and galectin-3 wildtypes; 
representing a -40% increase (p-value < 0.05). No differences were found 
between galectin-3 heterozygotes and wildtypes. The K/B ratio of gal-3 +/+ is 
0.79%, and gal-3 +/- is 0.94% and gal-3 -I- is 0.92%. Compared with gal-3 +/+ 
the p-values were 0.10 and 0.12 in respect to gal-3 +/- and gal-3 -/-. They 
were relatively close to being biologically significant, suggesting that there 
may be a tendency of having higher K/B ratios. Unfortunately I did not have 
the time to measure apoptosis and proliferation in these mice. It is perhaps a 
good idea to collect more samples in order to see if that would affect the K/B 
ratio of different galectin-3 genotypes and the changes on the p-values.
This set of results support previous findings on the mixed background that 
galectin-3 null mutants were more cystic. Therefore I am confident to 
conclude that cpk mice that lack galectin-3 have accelerated cystogenesis 
and galectin-3 suppresses cyst growth in vivo.
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G a l e c t in -3  w a s  e x p re s s e d  o n  t h e  p r im a r y  c il iu m
OF RENAL EPITHELIAL CELLS
In the past few years, the primary cilium has emerged to play a very important 
role in the development of PKD. Many proteins associated with the disease 
were found to locate on this organelle, such as PC-1, PC-2, cystin, OFD-1 
and polaris. As I proposed that galectin-3 is important to the development of 
renal cysts, I was interested to see if the protein was also expressed on this 
organelle. As predicted, the protein was found on the primary cilium in all 
samples tested: IMCD cells, primary culture of normal mice and cpk mice 
kidney epithelial cells, kidney sections of normal and cpk samples, human 
ARPKD and ADPKD samples. The expression pattern of galectin-3 on the 
primary cilia on each samples varied from cilium to cilium, even within the 
same colony, from punctuate expression along the shaft of the cilia to sole 
expression at the end/bulb of the cilia. Galectin-3 location on the primary cilia 
may reflect different developmental or functional state of the organelle, or that 
it is localised to the cargos of the intraflagellar transport (IFT) system which 
moves up and down the shaft of the cilia.
Other PKD causing proteins, PC-1, PC-2, polaris and cystin were previously 
shown to be expressed all along the cilia (Yoder et a i, 2002a), with an 
expression pattern similar to that of galectin-3; whereas inversin functional 
site is restricted to the base of the cilia (Shiba et at., 2005). It is difficult to 
suggest a function of a protein based on its location, in particular when the 
size of the organelle is so small. Using the confocal microscope, it is very 
difficult to identify the sub-location of the protein on either the membrane of 
the cilia, or associated with the microtubule network. Immunocytochemistry 
on non-permeablised IMCD cells was carried out and it revealed that at least
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some galectin-3 was on the outside of the primary cilia. A better way to 
examine this would be to use scanning immuno-electron microscopy.
The primary cilium has been shown to act as a mechano-sensor which 
induces calcium influx into the cell (Nauli et al. 2003, Praetorius and Spring, 
2001). I attempted to repeat the calcium influx study, however I was unable to 
obtain the low flow rate required to bend the primary cilium. A specially 
designed flow chamber was absent in my experiments. Therefore the use of 
AFM was explored as it may be applied to bend the primary cilium.
AFM is able to produce detailed topographs and give quantitative 
measurement of substances in the nanometer range. So far, I have been able 
to obtain topographs of quick dried primary cilia in IMCD cells, showing that it 
is possible to detect and give an accurate quantitative picture of the organelle 
using the cantilever of the AFM. Preliminary testing revealed that the 
organelle could also be detected in solution, which is a more fragile state. The 
use of AFM depends on a good contact between the cantilever and the cell 
surface; liquid phase is a less rigid environment and it exhibits a force against 
the cantilever thus disrupting the engagement it has with the primary cilia, 
which itself is unstable in liquid. The ultimate goal is to detect and manipulate 
the primary cilia of live cells (fig. 11.2). The cantilever of the AFM can used to 
bend the primary cilium. And by incorporating the AFM with a fluorescent 
microscope, one would be able to investigate the effect of calcium influx upon 
manipulation of the primary cilia with the cantilever. Such integration of AFM 
and fluorescent microscope are being carried out by my collaborator Prof. 
Horton.
Also I believe that in order to investigate the subtle differences between 
galectin-3 null mutant primary cilia and normal primary cilia, an alternative 
technique must be used that can provide a more detailed analysis particularly 
of its structure. It was partly this belief that encouraged me to explore the 
application of AFM in the study of the organelle.
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Figure 11.2. Illustration of calcium influx triggered by the 
cantilever of AFM.
Two renal epithelial cells are represented with the primary cilia at the 
top of the cells. The cell on the left is under stable condition whereas 
the one on the right is in contact with the cantilever of the AFM: the 
cantilever physically bends the primary cilium thus triggers calcium 
influx into the cells. Under fluorescent microscope, calcium influx can 
be detect by the green signal. The signal is produced by a fluorescent 
dye, Fura-2, which reacts to free intracellular calcium.
stable cilium
no contact with cantilever cantilever of AFM
centrosome/ 
basal bodyCF
i f l b  nucleus
Calcium entry
Calcium entry
Possible roles for galectin-3 in the primary cilium
This study shows for the first time that galectin-3 is expressed on the primary 
cilium, and no investigations have been conducted to look into the functions 
of lectins and glycoproteins on this organelle. It is certain that galectin-3 
exhibtis a diverse cellular functions depending on its binding ligands. Many 
PKD associated proteins have been identified to be located at the primary 
cilium, they have a diverse range of actions from calcium channel to the 
assembly of the organelle. Many of these proteins are highly glycosylated:
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there are 64 potential N-glycosylation sites in fibrocystin, 60 in PC-1 and 5 in 
PC-2. Both fibrocystin and PC-1 have very large extracellular domains which 
contains many of these glycosylation sites, which are potential sites for 
galectin-3 interaction. Immuno-staining revealed that galectin-3 is expressed 
on the outside of the primary cilia, where it can potentially interact with the 
PKD glycoproteins.
Galectin-3 may modulate the function of PC-1 and other PKD proteins by 
forming a lattice thus clustering these proteins on the ciliary surface. The 
ability of protein clustering is similar to the role of lipid rafts on the membrane.
Galectin-3 was found in lipid rafts
Cystin was found to be in the lipid raft fraction of IMCD cells; suggesting that 
lipid raft may serve a role in protein transport and/or retention on the ciliary 
membrane (Yang et a l, 2004). Galectin-4 is a well established lipid raft 
associated protein in intestinal epithelial cells (Danielsen and Hansen, 2003). 
With these two factors I set out to determine if galectin-3 can also be found in 
the lipid raft compartment in renal epithelial cells. As expected, galectin-3 was 
found associated with caveolae, which is a marker of lipid rafts, thus it 
provides a strong evidence that galectin-3 is a raft associated protein at least 
in IMCD cells. Attempts were made to extract lipid raft from cpk kidney but 
failed due to technical difficulties, although the precise reason was unknown.
Lipid rafts are implicated in several biological functions, including cell 
signalling, polarisation, protein secretion and endocytosis (Brown and 
London, 1998). The function of these microdomains in cell polarisation is of 
most interest. Protein polarisation is disrupted in cystic epithelial cells; primary 
cilia are thought to play a role in cell differentiation which is partly marked by 
protein targeting to either the apical or the basolateral domains; N-glycans, 
which are potential ligands for galectin-3, can mediate apical targeting of
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proteins, a process that may involve lipid rafts (Benting et a/., 1999; 
Rodriguez-Boulan and Gonzalez, 1999; Pang et al., 2004). Also, findings of 
galectin-3 in the lipid rafts may provide clues to how galectin-3 is secreted 
from cells, a process that is yet unidentified (Hughes, 1999).
Galectin-4 is a major component of lipid raft in intestinal epithelial cells, it acts 
as a stabiliser for other more loosely raft-associated proteins (Danielsen and 
Hansen, 2003). Both galectin-4 and galectin-3 have an ability to self- 
polymerise (Yang etai ,  1998; Braccia et al., 2003; Partridge eta i ,  2004), 
forming a lattice which results in a “gluing” effect that keeps the glycoproteins 
and glycolipids in place. Lipid rafts are microdomains on the cell surface, they 
are commonly perceived as the more ordered domains within the lipid bi-layer 
that are rich in cholesterol and glycosphingolipids. Glycosphingolipids contain 
a high degree of acyl chain which raises the melting temperature of lipid. This 
results in a more stabilised lipid phase, where proteins is able to cluster 
together in order to induce reaction such as initiation of signalling pathway.
Studies on the role of galectin-3 in clustering cell surface receptors (namely 
EGFR and TGF-p-R, both are glycosylated and are found in lipid rafts) 
suggest that it may be a raft associated protein (Schwartz et ai,  2005; Pike et 
al., 2005). It was found that galectin-3 is able to cross-link Mgat5-modified N- 
glycans on the cell surface resulting in the formation of galectin-3/glycoprotein 
clusters. Mgat5 promotes the substitution of N-glycan with poly N- 
acetyllactosamine, the preferred ligand for galectin-3. This cross-linking action 
retains receptors on the surface against loss via endocytosis. Mgat5 deficient 
mice had a delayed reaction in response to EGF, IGF (Insulin growth factor), 
FGF (fibroblast growth factor); Scatchard analysis revealed sixfold fewer 
EGFR at the cell surface or Mgat5 -/- cells, although total EGFR amounts 
were not different between mutant and wildtype cell lysates. Suggesting that 
suppressing the interaction of galectin-3 with EGFR leads to less EGFR 
retained on the cell surface. Mga5-/- cells also exhibits a threefold decrease
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in sensitivity to TGF-p (Partridge et al., 2004). Galectin-3 can also modulate 
TCR (T-cell receptor) clustering. It interacts with TCR at the cell surface of 
normal cells but not in Mgat5 deficient cells; the galectin-3/TCR lattice may 
contain galectin-1, which is shown to modulate T-cell activation in vitro 
(Fuertes et al., 2004; Toscano et al., 2006). The lectin/TCR lattice restricts 
TCR recruitment to the site of antigen presentation thus modulating the 
immune response of T-cells. This process is inhibited by lactose thus 
suggesting that the CRD of galectin-3 is responsible for the interaction 
(Demetriou et al., 2001). Conflicting results show that galectin-3 is not in the 
lipid raft of differentiated MDCK cells. The study suggests that galectin-3 is 
involved in a non-raft dependent apical protein sorting (Delacour et al., 2006).
Whether or not galectin-3 is in lipid raft, its ability to cluster proteins on the cell 
surface is perhaps most important. In terms of its role on the primary cilia; it 
may act by clustering and retaining PKD proteins on the surface thus 
facilitating adequate response to external stimulation. Galectin-3 localisation 
to lipid rafts remains speculative. The primary cilia have a high concentration 
of receptors, it may therefore contain a high proportion of lipid rafts, which 
provide a more ordered lipid bilayer to stabilise the position of these 
receptors. Apart from cystin, the polycystin complex may also be found in lipid 
rafts. The constituents of the complex PC-1, E-cadherin and p-catenin 
associate together with a cholesterol-containing signalling microdomain in 
human kidney epithelia (Roitbak et al., 2005). The relationships between lipid 
raft, primary cilium and cytogenesis remain to be determined.
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Figure 11.3. Illustration of galectin-3 forming a lattice and 
clustering PKD proteins on cell surface.
A hypothetical function of galectin-3 on the cell surface. A lipid bilayer 
membrane was shown where three glycosylated PKD proteins (blue) 
were found within. Galectin-3 (red) binds directly to the N-glycan 
(green) and also self-associates to form a lattice containing the PKD 
protein.
Galectin-3 lattice
Galectin-3 N-glycan P K D  protein
Galectin-3 was expressed on the centrosome of IMCD cells
Immunocytochemistry of IMCD monolayers showed that galectin-3 was 
expressed on the pericentriolar material (PCM), area around the centrioles, of 
the centrosome and at the spindle poles of dividing cells. The centrosome is 
regarded as the microtubule organising centre as well as a regulator of the 
cell cycle. It is also the precursor of the primary cilium. This is the first time 
that a galectin was shown localised to this important organelle.
The link between the centrosome and PKD
Several ciliary proteins associated to PKD are found to localised to the 
centrosome: OFD1(Romio etai., 2004), BBS4 (Kim etai., 2004), BBS6 (Kim 
etai., 2005), Nek8 (Quarmby and Mahjoub, 2005), all are found in the basal 
body of the primary cilium. PC-L, a protein closely related to PC-2, is found in 
centrosome of unciliated cells (Bui-Xuan et al., 2006) whereas PC-2 is
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proposed to form a complex with intraflagellar transport (IFT) proteins and 
centrosome protein pericentrin (Pent) that is required for the assembly of 
primary cilia (Jurczyk et al., 2004). The primary cilium is derived from the 
mother centriole near the end stage of cell differentiation when the 
centrosome migrates close to the apical surface (Rieder et al., 2001). The 
roles of PKD proteins in centrosome are unclear; however, they may 
participate in regulation of the cell cycle and/or the formation of the primary 
cilia. There may be shared functions, such as organising microtubules, 
between the centrosome and the cilium, which are carried out by this group of 
proteins. Although it is well established that some galectins are capable of 
regulating cell cycle, the mechanism of this control and their subcellular 
targets are yet to be resolved. This result suggests a possible target for 
galectin-3 in regulating the cell cycle.
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G a l e c t in -3  w a s  r e l o c a l is e d  in c y s t ic  e p it h e l ia l
CELLS AFTER TREATMENT WITH PACLITAXEL
Results from the examination of paclitaxel treated kidneys revealed that the 
reagent relocalises the expression of galectin-3 from cytoplasmic to apical. In 
vitro studies done by Dr. Tanya Johnson showed that paclitaxel enhanced the 
secretion of galectin-3 to the medium. The renal primary cilia from treated cpk 
samples were examined using confocal microscopy: no differences were 
found on the appearance of the primary cilia; the localisation of galectin-3 
remained on paclitaxel treated primary cilia.
Paclitaxel (50 pM) and galectin-3 (30 pg/ml) reduced the number of cyst 
formed in culture when added separately (Woo et al 94, Johnson’s Thesis 
2001). Here I carried out in vitro experiments where the two reagents were 
added together and found that there was no significant cumulative effect. The 
two reagents may therefore work in the same pathway in reducing 
cytogenesis. However, one can argue that the concentration of paclitaxel 
used was high enough to saturate the effect that galectin-3 might impose, or 
that paclitaxel altered the physiology of the cells to a point that galectin-3 
could no longer influence the cells. Paclitaxel may encourage the secretion of 
galectin-3.
Linking the paclitaxel data to other work in this thesis: galectin-3 was found 
localised to the outside of the primary cilia, together with the fact that 
paclitaxel did not appear to alter the structure of the organelle. I hypothesized 
that the increased concentration of galectin-3 in cyst fluid caused by paclitaxel 
modulates cytogenesis by binding to the outside of the primary cilia, thus 
stabilising the protein receptors on the outside of the cilia.
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Previous studies of the effect of paclitaxel on other PKD animal models found 
that the reagent is not effective on orpk mice (Sommardahl et al., 1997), pcy 
mice and Han:SPRD-cy rats (Martinez et al., 1997). Although in vitro culture 
of Han:SPRD-cy derived cysts showed a positive effect in inhibiting 
cytogenesis (Pey et al., 1999). In Chapter 6, I examined the dosages used for 
each models and found that all other models used a dosage that was at most, 
half the dosage used in the cpk mice. Hence, the inefficiency observed could 
be due to this reduced dosage. If my hypothesis is true, that part of the effect 
of paclitaxel is due to an increased concentration of galectin-3 in cysts fluid, 
which stabilises protein receptors on the outside of the primary cilia, then 
paclitaxel might not have any effect on models that do not have structurally 
normal cilia. I know from this study and from various published data that cpk 
mice develop primary cilia that are structurally indistinguishable to normal 
cilia. On the other hand, the majority of cystic cells in orpk mice either lack the 
expression of primary cilium or express shortened cilia (Brown and Murcia,
2003); in this case, according to the hypothesis, paclitaxel would have no 
effect on cystogenesis in orpk mice. The expression of primary cilia in pcy 
mice and Han:SPRD-cy rats have not been published.
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C h a p t e r  12: C o n c l u s io n
Taking all these results together, I am confident that galectin-3 plays a role in 
inhibiting cyst growth in cpk animals, and I speculate that its effect may 
extend to other PKD models. The results obtained in this thesis: the wide 
expression of galectin-3 on cystic epithelia of several PKD models; lack of 
galectin-3 in cpk models led to an accelerated cystogenesis in vivo; the 
presence of galectin-3 in primary cilia. All these point towards the significance 
of this lectin in cyst development. The in vivo data in particular, together with 
previous in vitro data showing that addition of exogenous galectin-3 reduces 
cyst formation, support the hypothesis that galectin-3 acts by suppressing 
cyst growth.
The finding that galectin-3 was on the outside of the primary cilia; the 
presence of galectin-3 in cyst fluid; and that paclitaxel treated in vitro cysts 
secreted more galectin-3. All these suggest that galectin-3 may work on the 
outside of the primary cilium. Preliminary data revealed that galectin-3 was 
found in the lipid raft fraction of IMCD cells, provokes the idea that galectin-3 
function on the cell surface by forming a lattice, which stabilises and retains 
receptors on the cell surface against endocystosis. Referring back to the in 
vivo data; among cpk animals galectin-3 heterozygotes had the same K/B 
ratio as galectin-3 null mutants. This reflected a similar degree of cyst growth 
between the two groups of samples. If the role of galectin-3 depends on the 
formation of a functional lattice, one may expect the concentration of galectin- 
3 to be critical in the formation of lattice with an adequate size. Galectin-3 
heterozygotes may have a reduced level of secreted galectin-3, thus are 
unable to create a significant lattice to cluster PKD proteins on the cell 
surface.
It is sometimes thought that if a protein is widely expressed in diseased 
tissues, it contributes to the pathophysiology. Specifically in PKD, several
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proteins that are upregulated in the cystic epithelia are implicated in the 
worsening of the disease: EGFR, P2X(7), cAMP. However, in the case of 
galectin-3, I am proposing that it has a beneficial effect on the disease. Its 
expression in cystic epithelia acts as an inhibitory factor on cyst development 
but it is insufficient to prevent cysts completely. The protective effect of 
galectin-3 against disease progression is apparent in a few other renal 
diseases. Diabetic glomerulopathy is one such example; Galectin-3 null 
mutant mice developed accelerated glomerulopathy, the lectin would 
otherwise be up-regulated in diabetic individuals (Pugliese et al., 2001a) 
glomerular lesion caused by the accumulation of AGEs (advanced glycation 
end-products) is also protected by galectin-3. Aging galectin-3 knockout mice 
develop more pronounced changes in renal function and structure than 
wildtype mice. This changes is associated with the higher accumulation of 
AGEs, suggesting that galectin-3 may be a AGE receptor that assists in the 
clearing of AGEs (lacobini et al., 2005). The protein was found to be markedly 
up-regulated in both ischaemic (bilateral renal pedicles clamped for 40 
minutes) and toxic types (folic acid) of acute renal failure (ARF) in rats. 
Upregulation of galectin-3 mRNA was observed as early as 2 hours after 
injury. In the ischaemic ARF, the mRNA level extended by 6.2-fold at 48 
hours, and then decreased by 28 days after injury. In toxin induced ARF, 
increased levels continued until at least 7 days post injury (Nishiyama et al., 
2000).
Galectin-3 posses multiple functions, many of those mimic the 
pathophysiology of PKD: alteration in cell adhesion, alteration of proliferation 
and apoptosis, importance of primary cilia in the renal cyst development. And 
galectin-3 can potentially interact with the highly glycosylated PC-1, 
fibrocystin and perhaps other glycosylated PKD proteins. Therefore it is no 
surprise that galectin-3 may modulate their functions and cystogenesis. This 
thesis has provided many novel findings and it shows the importance of 
galectin-3 in the development of renal cysts. The fact that galectin-3 is able to
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inhibit cyst growth raises the possibility of developing the lectin into a 
therapeutic treatment against PKD.
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C h a p t e r  13 : F u t u r e  w o r k
Detailed examination of galectin-3 null mutant cpk mice
Detailed examination of the cystic kidney samples on the pure 129Sv and 
C57BL/6j backgrounds: proliferative and apoptotic indexes, would provide 
further insight into the role of galectin-3 in ameliorating the disease. It is 
important to find out the physiological changes associated with the lack of 
galectin-3, which leads to the accelerated cyst growth. This may provide 
insight to the mechanism of how galectin-3 modulates cyst growth.
To further investigate the hypothesis that galectin-3 form lattice on cell 
surface and retains protein receptors, in particular PKD proteins, on the 
primary cilium. One can examine the precise localisation of several PKD 
proteins on the primary cilium in galectin-3 wildtype and galectin-3 knockout 
samples, as well as the location of galectin-3 on the ciliary membrane. The 
association of galectin-3 and PKD proteins to lipid raft in kidney epithelial cells 
also needs to be confirmed.
Examination of galectin-3 null primary cilia
One of the most established functions of primary cilia is its role in initiating 
calcium influx in response to mechanical force that bends the organelle. I 
began searching for ways to replicate the experiment in triggering calcium 
influx in IMCD cells, however, without the appropriate equipment, it was 
impossible to achieve the required flow rate. Instead I look at AFM (atomic 
force microscopy) in bending the primary cilium, thus initiating the calcium 
response. Progress was slower than expected, but I did determine that the 
AFM is able to detect the primary cilium. To test the physiology effect, one 
must carry out the experiment in live cells, which poses the biggest challenge. 
However, examination of live cells using AFM is not a new technique and a
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tailor-made biological chamber (which controls the temperature and humidity 
of samples) is already available. The challenge lies in optimising the process 
to yield results. The AFM is already integrated to a confocal microscope; 
again the challenge here depends on development of an effective imaging 
protocol. The strategy of the experiment would be to culture galectin-3 null 
mutant kidney epithelial cells in monolayer, prior to testing the cells would be 
equilibrate with Fura-2 (a fluorescent dye that binds to free intracellular 
calcium and causes an emission between 300 and 400 nm). Using the 
cantilever on the AFM to physically bend the primary cilia, and calcium influx 
can be measured and timed using the confocal microscope. This result could 
then be compared to that of wildtype cells to assess any differences in the 
strength and duration of the reaction. Finally, I would repeat the experiment 
with the addition of galectin-3 in medium and determine if exogenous 
galectin-3 alter the rate and strength of response of calcium influx compared 
with cells treated with media alone.
The AFM can also be used to give an accurate assessment of the size and 
surface structure of galectin-3 null mutant primary cilia in comparison to 
wildtype cilia.
Galectin-3 binding ligands on the primary cilia and cpk cells
It is important to determine which proteins galectin-3 interacts with on the 
primary cilia, specifically PC-1, PC-2, fibrocystin, polaris, inversin, kinesins 
and dyenin. Co-immunoprecipitation can be done with these specific proteins 
using IMCD cells. In addition, one should assess the differences in the 
constituent of galectin-3 ligands in cpk cells and wildtype cells, which is also a 
good way to search for novel ligands of galectin-3. This may be determined 
by affinity chromatography. The technique was successfully used to identify 
macrophage surface glycoproteins that bind galectin-3 (Dong et al., 1997). 
Primary culture of cpk kidney epithelial cells and IMCD cells will be used for 
protein extraction. These protein lysates will be used as substrates to run
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through a column containing either galectin-3 or specific antibodies against 
the lectin. Proteins that interact with galectin-3 will be selected and eluted. It 
can then be separated by 1D or 2D SDS-PAGE and visualised by silver 
staining. Individual protein bands will be excised and in-gel tryptic digestion 
will be preformed. The released peptides will be extracted from the gel and 
analysed by mass spectrometry. Data analysis will be carried out using 
specific softwares to identify “pulled-down” proteins.
Treatment of cpk mice with recombinant galectin-3 protein
The hypothesis is that galectin-3 has a beneficial effect in delaying 
cystogenesis and it raises a possibility of using the lectin as a therapeutic 
drug. To ultimately prove the application of galectin-3 as a therapeutic drug, 
one must show that the administration of the lectin to diseased animals 
delays the progression of the disease. Recombinant galectin-3 can be made 
using E.coli (the protein is not glycosylated) and it would be administered to 
cpk litters, some treated with vehicle only as control. Treatment with 
recombinant galectin-3 was tested in nude mice bearing orthotopically 
implanted tumours derived from breast cancer cell line. Toxicity, 
pharmacokinetic and organ biodistribution studies were performed. The 
maximum tolerated dose of galectin-3 in adult nude mice was >125mg/kg 
without obvious adverse effects. The elimination half-life when administered 
via the intramuscular route was found to be 3 hours in the serum and 4.3 
hours in the cellular fraction of the blood. Organ biodistribution studies 
revealed that galectin-3 localised in the liver, kidneys and spleen but not in 
the heart or lungs. The published data showed that mice with tumours were 
injected with galectin-3 via the intramuscular route, twice a day of 125 pg 
(5mg/kg) with an approximately 6-8 hours interval for 90 days. This dosage 
was able to reduce the growth of the tumour compared with vehicle-treated 
mice (John et al., 2003). Cpk mice would be treated much earlier, as they do 
not survive to adulthood. The treatment might start before day 7, the dosage 
should be much less than 125mg/kg.
240
This thesis represents a very exciting new research area in the field of 
ARPKD research. There are clearly much more work to be done in order to 
determine the mechanism of galectin-3 in modulating cystogenesis and to 
enhance out understanding of the disease. Many of the proposed work are 
based on the cpk model, however if it does prove that galectin-3 can retards 
cyst growth in these animals, the next step woud be to verify its effects in 
other PKD models, especially in the genotypic models to the human ARPKD 
and ADPKD disease such as pcy mice.
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